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Chapter 
INTRODUCTION 
Cognitive impairment is one of the major symptoms of dementia. The main cognitive functions acc orientation to time and place, recall and memory, attention, language, calculation, and visual construction. Impairment of cognitive functions in-
fluences the ability of an individual to live independently, and it dimin-
ishes the quality of life. In addition to the consequences for an indi-
vidual, cognitive impairment imposes a major burden on the health care 
system because it induces an increased risk of institutionalization and 
hospitalization. 
Although cognlttve impairment is a less severe disorder than de-
mentia, it is much more common. In a representative papu lation of 
subjects over 65 years of age, the prevalence of cognitive impairment 
was 15.8%, whereas the prevalence of dementia was 4.2%.' The risk of 
cognitive impairment rises exponentially with age. Therefore, we may 
expect an increase in the number of people with cognitive impairment 
in our aging society. At present, there acc a number of medications that 
can delay the progression of dementia and that can stabilize cognitive 
function. However, no cure or prevention for these disorders has been 
found yet. Therefore, it is important to identify modifiable risk factors 
for cognitive impairment and dementia. If these risk factors can be 
found, preventive intervention may become feasible. 
In the past decade, knowledge on risk factors for cognitive impair-
ment and dementia has accumulated. The most commonly mentioned 
risk factors include age, sex, education, head trauma, smoking, family 
history and the apolipoprotein E gene. Recently, new risk factors have 
emerged, such as atherosclerosis (Le. plaques in the carotid arteries, in-
tima-media wall thickness of the carotid artery, and ankle-brachial index) 
and risk factors for cardiovascular diseases. These new risk factors in-
crease the risk of stroke, lacunar infarcts, and white matter lesions, 
which in turn can lead to cognitive impairment and vascular dementia, 
and perhaps even to Alzheimer's disease.l ·S In addition, experimental, 
clinical and epidemiological data suggest that other processes, such as 
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oxidative strcss6, inflammation7, and hypothalamic-pituitary-adrenal axis 
overactivity8, may also be involved in the pathogenesis of cognitive im-
pairment and dementia. We thus focused on nutritional and metabolic 
factors that are involved in these processes. Most of the risk factors we 
studied have not been linked to cognitive decline or dementia in previ-
ous studies. 
It is well known that specific nutrients influence the risk of coro-
nary heart disease, certain types of cancer, and all-cause mortality. Diet 
has, however, not received much attention as a risk factor for cognitive 
decline and dementia. In Part I the results of studies on nutritional risk 
factors are reported. Chapter 2 focuses on nutrients that are related to 
oxidation. Polyunsaturated fatty acids increase the susceptibility of LDL 
cholesterol to oxidation, rendering it more atherogenic. Antioxidants de-
crease this susceptibility. Apart from the oxidation of LDL cholesterol, 
oxidation in itself may induce damage to neurons, especially after brain 
infarction. In Chapter 3 established dietary risk factors for coronary 
heart disease, i.e. fat intake and fish consumption, arc examined as risk 
factors for the incidence of dementia. 
The results of studies on metabolic risk factors are described in 
Part II. In Chapter 4 the relation of diabetes, and pre-clinical stages of 
diabetes, i.e. hyperinsulinemia and impaired glucose tolerance, to cogni-
tive impairment is reported. Diabetes is considered a major risk factor 
for cardiovascular diseases, and the pre-clinical stages have also been 
related to coronary heart disease and stroke. The association between a 
relatively new cardiovascular risk factor, serum homocysteine and cogni-
tive decline is examined in Chapter S. Chapter 6 describes the associa-
tion between two adrenal steroids. cortisol and dehydroepiandrosterone, 
and cognitive decline. The concentrations of these steroids are influ-
enced by the hypothalamic-pituitary-adrenal axis activity and they have 
different effects on the hippocampus, which is involved in memory and 
learning. 
Furthermore, to gain better insight in the role of risk factors in the 
pathogenesis of cognitive decline, we examined the combined effect of 
two risk factors and the major susceptibility gene for Alzheimer's 
disease, the apolipoprotein E gene. In Chapter 7 the interaction be-
tween education and the apolipoprotein E gene is described. In Chapter 
8 . we studied the combined effect of a history of cardiovascular diseases 
and the apolipoprotein E gene on cognitive decline. 
It is known that subjects with dementia have a higher mortality 
risk, but cause-specific mortality has not been investigated yet in a 
population-based follow-up study. Therefore, in Chapter 9 we investi-
gated total and cause-specific mortality in subjects with (subtypes of) 
dementia. It is important for relatives and caregivers of demented 
subjects, and for clinicians and planners of health care facilities to have 
detailed information on the prognosis of dementia. 
INTROOIJCTION 3 
In the general discussion the results described in this thesis are 
briefly summarized. Some methodological problems are discussed. The 
hypotheses on the etiology of cognitive decline and dementia are ad-
dressed in the light of our findings, and finally, some suggestions for 
future research are given. 
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POLYUNSATURATED 
FATTY ACIDS, ANTIOXIDANTS, 
AND COGNITIVE FUNCTION 
The Zutphen Elderly Study 
Abstract 
Atherosclerosis and thrombosis may lead to cognltlve impairment througl1 
cerebral infarcts or white matter hyperintensities. Oxidative stress is now 
seen as a major contributor to the process of atherogenesis. High intake 
of polyunsaturated fatty acids (PUFA), e.g. linoleic acid, or low intake 
of antioxidants can increase oxidative stress. High intake of n-3 PUFAs 
and its main sourCe fish may reduce the risk of thrombosis. Little is 
known, however, about the relation between these dietary factors and 
cognitive function. The authors investigated tlus relation with data 
derived from a cohort of men, aged 69 to 89, who lVele participants in 
the Zutphen Elderly Study. The 30-point Mini-Mental State 
Examination lVas used to assess cognitive impairment in 1990 (score ::; 
25 in 153/476 men, 32%) and cognitive decline from 1990 to 1993 
(drop>2 points in 51/342 men, 15%). Food intake was estimated in 1985 
and 1990 by the cross-check dietary history method. High linoleic acid 
intake lVas associated with cognitive impaiIment, after adjustment for 
age, education, cigarette smoking, alcohol consumption, and energy 
intake (odds ratio (OR) highest versus lowest tertile ~ 1.76, 95% 
confidence interval (CI) 1.04-3.01). Intake of n-3 PUFAs was not as-
sociated witb cognitive impairment, wbereas bigh fisb consumption 
tended to be inversely associated with cognitive impairment (OR~0.63, 
95%CI 0.33-1.21) and cognitive dec/ine (OR~0.45, 95%CI 0.17-1.16). 
Intakes of beta-carotene, vitamin C and E and flavonoids were not 
inversely associated with cognitive impairment Of decline. In conclusion, 
this study raises the possibility that high linoleic acid intake is positively 
and high fish consumption inversely associated with cognitive 
iInpairment. 
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Introduction 
Cognitive performance decreases with increasing age. Cognitive impair-
ment is a major component of dementia and influences the individual's 
ability to function independently. Due to aging of the population, the 
prevalence of cognitive impairment is expected to increase. Therefore, it 
is important to elucidate possible modifiable risk factors for impaired 
cognitive function, such as diet. 
Polyunsaturated fatty acids (PUFA) and antioxidants may affect the 
development of cognitive impairment through their impact on atheroscle-
rosis and thrombosis. These processes have been associated with an in-
creased risk of stroke, lacunar infarcts, and white matter changes. as 
seen on neuroimaging, which can subsequently lead to cognitive im-
pairment. I-4 Oxidative stress is now seen as an important contributor to 
the process of atherogenesis.s PUFAs are highly susceptible to oxidation, 
and may increase the oxidative modification of low density lipoprotein 
(LDL) cholesterol, making it more atherogenic.6•7 Since linoleic acid, 
which is an n-6 PUFA, constitutes nearly 90% of the PUFAs in LDL 
cholesterol, it is the major substrate of LDL oxidation.6 Dietary antioxi-
dants, such as vitamin E, beta-carotene and flavonoids, may protect 
against oxidative damage and thus reduce the risk of atherosclerosis.B. 1O 
PUFAs may also influence the risk of thrombosis. N-3 PUFAs, 
such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 
compete with linoleic acid in the eicosanoid metabolism. II A high lino-
leic acid intake may lead to increased production of the proaggregatory 
thromboxane A2. N-3 PUFAs, on the other hand, reduce the production 
of thromboxane A2 and increase the production of the antiaggregatory 
prostacyclin PGI3, consequently reducing the risk of thrombosis. II 
Therefore, we examined the association of PUFAs and antioxidants with 
cognitive function. We also investigated the association between fish 
consumption and cognitive function, because fish is the main source of 
n-3 PUFAs. We investigated these associations in a community-based 
longitudinal study of very old men. 
Methods 
Study population 
The Zutphen Elderly Study is a longitudinal study on risk factors for 
chronic diseases in men who live in Zutphen, a town in the eastern 
part of the Netherlands. 12 It is the continuation of the Zutphen Study, 
which was initiated in 1960 as the Dutch contribution to the Seven 
Countries Study.13 In 1985, 555 subjects from the original cohort, born 
between 1900 and 1920, were still alive. In addition, 711 men of the 
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same age (64-84 years) were randomly selected from all other men liv-
ing in Zutphen. This resulted in a population of 1,266 men, of which 
939 participated (response rate, 74%). In 1990, 560 of 718 surviving men 
(78%) were reexamined. The examinations were repeated in 1993 on 
390 of 553 surviving men (71%). The study has been approved by the 
medical ethics committee of the University of Leiden, the Netherlands, 
and informed consent was obtained from all participants. 
Examinations 
In the spring of 1985 and 1990, interviews and examinations were car-
ried out at home and in a study center. In the spring of 1993, inter-
views were conducted at home. Dietary intake was assessed in 1985 and 
1990 and cognitive function was tested in 1990 and 1993. For the 
analyses on prevalent cognitive impairment, information on cognitive 
function in 1990 was used; complete information on dietary and other 
risk factors was available for 476 men. For the longitudinal analyses on 
cognitive decline, information on cognitive function in 1990 and 1993 
was used; complete information was available for 342 men. 
Food and beverage intake was estimated by the cross-check dietary 
history method l4, adapted to the Dutch situation. IS This method pro-
vides information about the usual food consumption pattern during the 
2-4 weeks preceding the interview. The interviews were carried out by 
well-trained dietitians in 1985 and 1990, using the same methodology in 
both years. All subjects were interviewed at home, preferably in the 
presence of the partner. First the usual food consumption pattern of a 
person was assessed during weekdays and weekends. Thereafter, a 
checklist with an extensive number of foods was reviewed, and the fre-
quencies and amounts consumed were recorded. Portion sizes Were es-
timated by a portable scale. The results were checked by comparing 
the average consumption of foods during a week with the quantities of 
food purchased for the family during a week. At the same time, the 
use of prescribed diets, diet products, vitamins and health food products 
was assessed by a standardized questionnaire. The whole interview took 
approximately one and a half hours. 
Food intake data were coded and converted into energy and nutri-
ents using a computerized version of the Dutch food table (Uniform 
Food Encoding food table 1984 and NEVO table 1989), updated with 
information on beta-carotene, vitamin E and flavonoids lO, and with ad-
ditional information on the n-3 PUFAs EPA and DHA.16 The flavonoid 
content was defined as the sum of quercetin, kaempferol, myricetin, 
apigenin, and luteolin, the five major antioxidant food flavonoids. The 
average daily intake of 1985 and 1990 combined was calculated for all 
dietary factors of interest and used for the analyses, because this gives a 
more reliable estimate of a subject's true intake than only one measure-
ment. 17 The average intake was then categorized into teetiles, and the 
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first tertile, which corresponded to the lowest intake, used as the refer-
ence. Fish consumption was divided into three categories: 0 grams/day, 
> 0-20 grams/day, and > 20 grams/day. We defined use of vitamin C or 
E supplements as use in 1985 or 1990, either during the whole year or 
during winter time only. Users of vitamin C and E supplements were 
assigned to the highest vitamin C and E tertiles. 
Global cognitive function was tested with the Dutch version of the 
3D-point Mini-Mental State Examination (MMSE).18,19 The MMSE in-
cludes questions on orientation to time and place, registration, attention 
and calculation, recall, language and visual construction. This screening 
test was originally created for a clinical setting18, and is extensively used 
in epidemiologic studies.2o Although it tests a limited set of cognitive 
functions, these are important to daily functioning and severely affected 
in dementia. In 1990, it was administered in a controlled hospital set-
ting, while in 1993, it was administered at the subject's homes. Re-
search assistants were uniformly trained to administer the MMSE and 
the scoring was checked by the same person in 1990 and 1993 with 
strict scoring criteria. If less than four individual items (out of a total of 
20 items) were not answered by the subject, these were rated as ec-
rors. 21 If items could not be performed because of severe physical dis-
ability a weighted total score was given. If a subject did not answer 
four or more individual items the total MMSE score was considered 
missing. We used a score of 5 25 as the cut-off point, because this is 
indicative of cognitive impairmcnt.22 Cognitive decline was defined as a 
drop of more than two points in the MMSE over a 3-year period (> 1 
SO, which corresponds to the 15th percentile of change). 
We considered the following potentially confounding variables in 
our analyses: age (continuous); education, obtained from a self-adminis-
tered questionnaire (5 6 years, 7-12 years and> 12 years of education); 
cigarette smoking in 1990 (current: yes/no) assessed by a trained physi-
cian, with the use of a standardized questionnaire23; usual alcohol con-
sumption in 1990, obtained from the cross-check dietary history (none, 
<1 drink/day (<13.2 grams), :2:1 drink/day)23; and energy intake 
(continuous). 
Statistical methods 
Univariate associations were tested with the nonparametric Mann-Whit-
ney test for continuous variables. We used logistic regression with cog-
nitive impairment (MMSE score > 25 as reference) and cognitive de-
cline (change in MMSE score 5 2 points as reference) as dependent 
variables and the following dietary factors as independent variables: PU-
FAs, which were divided into the n·6 fatty acid linoleic acid and the n-
3 fatty acids EPA and OHA; fish; and the antioxidants beta-carotene, 
vitamin C, vitamin E and flavonoids. Age, education, current cigarette 
smoking, alcohol and energy intake were added to the model as pot en-
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tial confounding factors. In the analyses on cognttlve decline, we also 
adjusted for baseline MMSE score. When analyzing intake of vitamin E, 
we in addition adjusted for PUFA intake, because these variables were 
highly correlated (r~0.6). 
Since high antioxidant intake may diminish the oxidation of LDL 
induced by linoleic acid6, and thereby may attenuate the relation be-
tween linoleic acid and cognitive impairment, we examined the interac-
tion between intake of linoleic acid and antioxidants. This was done by 
including the product terms of the linoleic acid and antioxidant dummy 
variables into the adjusted model. We investigated the interaction be-
tween antioxidants and smoking in the same manner to see whether 
antioxidants were more strongly associated with cognition in smokers, in 
whom the increased free radical load may lead to an increased need for 
antioxidants. 24 All tests were two-sided and a p-value of less than 0.05 
was considered to be statistically significant. We used SAS-program ver-
sion 6.09 software in the analyses.25 
Results 
Description of the sample 
The median MMSE score was 27 (10th centile: 22, 90th centile: 29). 
Twenty-two percent of subjects currently smoked. Mean energy intake 
decreased from 9,668 ± 2,078 kJ in 1985 to 8,858 ± 1,951 kJ in 1990. 
Fifty-two subjects (11%) used vitamin C supplements in 1985 or 1990, 
and seven subjects (1%) used vitamin E supplements. Eighty-six percent 
of the men consumed fish. 
Cognitive impairment 
Thirty-two percent of the subjects were cognitively impaired in 1990 
(MMSE score :$; 25). Subjects with cognitive impairment were 0lderl9 
and concluded less years of education (data not shown). To determine 
whether cognitive impairment altered dietary intake, we investigated the 
change in nutrients of interest from 1985 to 1990 in subjects who were 
cognitively impaired in 1990 and in those who were unimpaired. We 
found no significant differences in change in total energy and PUFA 
intake between these two groups (table 1) or in change in antioxidant 
intake (data not shown). The 1985-1990 average intakes of total fat, 
PUFAs and linoleic acid were higher in subjects with cognitive impair-
ment, while total energy, fish, EPA, and DHA intakes were lower (table 
2). 
Cognitive impairment was associated with high linoleic acid intake, 
after adjustment for potential confounding (table 3). The intake of n-3 
PUFAs was not independently related to cognitive impairment. Com-
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Table 1 
Mean change (SO) in daily intake of selected nutrients and fish from 
1985 to 1990 by level of cognitive function. 
Total energy (kJ) 
n-6 PUFA: 
Linoleic acid (en%) 
n-J PUFA: 
EPA (mg) 
OHA (mg) 
Fish (g) 
Cognitive function in 1990 
Normal' Impairedt 
(n = 323) (n = 153) 
-196.7 (447.9) -172.9 (427.8) 
0.65 (2.77) 
-1504 (189.0) 
-19.6 (224.2) 
-1.54 (21.66) 
1.02 (3.36) 
10.5 (149.8) 
10.7 (173.5) 
-3.13 (22.61) 
PUFA = polyunsaturated fatty acids 
EPA = eicosapentaenoic acid 
OHA = docosahexaenoic acid 
• MMSE score> 25 
t MMSE score :0; 25 
:j: Mann-Whitney test 
p:j: 
0.7 
0.3 
0.6 
0.7 
0.8 
pared with no fish consumption, fish consumption of more than 20 
grams per day was inversely associated with cognitive impairment in the 
crude analysis (odds ratio (OR) = 0.43, 95% confidence interval (CI) 
0.23-0.78, p-trend = 0.004). This association was weakened after adjust-
ment (OR = 0.63, 95% CI 0.33-1.21, p-trend = 0.13). There was no 
relationship between cognitive function and intake of any of the anti-
oxidants. The results reported above did not change essentially after 
exclusion of subjects with stroke or myocardial infarction (n=83). Like-
wise, the results did not change either when we excluded subjects who 
were on a prescribed diet in 1990 (18%). There were no significant in-
teractions between linoleic acid intake and any of the antioxidants, nor 
between antioxidants and smoking (p > 0.1). 
Cognitive decline 
The 3-yr decline in MMSE score was studied in 342 men who took 
part in both examination years. Participants did not differ from nonpar-
ticipants in nutrients of interest, except in vitamin C intake in 1990, 
which was lower in the 1993 nonparticipants (mean intake 87.3 mg ver-
sus 98.6 mg, p-value = 0.03). The baseline MMSE score was lower in 
the nonparticipants as well (median MMSE score 26 versus 27, p-value 
= 0.005). The associations between the nutrients of interest and cogni-
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Table 2 
Mean (SD) daily intake" of selected nutrients and fish by level of 
cognitive function. 
Cognitive function in 1990 
Normal t Impaired * 
(n = 323) (n = 153) 
Energy (kJ) 9,364 0,774) 8,975 0,799) 
Total rat (en%) 38.8 (5.6) 40.0 (5.1) 
Saturated fat (en%) 16.7 (3.1) 16.8 (2.5) 
MUFA (en%) 14.3 (2.8) 14.7 (2.6) 
PUFA (en%) 6.5 (2.5) 7.3 (2.7) 
n-6 PUFA: 
Linoleic acid (en%) 5.4 (2.5) 6.1 (2.8) 
n-J PUFA: 
EPA (mg) 88.2 037.2) 78.6 (129.6) 
DHA (mg) 103.0 (156.8) 89.5 (147.6) 
Fish (g) 18.8 08.4) 14.9 05.7) 
Antioxidants: 
Beta-carotene (mg) 1.42 (0.52) 1.42 (0.61) 
Vitamin C (mg) 97.3 (40.4) 96.9 (38.9) 
Vitamin E (mg) 8.49 (2.23) 8.44 (2.03) 
Flavonoids (mg) 26.8 (12.9) 26.6 (10.8) 
p§ 
0.03 
0.02 
0.6 
0.2 
0.002 
0.006 
0.1 
0.05 
0.02 
0.6 
0.9 
0.7 
0.6 
MCFA = monounsaturated fatty acids; PCFA = polyunsaturated fatty 
acids; EPA:;;: eicosapentaenoic acid; DHA = docosahexaenoic acid 
• Average of intake in 1985 and 1990 
t MMSE score > 25 
:j: MMSE score S; 25 
§ Mann-Whitney test 
tive impairment in 1990 were not different for the nonparticipants com-
pared with the participants. 
Mean 3-yr decline in MMSE score was 0.27 (standard deviation = 
2.62). Fifteen percent of the men (n=51) showed a decline of more 
than two points. After adjustment for possible confounding factors there 
was no association between linoleic acid intake and cognitive decline 
(table 4). Fish consumption was inversely but not significantly associated 
with cognitive decline (adjusted OR = 0.45, 95% CI 0.17-1.16, p-trend = 
0.09). Vitamin C intake was positively related to decline of cognitive 
function (table 4). All results were essentially the same when subjects 
who were on a prescribed diet (18%) were excluded from the analyses. 
To examine whether the mechanism behind the observed associations 
was more acute (i.e. thrombosis) we performed an analysis with 1990 
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Table 3 
Adjusted odds ratios for the association between nutrient intake* and 
prevalent cognitive impairmentt in 476 men. 
Teetiles 
Daily intake Low Medium High p-trend 
Linoleic acid (g) Range 2.S-9.3 9.3-15.3 15.3-4S.7 
OR :j: 1.00 1.23 1.76 
(0.73-2.07) (1.04-3.01) 
N-3 Fatty acid§ (mg) Range 0-37.5 37.5-155.5 155.5-2110.5 
OR 1.00 1.09 0.96 
(0.65-1.S0) (0.57-1.62) 
Beta-carotene (mg) Range 0.55-1.14 1.14-1.54 1.54-4.S1 
OR 1.00 0.S7 1.26 
(0.52-1.47) (0.76-2.09) 
Vitamin C (mg)'l< Range IS.0-74.4 74.4-IOS.8 IOS.S-295.6 
OR 1.00 1.00 1.19 
(0.60·1.65) (0.71-1. 97) 
Vitamin E (mg)¥j[ Range 3.3-7.5 7.5-9.1 9.1-17.5 
OR 1.00 1.19 1.40 
(0.69-2.07) (0.71-2.77) 
Flavonoids (mg) Range 2.4-20.7 20.7-30.0 30.0-96.1 
OR 1.00 1.50 1.44 
(0.90-2.4S) (0.S6-2.41) 
*' Average of intake in 1985 and 1990, categorized into tertiles 
t MMSE 1990 with score > 25 as reference 
0.04 
0.9 
0.4 
O.S 
0.3 
0.2 
* Odds ratio (95% CI), adjusted for age, education, cigarette smoking, alcohol 
and energy intake 
§ Eicosapentaenoic acid and docosahexaenoic acid 
IfcVitamin C and E supplement users were assigned to the highest tertile 
'1Also adjusted for polyunsaturated fatty acids 
diet and cognitive decline from 1990 to 1993. The results for fish or for 
the other nutrients did not change. 
In addition, we investigated the incidence of cognitive impairment 
at three years of follow-up by excluding subjects with cognitive impair-
ment at baseline (1990. n ~ 105/342). High linoleic acid intake was as-
sociated with an increased risk of becoming cognitively impaired 
(adjusted OR ~ 2.57. 95% CI 1.05-6.27. p-trend ~ 0.04). For fish the 
risk was similar to the risk of cognitive decline. 
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Table 4 
Adjusted* odds ratios (95% confidence interval) for the association 
between nutrient intaket and risk of cognitive decline* (1990-1993) in 342 
men. 
TertHes 
Daily intake Low Medium High e-trend 
Linoleic acid (g) 1.00 0.95 LOS 0.9 
(0.45-2.05) (0.49-2.27) 
N-3 Fatty acid§ (mg) 1.00 0.85 0.78 0.5 
(0.40-1.82) (0.35-1.73) 
Beta-carotene (mg) 1.00 0.83 0.67 0.3 
(0.39-1. 77) (0.30-1.48) 
Vitamin Col< (mg) 1.00 1.42 2.02 0.09 
(0.62-3.25) (0.90-4.52) 
Vitamin E¥JI (mg) 1.00 1.13 1.20 0.7 
(0.48-2.62) (0.43-3.31) 
Flavonoids (mg) 1.00 0.89 0.86 0.7 
(0.41-1.93) (0.39-1.89) 
1= Adjusted for age, education, cigarette smoking, alcohol, energy intake and 
baseline MMSE score 
t Average of intake in 1985 and 1990, categorized into tertHes 
* >2 points decline in the MMSE score 
§ Eicosapentaenoic acid and docosahexaenoic acid 
~Vitamjn C and E supplement users were assigned to the highest tertile 
'IIAlso adjusted for polyunsaturated fatty acids 
Discussion 
Our data suggested that high linoleic acid intake was associated with 
cognitive impairment. High fish consumption was inversely associated 
with cognitive impairment and decline in the univariate analysis, al-
though this was weakened after adjustment for confounding. None of 
the antioxidants we investigated were inversely related to cognitive im-
pairment. These results could not be explained by differences in age, 
education, smoking behavior, alcohol or energy intake. 
Linoleic acid and fish 
We found a positive association between intake of linoleic acid and 
cognitive impairment. The most important food groups tha~ predicted 
absolute intake of linoleic acid in this population were margarines (with 
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AD gr linoleic acid added), butter, baking fats, sauces, and cheese. 
Studies have shown that replacement of saturated fatty acid intake by 
linoleic acid decreases serum total and LDL cholesterol concentrations26 
and that linoleic acid intake is inversely related to coronary heart dis-
ease.27 On the other hand, high linoleic acid intake may increase the 
susceptibility of LDL to oxidation, which makes it more atherogenic.S•7 
However, the association between linoleic acid and atherosclerosis is not 
consistent. Some studies show an inverse association28, some a positive 
association29-3l , and others no association.32,33 OUf findings are consistent 
with the hypothesis that linoleic acid is atherogenic. Apart from the role 
of oxidation in atherogenesis, several in vitro and in vivo studies have 
shown that free radicals may increase vasogenic edema after cerebral 
ischemia and that they may aggravate the neurological consequences of 
ischemia, which could increase the risk of vascular related cognitive Iffi-
pairment.34,35 The association between linoleic acid and cognitive im-
pairment was not modified by any of the antioxidants, including the 
relatively high correlated vitamin E (r=0.6). 
We did not observe an association between linoleic acid intake and 
cognitive decline. This may be due to regression toward the mean36; 
subjects with the lowest MMSE scores, and also the highest linoleic 
acid intake, in our sample will on average have a smaller decline. Fur-
thermore, the mechanisms by which linoleic acid may affect cognitive 
function could be more chronic, in which case a follow-up period of 
three years would be too short. Theoretically, cognitive impairment 
could have led to a high linoleic acid intake. It is conceivable that 
subjects with cognitive impairment have a higher prevalence of cardio-
vascular disease and therefore might have changed their diet, favoring 
linoleic acid above saturated fatty acids. However, exclusion of subjects 
who were on a prescribed diet or of subjects with a history of stroke or 
myocardial infarction did not change the results. Moreover, confining the 
analyses to subjects with normal cognitive function at baseline (1990) 
showed a significantly increased risk of becoming cognitively impaired 
for subjects with high linoleic acid intake, which is consistent with the 
analyses on cognitive impairment. 
A diet with a high intake of n-3 PUFAs or fish may reduce the 
risk of thrombosis. II In addition, n-3 PUFAs are important for the de-
velopment of the brain and play a role in the functioning of cerebral 
membranes. Several studies on infants have suggested that breastfeeding, 
which leads to higher DHA concentrations in the brain, or supplemen-
tation with DHA, is related to better cognitive performance at later 
age.37-39 An inverse association between fish consumption and cognitive 
impairment and decline was suggested by our results. However, we 
found no association between the n-3 PUFAs, EPA and DHA, and 
cognitive function, despite the fact that consumption of even small 
amounts of fish has been shown to be reflected in the concentration of 
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plasma phospholipid EPA and DHA.4o Possibly, other nutrients than the 
n-3 PUFAs in fish play a role in the protection against cognitive im-
pairment, such as selenium, which has antioxidant properties.41 Or 
maybe non-fish eaters are different in factors that are related to cogni-
tive impairment. 
Antioxidants 
We observed no protective effect from any of the antioxidants on cog-
nitive impairment or decline. In contrast, vitamin C was associated with 
a higher risk of cognitive decline. We found no interaction between 
antioxidants and smoking. This study may be too small to examine in-
teraction, and we suggest that larger studies examine this issue. Most 
studies that have investigated the association between antioxidants and 
cognition have been cross-sectional. They found no clear association of 
vitamin E and C to dementia42,43 and an inverse association between a 
high intake of beta-carotene and cognitive impairment.44 In the cohort 
of the Honolulu Heart Program users of vitamin E, C and multivitamin 
supplements four years prior performed better on cognitive tests.4S Two 
intervention studies on geriatric patients found improvement of cognitive 
capacities after one year of supplementation with a mixture of antioxi-
dants.41 ,46 
In the present study the intake of antioxidants was relatively low 
and only a few people used supplements. The positive association be-
tween vitamin C and cognitive decline did not change appreciably after 
exclusion of subjects who used a prescribed diet. Stroke and myocardial 
infarction were more prevalent in subjects with the highest vitamin C 
intake, but exclusion of these subjects did not alter the results. Perhaps 
unknown and unmeasured confounding factors account for this associa-
tion. However, it is possible that vitamin C behaves as a pro-oxidant in 
the presence of free iron47, which is highly concentrated in the brain. 
Methodological considerations 
Habitual food intake of the participants was assessed with the cross-
check dietary history method. The validity and reproducibility of this 
method have been well described. ls,48 The average intake between 1985 
and 1990 was used to obtain a more reliable estimate of the diet during 
the five years prior to measurement of cognitive function. Nevertheless, 
differential misclassification could have influenced the results, because 
subjects with poor cognitive function might give less precise information 
on their food intake.49 This could either lead to overestimation or un-
derestimation of the association between diet and cognitive function. 
Yet, we found that change in dietary intake from 1985 to 1990 Was not 
different in subjects who were cognitively impaired in 1990 compared 
with those who were unimpaired. Still, we can not be completely sure 
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that cogntttve impairment did not alter (the report of) dietary intake, 
because subjects could already have been impaired in 1985. 
The Mini-Mental State Examination was used to assess cognitive 
function. It has proven to be a reliable and valid indicator of cognItive 
impairment, with a test-retest reliability generally between 0.80 and 
0.95.22 The MMSE can measure a substantial decline in cognitive func-
tion that may result from a strong risk factor, such as the apolipoprotein 
e4 allele.50 Nevertheless, dietary risk factors may be associated with 
small effects on cognitive decline, which may not be detected with the 
MMSE.51 
It could be argued that selective participation may have affected 
the validity of our results. Subjects who did not participate in 1993 had 
a significantly lower baseline MMSE score and a lower vitamin C intake 
than subjects who did participate. However, the cross-sectional associa-
tion between cognitive function and intake of vitamin C or other nutri-
ents in 1990 was essentially the same for the nonparticipants and the 
participants. Thus, it is unlikely that selection bias accounted for our 
results. 
In conclusion, this study raises the possibility that high linoleic acid 
intake is positively and high fish consumption inversely associated to 
cognitive impairment in elderly meo. None of the antioxidants were 
protective. Because this is one of the first studies on this subject cau-
tion is called for in the interpretation of our findings. Modest associa-
tions are difficult to detect with dietary data in a relatively small study. 
Our findings therefore need confirmation in large prospective studies, 
preferably with a longer follow-up period, or using a more sensitive 
measure of cognitive decline. 
References 
1. Bots ML, Swieten JC van, Breteler 
lesions and atherosclerosis in 
1993;341:1232-7. 
MMB, et al. Cerebral white matter 
the Rotterdam Study. Lancet 
2. Wilhelmsen L, Svrdsudd K, Korsan-Bengtsen K, et al. Fibrinogen as a 
risk factor for stroke and myocardial infarction. NEJM 1984;311:501-5. 
3. Breteler MMB, van Swieten JC, Bots ML, et al. Cerebral white matter 
lesions, vascular risk factors, and cognitive function in a population-
based study: The Rotterdam Study. Neurology 1994;44:1246-52. 
4. Erkinjuntti T, Hachinski VC. Rethinking vascular' dementia. 
Cerebrovasc Dis 1993;3:3-23. 
5. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in 
atherogenesis. J Clin Invest 1991;88:1785-92. 
Polyunsaturated fatty acids, antioxidants, and cognitive function 19 
6. Reaven PD, Grasse BJ, Tribble DL. Effects of Iinoleate-enriched and 
oleate-enriched diets in combination with alpha-tocopherol on the 
susceptibility of LDL and LDL subfractions to oxidative modification 
in humans. Arterioscler Thromb 1994; 14:557 -66. 
7. Abbey M, Belling GB, Noakes M, et al. Oxidation of low-density 
lipoproteins: intra individual variability and the effect of dietary 
Iinoleate supplementation. Am J Clin Nutr 1993;57:391-8. 
8. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E 
consumption and the risk of coronary disease in women. N Engl J 
Med 1993;328: 1444-9. 
9. Rimm EB, Stamp fer MJ. Ascherio A, et al. Vitamin E consumption 
and the risk of coronary heart disease in men. N Engl J Med 
1993;328: 1450-6. 
10. Hertog MGL, Feskens EJM, Hollman PCH, et al. Dietary antioxidant 
flavonoids and risk of coronary heart disease. The Zutphen Elderly 
Study. Lancet 1993;342:1007-11. 
11. Kinsella JE, Lokesh B, Stone RA. Dietary n-3 polyunsaturated fatty 
acids and amelioration of cardiovascular disease: possible mechanisms. 
Am J Clin Nutr 1990;52:1-28. 
12. Feskens EJM, Weijenberg MP, Kromhout D. A longitudinal study on 
diet, risk factors and cardiovascular disease in an aging cohort: the 
Zutphen Study. Neth J Cardiol 1993;4:200-4. 
13. Keys A, Aravanis C, Blackburn HW, et al. Epidemiological studies 
related to coronary heart disease: characteristics of men aged 40-59 in 
seven countries. Acta Med Scand (Suppl) 1967;460:1-392 
14. Burke BS. The dietary history as a tool in research. J Am Diet Assoc 
1947;23:1041-6. 
15. B10emberg BPM, Kromhout D, Obermann-De Boer GL, et al. The 
reproducibility of dietary intake data assessed with the cross-check 
dietary history method. Am J Epidemiol 1989;130:1047-56. 
16. Hepburn FN, Exler J, Weihrauch JL. Provisional tables on the content 
of omega-3 fatty acids and other fat components of selected foods. J 
Am Diet Assoc 1986;86:788-93. 
17. Liu K, Stamler J, Dyer A, et al. Statistical methods to assess and 
minimize the role of intra-individual variability in obscuring the 
relationship between dietary lipids and serum cholesterol. J Chron Dis 
1978;31:399-418. 
18. Folstein MF, Folstein SE, McHugh PRo 'Mini-Mental State'. A 
practical method for grading the cognitive state of patients for the 
clinician. J Psychiatr Res 1975;12:189-98. 
19. Kalmijn S, Feskens EJM, Launer LJ, et al. Glucose intolerance, 
hyperinsulinaemia and cognitive function in a general population of 
elderly men. Diabetologia 1995;38:1096-1102. 
20. Launer LJ. Overview of incidence studies of dementia conducted in 
Europe. Neuroepidemiology 1992;11(1 Suppl):2-13. 
20 NUTRITION AND COGNITION 
21. Fillenbaum GG, George LK, Blazer DG. Scoring nonresponse on the 
Mini-Mental State Examination. Psychol Med 1988;18:1021-5. 
22. Siu AL. Screening for dementia and investigating its causes. Ann 
Intern Med 1991;115:122-32. 
23. Launer LJ, Feskens EJM, Kalmijn S, Kromhout D. Smoking, drinking, 
and thinking. The Zutphen Elderly Study. Am J Epidemiol 
1996;143:219-27. 
24. Duthie GG, Arthur JR, Beattie JAG, et al. Cigarette smoking, 
antioxidants, lipid peroxidation, ahd coronary heart disease. Ann New 
York Acad Sci 1993;686:120-9. 
25. SAS Institute Inc. SAS/STAT Gser's Guide. Release 6.09. Cary NC: 
SAS Institute Inc., 1993. 
26. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids 
and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb 
1992;12:911-919. 
27. Wood DA, Riemersma RA, Butler S, et al. Linoleic and 
eicosapentaenoic acids in adipose tissue and platelets and risk of 
coronary heart disease. Lancet 1987;January 24:177-182. 
28. Tell GS, Evans GW, Folsom AR, et al. Dietary fat intake and carotid 
artery wall thickness: the Atherosclerosis Risk in Communities (ARIC) 
Study. Am J Epdimiol 1994;139:979-989. 
29. Blankenhorn DH, Johnson RL, Mack WJ, et al. The influence of diet 
on the appearance of new lesions in human coronary arteries. JAMA 
1990;263:1646-52. 
30. Hodgson JM, Wahlqvist ML, Roxall JA, et al. Can linoleic acid 
contribute to coronary artery disease? Am J Clin Nutr 1993;58:228-34. 
31. Kok FJ, van Poppel G, Meise J, et al. Do antioxidants and 
polyunsaturated fatty aCids have a combined association with coronary 
atherosclerosis? Atherosclerosis 1991 ;31 :85-90. 
32. Watts GF, Jackson P, Mandalia S, et al. Nutrient intake and 
progression of coronary artery disease. Am J Cardiol 1994;73:328-32. 
33. Foley JB, Younger K, Foley 0, et al. Lipids and fatty acids and their 
relationship to restenosis. Cathet Cardiovasc Diagn 1992;25:25-30. 
34. Hall ED, Braughler JM. Central nervous system trauma and stroke. II. 
Physiological and pharmacological evidence for involvement' of oxygen 
radicals and lipid peroxidation. Free Radic Bioi 1989;6:303-13. 
35. Siesj BK, Agardh CoD, Bengtsson F. Free radicals and brain damage. 
Cerebrovasc Brain Metab Rev 1989;1:165-211. 
36. Hannan PJ, Jacobs DR Jr, McGovern P, et al. Estimating 'the effects 
of regression toward the mean under stochastic censoring. Am J 
Epidemiol 1994;139:422-31. 
37. Makrides M, Neumann MA, Byard RW, et al. Fatty acid composition 
of brain, retina, and erythrocytes in breast- and formula-fed infants. 
Am J Clin Nutr 1994;60:189-94. 
Polyunsaturated fatty acids. antioxidants, and cognitive function 21 
38. Lanting CI, Fidler V, Huisman M, et al. Neurological differences 
between 9-year-old children fed breast-milk or formula-milk as babies. 
The Lancet 1994;344:1319-22. 
39. Agostoni C, Riva E, Trojan S, et al. Docosahexaenoic acid status and 
developmental quotient of healthy term infants. [letter] Lancet 
1995;346:638. 
40. Bonaa KH, Bjerve KS, Nordoy A. Habitual fish consumption, plasma 
phospholipid fatty acids, and serum lipids: the Tromso Study. Am J 
Clin Nutr 1992;55:1126-34. 
41. Tolonen M, Halme M, Sarnass S. Vitamin E and selenium 
supplementation in geriatric patients. Bioi Trace Elem Res 1985;7:161-
8. 
42. Broe GA, Henderson AS. Creasey H, et al. A case-control study of 
Alzheimer's disease in Australia. Neurology 1990;40: 1698-1707. 
43. Burns A, Marsh A, Bender DA. Dietary intake and clinical, 
anthropometric and biochemical indices of malnutrition in elderly 
demented patients and non-demented subjects. Psychol Med 
1989;19:383-91. 
44. Warsama n, Launer LJ, Witteman JCM, et al. Dietary anti-oxidants 
and cognitive function in a population-based sample of older persons: 
the Rotterdam Study. Am J Epidemiol 1996;144:275-80. 
45. Masaki KH, White LR, Petrovitch H, et al. The influence of prior 
and concurrent use of aspirin and vitamins on cognitive function scores 
in elderly Japanese-American men [abstract]. Neurobiology of aging 
1994;15(1 Suppl):S74. 
46. Clausen J, Nielsen SA, Kristensen M. Biochemical and clinical effects 
of an antioxidative supplementation of geriatric patients. A double 
blind study. Bioi Trace Elem Res 1989;20:135-151. 
47. Heikkila RE. Ascorbate-induced lipid peroxidation and the binding of 
[3H]dihydroalprenolol. Eur J Pharmacol 1983;93:79-85. 
48. Block G. A review of validations of dietary assessment methods. Am J 
Epidemiol 1982;115:492-505. 
49. Staveren WA van, Groot LCPGM de, Blauw YH, et al. Assessing diets 
of elderly people: problems and approaches. Am J Clin Nutr 
1994;59(Su ppl):221 S-3S. 
50. Feskens EJM, Havekes LM, Kalmijn S, et al. Apolipoprotein e4 allele 
and cognitive decline in elderly men. Br Med J 1994;309: 1202-6. 
51. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: a 
comprehensive review. J Am Geriatr Soc 1992;40:922-35. 

DIETARY FAT INTAKE 
AND THE RISK OF 
DEMENTIA 
The Rotterdam Study 
Abstract 
A high intake of saturated filt and cholesterol and a 10IY intake of 
polyunsaturated filtty acids have been related to an increased risk of 
cardiovascular disease. Cardiovascular disease has been associated with 
dementia. We investigated the association between filt intake and 
incident dementia among participants, age 55 years or a/del; from the 
population-based prospective Rotterdam Study. Food intake of 5,386 
nondemented participants was assessed at baseline with a semi-
quantitative food-ffequency questionnaire. At baseline and after an 
average of 2.1 years of follow-up, we screened for dementia with a 
three-step protocol that included a clinical examination. The risk of 
dementia at follow-up (RR (95% CI)) was assessed with logistic regres-
sion. After adjustment for age, sex, education, and energy intake, high 
intakes of the following nutrients were associated with an increased risk 
of dementia: total filt (RR~2.4 (1.1-5.2)), saturated filt (RR~1.9 (0.9-4.0)), 
and cholesterol (RR~1.7 (0.9-3.2)). Dementia with a vascular component 
was most strongly related to total filt (p-trend~0.02) and saturated filt 
(p-trend~O.Ol). Fish consumption, an important source of n-3 
polyunsaturated filtty acids, was inversely related to incident dementia 
(RR~O.4 (0.2-0.9)), and in particular to Alzheimer's disease (RR~0.3 (0.1-
0.9)). This study suggests that a high saturated filt and cholesterol 
intake increases the risk of dementia, whereas fish consumption may 
decrease this risk. 
23 
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Introduction 
As the population includes a growing proportion of older people, de-
mentia wi1l become an increasing burden to society and the individual. 
Therefore, research on potentially modifiable risk factors, such as diet, is 
of enormous relevance. Few studies have reported on the relation be-
tween diet and dementia,t-3 Because the study designs were 
cross-sectional and the demented subjects were usually nursing-home 
residents, it was difficult to ascertain whether their diet was the cause 
Of consequence of dementia. 
In this study, we focused on different components of fat intake, 
including total fat, saturated fat, cholesterol and polyunsaturated fatty 
acids (PUFAs). Saturated fat and cholesterol may increase the risk of 
dementia, because they are associated with adverse cardiovascular 
events.4-6 These events, in turn, have been related to both vascular 
dementia and Alzheimer's disease. 7-1O On the other hand, n-3 PUFAs, 
which have anti thrombotic effects", and n-6 PUFAs, which have a 
beneficial effect on the lipid profileI2.13, may reduce the risk of demen-
tia. We examined the association between fat intake and (subtypes of) 
dementia in a prospective population-based study, in which dietary data 
were collected at baseline before the onset of dementia. 
Methods 
Study population 
We used data from the Rotterdam Study, which is a single-center pro-
spective population-based study, designed to investigate determinants of 
selected chronic diseases and disabilities in older persons. 14 The conduct 
of the study was approved by the Medical Ethics Committee of the 
Erasmus University and written consent was obtained from all partici-
pants. All residents of a suburb in Rotterdam, age 55 years or older, 
were invited and of the 10,275 eligible subjects, 7,983 (78%) agreed to 
participate. During a home visit, trained interviewers administered a 
questionnaire, covering, among other areas, sociodemographic background, 
medical history, and medication use. This was followed by two clinical 
examinations at the research center. Subjects living in nursing homes 
were visited at home. The food-frequency questionnaire was included in 
the baseline examinations after the pilot phase, and offered to inde-
pendently living subjects, who underwent additional clinical examinations 
(n=6,250). As part of the protocol, subjects who scored below 80 points 
on the CAMCOOIS (n=122), which is the neuropsychological test admin-
istered in the case-finding procedure for dementia, were excluded be-
cause they were thought to be unable to provide reliable answers re-
Dietary fat intake and the risk of dementia 25 
garding their food patterns. Furthermore, 482 unselected subjects did 
not receive a dietary questionnaire due to logistic reasons, and 212 re-
spondents were excluded from the sample because of logical inconsis-
tencies in the dietary interviews, resulting in 5,434 completed question-
naires. Baseline data were collected from May 1990 to June 1993. F 01-
low-up data were obtained until December 1994. Incident dementia was 
ascertained in two ways; i.e., on the basis of a study examination in 
those attending the follow-up visit, or from medical records if the sub-
ject refused reexamination or had died before reexamination. 
Dietary intake 
Dietary intake was assessed with a 170-item semiquantitative food-fre-
quency questionnaire, which is a modified version of a reliable and 
valid questionnaire. 16,17 Modifications of the original questionnaire in-
cluded a different mode of administration and the addition of more de-
tailed questions on vegetable, fruit, and meat consumption. The ques-
tionnaire was administered in two stages. In the first stage, respondents 
were asked to report foods consumed regularly (at least twice a month) 
in the last year. This took place at home. The second stage was com-
pleted during the second visit to the research center. After a review of 
the checked food items, a trained dietician asked the respondent how 
much and how often each food item was consumed. The whole proce-
dure was completed in 40 minutes. Average daily nutrient intake was 
calculated by multiplying the frequency and amount consumed for each 
food item by its nutrient content listed in an automated version of the 
Dutch Food Composition Table. ls We used linoleic acid intake as a 
marker of n-6 PUFA intake, because it is the most important n-6 
PUFA in Western populations,13 The intake of the n-3 PUFAs eicosa-
pentaenoic acid and docosahexaenoic acid was estimated by fish con-
sumption, since fish is their main source. 
Dementia casefinding 
Case-finding procedures for dementia have been described elsewhere. 19 
As in the baseline examination, the follow-up study examination con-
sisted of a three-stage procedure. First, all participants were screened 
with the 30-point Mini-Mental State Examination (MMSE)20 and the 
short version of the Geriatric Mental State schedule (GMS-A, organic 
level).21 Subjects with an MMSE score below 26, or a GMS score 
greater than 0 were considered screen positive. They were subsequently 
examined with the Cambridge Mental Disorders of the Elderly Exami-
nation (CAMDEX), which included an informant interview. IS Participants 
who were judged to be demented or suspected of dementia after the 
CAMDEX were examined by a neurologist and tested by a neuropsy-
chologist; a part also underwent magnetic resonance imaging of the 
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brain. Additional information for those who did not complete the diag-
nostic phase was obtained from the general practitioner, the regional 
institute for outpatient mental health carc, and specialist medical files. 
Diagnosis of Alzheimer's disease (AD) was based on NINCDS-ADRDA 
criteria.22 Patients with this diagnosis had a gradually progressive global 
decline of cognitive functions for which no medical cause was found. 
Dementia patients with a history of stroke, who otherwise fulfilled AD 
criteria, were subclassified as AD with cerebrovascular disease. Vascular 
dementia was diagnosed in accordance with NINDS-AIREN criteria.23 
In these patients the onset of dementia was related to cerebrovascular 
disease. They generally had an acute onset of dementia symptoms with 
stepwise progression of the disease. DSM-III-R criteria were used to 
classify other dementias.24 
Other measurements 
The following variables were considered as possible confounding vari-
ables: age, sex, total energy intake, cigarette smoking (current, former, 
or never), alcohol consumption (none, <I drink (13.2g), 1-2 drinks, or 23 
drinks per day), fiber consumption, antioxidant intake, and level of edu-
cation (completed primary education; lower vocational training Of general 
education; intermediate vocational training or intermediate and higher 
general education; and higher vocational training, college, or university) 
(UNESCO). 
A history of cardiovascular disease at baseline, indicators of athero-
sclerosis, and total and high-density lipoprotein cholesterol were consid-
ered as possible mediators of the association between dietary factors and 
dementia. Data on medical history were obtained at the home interview. 
A history of myocardial infarction was considered present if the subject 
reported an event that was diagnosed by a physician and led to hospi-
talization. A history of stroke was considered present if a self-reported 
event was confirmed by either a detailed history, neuroimaging, or dis-
charge reports collected from the general practitioner or neurologist. 2S 
The following indicators of atherosclerosis were used: plaques in the 
carotid arteries} intima-media wall thickness of the carotid artery} and 
ankle-brachial index of systolic blood pressure. Measurement methods 
are extensively described elsewhere. 26 Wall thickness was measured in a 
relatively small but random subset of subjects (n~1935), and we restrict-
ed the analyses on atherosclerosis to this subset. 
Statistical analysis 
Complete information on diet, incidence of dementia, and confounding 
factors was available for 5,386 respondents. Mean daily nutrient intake 
in incident demented and non-demented subjects, and the difference 
(95% confidence intervals (CI» between the two groups, was obtained 
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Table I 
Baseline characteristics of participants who completed the food~ 
frequency questionnaire (n=5386): the Rotterdam Study 
Characteristics 
Mean age (yrs) 
Sex (men/women) 
Primary education only (%) 
Median baseline MMSE score (range) 
Mean alcohol consumption (~1 drink/day) (%) 
Current smokers (% It 
Former smokers (%)t 
History of stroke (%)* 
History of myocardial infarction (%)§ 
MMSE = Mini-Mental State Examination 
'* Standard deviation between parentheses 
t Information available for 5377 subjects 
* Information available for 5290 subjects 
§ Information available for 5321 subjects 
67.7 (7.8)' 
2204/3182 
1871 (34.7%) 
28 (16-30) 
1518 (28.2%) 
1256 (23.4%) 
2305 (42.9%) 
97 (1.8%) 
380 (7.1%) 
27 
from analysis of covariance, controlling for age. Because of the high cor-
relation between fat and total energy intake, energy-adjusted fat and 
fish intakes were calculated with the residual method.27 This method 
gives an estimation of the regression coefficient which is independent of 
total energy intake. Energy-adjusted intake of, for example, saturated fat 
was calculated as the summation of the residuals from regressing satu-
rated fat on total energy intake and a constant equal to the expected 
saturated fat intake at the level of the mean total energy intake. Ener-
gy-adjusted intakes of the nutrients of interest were grouped into terti-
les, with the lowest tertile as the reference group. 
We used multiple logistic regression analysis to estimate the relative 
risks (RR) for the associations between fat intake, fish consumption and 
incident dementia. We included confounding variables in the model. 
The p-value for linear trend was assessed by putting the categorical 
variable as a continuous variable in the model. We also investigated 
whether there was effect modification by sex or age by including the 
product terms of the nutrients with sex or age in the model. 
Results 
Baseline characteristics are given in Table I. Fifty-eight (1.1%) of the 
5,386 subjects became demented during follow-up (mean = 2.1 years 
(SO = 0.8»; 42 (72%) were classified as having AD (including five with 
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Table 2 
Age-adjusted mean daily intake of selected nutrients and fish according to 
incidence of dementia: the Rotterdam Study 
Dementia at follow-u~ 
Daily intake No Yes 
(5328) (58) 
Total energy (kJ) 8254 (28.8)' 8763 (278.5) 
Total fat (en%) 36.5 (0.08) 38.2 (0.82) 
Saturated fat (en%) 14.4 (0.04) 15.5 (0.42) 
Cholesterol (mg/MJ) 28.5 (0.10) 30.1 (0.99) 
Linoleic acid (en%) 5.7 (0.04) 5.3 (0.38) 
Fish (g) 15.8 (0.26) 10.9 (2.48) 
CI = confidence interval 
en% = intake as percentage of total energy intake 
'*' Standard error between parentheses 
Difference 
(95% CI) 
509 (-40. 1058) 
1.7 (0.1. 3.3) 
1.1 (0.3. 1.9) 
1.6 (-0.53. 3.44) 
-0.4 (-1.2. 0.3) 
-4.8 (-9.7. O.l) 
AD and cerebrovascular disease). seven (12%) as having vascular de-
mentia. and nine (16%) as having other types of dementia. Age-adjusted 
mean intake of total and saturated fat was higher. and fish consumption 
lower. in subjects with incident dementia (Table 2). 
Subjects in the highest tertiles of total fat. saturated fat and choles-
terol intake had an increased risk of dementia (RR = 2.4. 95%CI: 
1.1-5.2; RR = 1.9. 95%CI: 0.9-4.0; and RR = 1.7. 95%CI: 0.9-3.2. respec-
tively) (Table 3). 
High total and saturated fat intakes were most strongly associated 
with an increased risk of dementia with a vascular component (vascular 
dementia and AD with cerebrovascular disease). Fish consumption was 
associated with a reduced risk of dementia (RR = 0.4. 95%CI: 0.2-0.9) 
and especially of AD without cerebrovascular disease (Table 4). 
Linoleic acid was also associated with a lower risk of dementia, 
although not significantly (RR = 0.6. 95%CI: 0.3-1.2). These associations 
did not change after additional adjustment for cigarette smoking. alcohol 
consumption, fiber consumption, antioxidant intake, or serum total and 
high-density lipoprotein cholesterol. Entering the indicators of atheroscle-
rosis into the model did not change the associations. compared with the 
associations in the same subsamplc, but without atherosclerosis in the 
model (data not shown). Adjustment for stroke or myocardial infarction 
did not alter the results; neither did exclusion of subjects with a history 
of stroke or myocardial infarction or exclusion of subjects who were us-
ing a prescribed diet. 
Table 3. Risk of dementia according to tertiles of energy-adjusted fat intake estimated by multiple logistic regression: 
the Rotterdam Study 
AD without Dementia with a Total dementia 
cerebrovascular disease vascular component· (n=58) (n=37) (n=12) 
RR p- RR p- RR p-
n (95% CI) t trend (95% CI) t trend (95% CI) t trend 
Total fat (g/d) 
$75.5 1795 1.0 (ref) 1.0 (ref) 1.0 (ref) 
75.5-85.5 1768 2.1 (0.9-4.7) 1.8 (0.7-4.5) 1.7 (0.3-10.3) 
>85.5 1823 204 (Ll-5.2) 0.02 1.6 (0.6-3.9) 0.25 3.0 (0.6-14.7) 0.02 
Saturated fat (g/d) 
$29.0 1873 1.0 (ref) 1.0 (ref) 1.0 (ref) 
29.0-34.0 1653 1.8 (0.8-4.1) 1.8 (0.7-4.7) 1.0 (0.1-7.2) 
>34.0 1860 1.9 (0.9-4.0) 0.12 1.3 (0.5-3.3) 0.66 2.9 (0.6-13.8) 0.01 
Cholesterol (mg/d) 
$208.5 1808 1.0 (ref) 1.0 (ref) 1.0 (ref) 
208.5-254.5 1785 Ll (0.5-204) 1.2 (0.5-3.0) Ll (0.3-4.6) 
>254.5 1793 1.7 (0.9-3.2) 0.11 1.3 (0.6-3.1) 0040 0.9 (0.2-3.7) 0.80 
RR = relative risk; CI = confidence interval; ref. = reference category; AD = Alzheimer's disease 
.. Includes vascular dementia and Alzheimer's disease with cerebrovascular disease; other dementias are excluded 
from these analyses 
t Adjusted for age, sex, education. and total energy intake 
Table 4. Risk of dementia according to tertiles of energy-adjusted linoleic acid and fish intake estimated by multiple 
logistic regression: the Rotterdam Study 
Total dementia 
(n=S8) 
RR p-
n (9S% CI) t trend 
Linoleic acid (gld) 
59.S 1871 1.0 (ref) 
9.S8-IS.0 177S 1.2 (0.7-2.3) 
>IS.0 1740 0.6 (0.3-1.2) 0.23 
Fish (gld) 
53.0 1807 1.0 (ref) 
3.0-18.S 1773 0.8 (Q.4-1A) 
>18.S 1806 004 (0.2-0.9) 0.03 
AD without 
cerebrovascular disease 
(n=37) 
RR p. 
(9S% CI) t trend 
1.0 (ref) 
0.9 (0.4-1.9) 
0.7 (0.3-I.S) 
1.0 (ref) 
0.9 (0.4-1.8) 
0.3 (0.1-0.9) 
0.17 
O.OOS 
Dementia with a 
vascular component· 
(n=12) 
RR p-
(9S% CI) t trend 
1.0 (ref) 
1.0 (0.3-3.6 
004 (0.1-1.9) 
1.0 (ref) 
0.6 (0.2-2.S) 
0.7 (0.2-2.8) 
0.09 
0.39 
RR = relative risk; CI = confidence interval; ref = reference category; AD = Alzheimer's disease 
>II< Includes vascular dementia and Alzheimer's disease with cerebrovascular disease; other dementias are excluded 
from these analyses 
t Adjusted for age, sex, education, and total energy intake-
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Discussion 
This large follow-up study showed an association between dietary factors 
and incidence of dementia. High intakes of total fat, saturated fat, and 
cholesterol were related to an increased risk of dementia, and total and 
saturated fat in particular to dementia with a vascular component. Fish 
consumption was associated with a reduced risk of dementia, and most 
strongly with Alzheimer's disease. To our knowledge, this is the first 
prospective cohort study that investigated the association between fat 
intake and incident dementia. 
Some methodological problems of this study must be discussed. 
Dietary data collected from subjects who are cognitively impaired may 
be less reliable, because they may under- or overestimate their dietary 
intake, leading to differential misclassification.28 Subjects with dementia 
at follow-up may more often be cognitively impaired at baseline than 
those who were not demented at follow-up. It does not appear very 
likely, however, that they consistently overreported the consumption of 
foods with a high saturated fat and cholesterol content and underreport-
ed the consumption of fish. In addition, we attempted to reduce sys-
tematic reporting error by a priori excluding nursing-home residents, 
individuals with low baseline scores on the CAMCOG, and question-
naires with logical inconsistencies. This exclusion, on the other hand, 
increases the possibility of response bias. The incidence of dementia is 
more likely to have been higher in those who did not complete the 
dietary questionnaire, but it is not very likely that they also had a 
lower fat intake and a higher fish consumption. Therefore, response bias 
is not a plausible explanation for these findings. Another methodological 
problem would occur when subjects with incident dementia altered their 
food pattern at baseline, because of behavioral changes in pre-clinical 
stages of dementia. In our sample, however, subjects with incident de-
mentia performed relatively well at the baseline cognitive screening 
tests. Still, we can not fully exclude the possibility that these subjects 
changed their food pattern towards a higher consumption of high-fat 
foods and a lower consumption of fish. Finally, persons with prevalent 
cardiovascular disease may have altered their diet towards lower intake 
of saturated fat and cholesterol. Since they might also have a higher 
risk of dementia, this could have resulted in an underestimation of our 
estimates. However, the association between saturated fat or cholesterol 
and dementia did not change when we excluded subjects with cardio-
vascular disease or subjects using a prescribed diet. 
We found a borderline significant association of saturated fat and 
cholesterol intake with incident dementia. This association may have 
been mediated by cardiovascular disease. A high intake of saturated fat 
and cholesterol has been consistently associated with an increased risk 
of coronary heart disease4,s, and there are some data showing an asso-
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clatlOn between dietary saturated fat and cerebrovascular disease.6 Car-
diovascular disease has subsequently been related to dementia, especially 
vascular dementia,7-9 The hypothesis of a vascular mechanism is consis-
tent with the finding that a high saturated fat intake was most strongly 
related to dementia with a vascular component. Therefore, we expected 
that adjustment for cardiovascular disease would have attenuated our 
estimates, but it did not. The reason for this may be that we adjusted 
for cardiovascular disease at baseline, whereas it would have been opti-
mal to adjust for cardiovascular disease that developed during follow-up 
and before onset of dementia. Furthermore, only few subjects suffered 
from clinical stroke.25 Silent cerebrovascular disease, which may be an 
important intermediate as well, is thought to he at least four times 
more frequent than clinically recognized strokes. 29 We had information 
on indicators of atherosclerosis, but only in a relatively small su bset of 
subjects, and adjustment for them did not change the results either. 
This may have been due to measurement error, lack of power, or the 
fact that these indicators of atherosclerosis might not correlate exactly 
with subclinical lesions of the brain. 
The relation of a high-fat diet to dementia may also be related to 
other factors associated with socioeconomic status, such as lower educa-
tion, smoking, and alcohol consumption. Adjustment for these factors 
did not change our results, but we cannot exclude residual confounding. 
There may be alternative mechanisms; for instance, cholesterol may 
have a more direct effect on the brain. An experimental study in rab-
bits showed that -amyloid accumulated in a dose-dependent way in 
brains of rabbits fed a high-cholesterol diet.3o 
In the present study, a high linoleic acid intake was slightly, but 
not significantly, associated with a lower risk of dementia. Although 
some studies have suggested that linoleic acid may be atherogenic by 
increasing the oxidative modification of low-density lipoprotein choles-
terol3I , our result is compatible with a beneficial effect of linoleic acid 
on the lipid profile. I2 
Fish, as a marker of n-3 PUFAs in fish, was associated with a re-
duced risk of dementia, primarily of Alzheimer's disease, even at rela-
tively low levels of fish consumption. The results of the present study 
are similar to another study, in which we found an inverse association 
between a comparable fish consumption and the risk of cognitive im-
pairment and decline.32 A cross-sectional study in Norway indicated that 
increased plasma phospholipid levels of n-3 PUFAs were observed with 
a usual intake of one to two servings of fish per week.33 There are 
several biologically plausible mechanisms for the association between fish 
and Alzheimer's disease. First, fish may protect against dementia by re-
ducing the risk of cardiovascular disease.34,35 Among subjects with neu-
ropathological brain lesions typical for Alzheimer's disease, brain infarcts, 
and especially lacunar infarcts, more often resulted in clinical demen-
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tia. w In addition, results from the Rotterdam Study indicate that athero-
sclerosis is related to an increased risk of Alzheimer's disease.9 Our 
finding of a particular association with pure Alzheimer's disease may 
suggest a different mechanism as well. The n-3 PUFAs in fish have 
antiinflammatory properties; that is, they can decrease the production of 
proinflammatory cytokines in humans.36 Immune processes are believed 
to be involved in the pathogenesis of Alzheimer's disease. Increased 
concentrations of acute phase reactants and other markers of immune 
processes, such as cytokines, have been found in brain tissue of patients 
with Alzheimer's disease.37 In addition, interleukin-l may regulate the 
amyloid precursor protein synthesis, resulting in amyloid deposits.3B Epi-
demiological studies have suggested that the use of nonsteroidal anti-
inflammatory drugs reduced the risk of Alzheimer's disease.39 Finally, 
n-3 PUFAs also play a role in brain development and the functioning 
of nerve membranes4o, and they can still be incorporated in the brains 
of animals after the period of brain development.41 They may therefore 
be of importance in the regeneration of nerve cells.42 A human autopsy 
study showed that the PUFA content, including the n-3 PUFA docosa-
hexaenoic acid, was decreased in the hippocampus and frontal grey mat-
ter of Alzheimer's disease brains, whereas the fatty acid composition of 
normal aged brains was not altered.43 
In conclusion, this study suggests that a high saturated fat and 
cholesterol intake raises the risk of dementia, in particular of dementia 
with a vascular component. In addition, fish consumption may reduce 
the risk of dementia, and primarily of Alzheimer's disease. The associa-
tions we report here are biologically plausible. However, since this is 
the first prospective study examining the relation of dietary fat intake 
to the risk of dementia, additional epidemiological studies with a longer 
follow-up period are needed to address this issue. If these findings are 
replicated, they could have important implications for reducing the risk 
of dementia. 
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Part II 
Metabolism and cognition 

GLUCOSE INTOLERANCE, 
HYPERINSULINAEMIA, 
AND COGNITIVE IMPAIRMENT 
The Zutphen Elderly Study 
Abstract 
Chapter 
Cognitive impairment is highly prevalent among the elderly. Subjects 
with disturbances in glucose metabolism may be at risk for impaired 
cognitive function, as these disturbances can influence cognition through 
atherosclerosis, thrombosis and hypertension. We therefore studied the 
cross-sectional association of cognitive function to hyperinsuljnaemia, 
impaired glucose tolerance and diabetes in a population-based cohort of 
462 men, aged 69 to 89 years. Cognitive function was measured by the 
30-point Mini-Mental State Examination. Results were expressed as the 
rate ratio (95% confidence interval) of the number of erroneous answers 
given on the Mini-Mental State Examination by the index compared to 
the reference group. Compared to subjects with normal glucose 
tolerance, known diabetic patients had a rate ratio of 1.23 (1.04-1.46), 
newly diagnosed diabetic patients of 1.16 (0.91-1.48) and subjects with 
impaired glucose tolerance of 1.18 (0.98·1.41), after adjustment for con-
founding due to age, occupation and cigarette smoking (p-trend~O.Ol). 
Non-diabetic subjects in the highest compared to the lowest quartile of 
the area under the insulin curve had a rate ratio of 1.24 (1.03-1.50), 
after adjustment for confounding (p-trend~0.02). The results did not 
change appreciably when potentially mediating filCtors, including car-
diovascular diseases and risk f8ctors associated with the insulin resistance 
syndrome, were taken into account. These results suggest that diabetes 
mellitus, as well as impaired glucose tolerance and hyperinsulinaemia in 
non-diabetic subjects are associated with cognitive impairment. 
39 
40 METABOLISM AND COGNITION 
Introduction 
Cognitive impairment is an important component of dementia, and a 
major determinant of the quality of life. It is important to identify risk 
factors for cognitive impairment that are potentially modifiable. There is 
now substantial evidence that in addition to diabetes, impaired glucose 
tolerance and hyperinsulinaemia are also associated with atherosclerosis, 
thrombosis, and abnormal haemodynamic processes.'·4 All these processes 
may have an etiologic role in stroke and lacunar infarcts, which can 
subsequently lead to cognitive impairment and dementia. In addition, 
they are risk factors for white matter changes as seen on neufoimaging, 
which are associated with cognitive impairment,S 
Several clinical studies support the hypothesis that diabetes and 
hyperglycaemia may be related to reduced cognitive function.6-B How-
ever, little is known about the role of insulin in processes that may 
influence cognitive function. One study suggested, that among hyper-
tensives, hyperinsulinaemia increased the risk of cognitive impairment.9 
To our knowledge, no community-based studies have examined the re-
lation of cognitive function to diabetes mellitus, impaired glucose toler-
ance and hyperinsulinaemia. Therefore we examined these relations with 
data from the Zutphen Elderly Study. In addition we also assessed the 
role of possible mediators of this relation, including cardiovascular dis-
ease and risk factors associated with the insulin resistance syndrome. 
Methods 
Subjects 
The Zutphen Elderly Study is a longitudinal study of risk factors for 
chronic diseases in men. It is a continuation of the Zutphen Study, 
which was initiated in 1960 as the Dutch contribution to the Seven 
Countries Study.1O Zutphen is a small industrial town located in the 
eastern part of the Netherlands. Of the targeted 1266 men, 555 of 
whom were from the original cohort, born between 1900 and 1920, and 
711 of whom were randomly selected from all other men in the same 
age range living in Zutphen, 939 participated in 1985. In the Spring of 
1990, 544 of 718 (76%) surviving men were reexamined. Complete in-
formation on risk factors was available for 462 men in 1990, who 
formed the sample for the present cross-sectional analysis. 
Examinations 
An oral glucose tolerance test was performed according to World Health 
Organization guidelines" in subjects without known diabetes. In the 
morning, after an overnight fast, a blood sample was obtained and then 
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a glucose load of 75 g given. Blood samples were again taken after 1 
and 2 hours. Fasting glucose concentration was determined for subjects 
known to have diabetes mellitus. Samples were 'collected in tubes with 
sodium fluoride. Plasma glucose was determined with the hexokinase 
method. Serum insulin was measured with a radio-imm,une assay 
(Pharmacia Diagnostics, Uppsala, Sweden). Within- and between-run co-
efficients of variation ranged from 6 to 7%. The men were classified 
into three groups of glucose tolerance using the WHO criteria for dia-
betes and impaired glucose tolerance. II Diabetes was defined as a fast-
ing glucose concentration '?7.8 mmol/L or a 2-hour post-load glucose 
concentration '?11.1 mmol/L. Impaired glucose tolerance was defined as 
a fasting glucose concentration <7.8 mmol/L and a 2-hour post-load con-
centration between 7.8 and 11.1 mmol/L. Normal glucose tolerance was 
defined as both concentrations <7.8 mmol/L. In addition, a fourth group 
of known diabetic subjects was created on the basis of the medical in-
terview, independent of their fasting glucose measure. This group in-
cluded subjects who were treated with insulin, oral hypoglycaemic 
agents and diet. The area under the post-load glucose and the insulin 
curve was calculated with the trapezoidal rule «fasting concentration"30 
min) + (l-h concentration"60 min) + (2-h concentration"30 min». The 
area under the insulin curve correlated most strongly with I-hour post-
load insulin concentration (I-h: r=0.97, Z-h: r=0.71, fasting: r=0.71). 
Global cognitive function was tested with the Dutch version of the 
3D-point Mini-Mental State Examination (MMSE).12 The MMSE in-
cludes questions on orientation to time and place, registration, attention 
and calculation, recall, language and visual construction. Although this 
screening test was originally created for a clinical setting, it is extensive-
ly used in epidemiological studies, and has proven to be a reliable and 
valid indicator of cognitive impairment. 13,14 It was administered by two 
trained nurses in a controlled hospital setting. If the subject did not 
answer fewer than four individual items (of a total of 20) these were 
rated as errors (n=22) IS, except for items which could not be performed 
because of physical disability, in which case a weighted total score was 
given (n=lO). If a subject did not answer four or more individual items 
the total MMSE score was considered missing (n=5). We used a score 
of '?26 as cut-off point for unimpaired cognitive function, since cognitive 
impairment is not very likely above this point. We used a score of s23 
as an indicator of poor cognitive function, since this cut-off point has 
been shown to be indicative of dementia. 14 A score of either 24 or 25 
was called borderline cognitive function. 
Cardiovascular risk factors were obtained from a physical examina-
tion and a questionnaire, carried out by trained physicians. Body Mass 
Index (weight/height2) was calculated from height, measured to the 
nearest mm and body weight, recorded to the nearest 0.5 kg while the 
men Were in underwear. Systolic and diastolic (fifth Korotkoff phase) 
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blood pressure were measured with a random zero sphygmanometer in 
duplicate in the right arm in supine position. The mean of the two 
blood pressure values was used in the analyses. Hypertension was de-
fined as a systolic blood pressure greater than or equal to 160 mmHg or 
a diastolic blood pressure greater than or equal to 95 mmHg or the use 
of anti-hypertensive medication, regardless of blood pressure level. 16 
Fasting and non-fasting blood was obtained to determine the con-
centrations of lipoproteins and haemostatic factors. Non-fasting serum 
HDL cholesterol was determined enzymatically after precipitation of apo 
B containing particles by dextran sulphate-Mg2+17 by the standardized 
Lipid Laboratory at the Dept. of Human Nutrition, Wageningen Agri-
cultural University, Netherlands. Fasting triglyceride was determined en-
zymatically by the same laboratory using a test kit (Boehringer, Mann-
heim).18 Fibrinogen concentration was determined by the method of 
Clauss l9, in which the clotting time is measured in a solution of 
thrombin in constantly high concentration, added to diluted plasma. A 
standard curve is used to read the concentration of fibrinogen. Analyses 
were carried out at the Laboratory of the Dept. of Human Biology, 
University of Limburg, Maastricht, Netherlands. 
History of myocardial infarction, angina pectoris and intermittent 
claudication was obtained from the Dutch translation of a questionnaire 
developed at the London School of Hygiene and Tropical Medicine.20 A 
standardized history of stroke, transient ischemic attack and diabetes 
mellitus was also obtained. Medical records on all subjects, including 
ECGs, hospital discharge data and written information from general 
practitioners, were collected to verify diagnoses. Occupation was used as 
an indicator of intellectual capacity in this elderly Dutch population, 
that had a reduced access to education. Lifetime occupation was obtain-
ed from a self-administered questionnaire, and coded from class one 
(professionals, managers and teachers) to class four (manual workers). 
Finally, smoking habits were assessed by the physician, on the basis of 
a standardized questionnaire. 
Statistical analysis 
Nonparametric tests (Kruskall-Wallis) were used to compare continuous 
skewed variables and chi-square tests to compare categorical variables. 
The number of erroneous answers on the MMSE, defined as 30 minus 
the MMSE score, followed a Poisson distribution. Therefore, multiple 
Poisson regression was used to estimate the rate ratio (RR) of the 
number of erroneous answers on the MMSE in the index versus the 
reference group. Thus, an RR of 1.29 means that the number of erro-
neous answers on the MMSE in that group is on average 29% higher 
than in the reference group. Because of extra Poisson variation, the 
standard errors of the estimated betas were computed using the robust 
(i.e. independent of the Poisson assumption) method described by 
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RoyallZI , and used to calculate the 95% confidence intervals (GI). The 
SAS-program, version 6.09, was used.zz 
To examine the relation between glucose tolerance and cognitive 
function, we categorized subjects into normal and impaired glucose tol-
erance, and newly diagnosed and known diabetes, according to the 
WHO categories. For the analyses on insulin, subjects were categorized 
into quartiles of the area under the insulin curve, after excluding known 
and newly diagnosed diabetic patients, because insulin concentrations 
usually decline when a person becomes diabetic. which makes insulin 
levels difficult to interpret. Age. occupation, and cigarette smoking 
(current: yes/no) were added to the model to adjust for potential con-
founding. We examined whether the association changed after adjusting 
for possible mediating factors: those associated with the insulin resis-
tance syndrome (Body Mass Index, hypertension, HOL cholesterol, 
triglycerides, fibrinogen), and cardiovascular diseases, including stroke, 
transient ischemic attack, myocardial infarction, angina pectoris and in-
termittent claudication. To examine whether glucose tolerance and insu-
lin were independently related to cognitive function, we additionally 
adjusted for fasting insulin in the analysis on glucose tolerance, and for 
glucose tolerance in the analysis on hyperinsulinaemia. We also per-
formed a joint analysis in which the 2-hr glucose and the area under 
the insulin curve were both added to one model as continuous vari-
ables. As with the other analysis on hyperinsulinaemia, these analyses 
exclude known and newly diagnosed subjects. Interactions between age 
and insulin or glucose concentrations. and between insulin and glucose 
concentrations, were investigated by including interaction terms in the 
models. All p-values are based on two-sided tests of statistical signifi-
cance. 
Results 
The participants were aged 69 to 89 years, with a mean age of 75 ± 
4.6 (SO). The median MMSE score was 26. Sixteen percent had a poor 
cognitive function (MMSE score s23), and 31% had a MMSE score of 
24 or 25, indicating borderline cognitive performance. The subjects with 
the lowest scores were older and belonged more frequently to the man-
ual occupation group (Table 1). Other characteristics were not signifi-
cantly different across levels of cognitive function. 
Cognitive function in diabetes mellitus and impaired glucose 
tolerance 
Of the 37 known diabetic patients with complete information on risk 
factors, 8 were insulin treated. The subjects with impaired glucose tol-
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Table 1 
Selected characteristics of elderly men by level of cognitive function: 
the Zutphen Elderly Study, 1990. 
Cognitive function 
Poor Borderline Unimpaired All 
Characteristics MMSE :<;;23 MMSE 24-25 MMSE ~26 
(n=74) (n=76) (n=312) (n=462) 
Mean age (yrs) 77.5' 75.1 74.4 75.0 
(4.8)t (4.7) (4.3) (4.6) 
Manual occupation 36t 26 21 25 (%) 
Current cigarette 26 22 21 22 
smokers (%) 
Mean Body Mass 25.6 25.8 25.5 25.6 
Index (kglm2) (3.6) (2.6) (3.0) (3.1) 
Mean HOL choles- 1.11 1.14 1.17 1.15 
terol (mmol/L) (0.28) (0.27) (0.30) (0.30) 
Mean triglycerides 1.38 1.52 1.44 1.44 
(mmol/L) (0.70) (0.82) (0.76) (0.76) 
Mean fibrinogen 3.75 3.72 3.68 3.69 
(giL) (0.34) (0.28) (0.33) (0.32) 
Presence of (%): 
• Stroke 5 4 4 4 
I Transient 5 5 7 6 ischemic attack 
• Myocardial 14 13 14 14 infarction 
• Angina pectoris 20 14 13 IS 
• Intermittent 8 14 9 10 
claudication 
• Hypertension 34 42 41 40 
*' overall chi-square test: 
t (SO) 
p:<;;O.OOOI 
t overall chi-square test: p:<;;O.OOI 
era nee were older than the other subjects (Table 2). Occupational his-
tory did not vary significantly by level of glucose tolerance. 
As expected, the mean area under the insulin curve was highest in 
the subjects with impaired glucose tolerance and lowest in the subjects 
with normal glucose tolerance. However, the correlation between the 
area under the insulin curve and 2-hr glucose concentration in 000-
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Table 2. 
Selected characteristics and rate ratios (95% confidence interval) of the 
number of incorrect responses to the MMSE by glucose tolerance status: 
the Zutphen Elderly Study, 1990. 
Normal IGT New Known 
diabetes diabetes 
(n,340) (n,47) (n,38) (n,37) 
Characteristics p' 
• Mean age (yrs) 74.8 77.0 73.7 75.8 0.01 (4.5)t (5.1) (4.2) (4.8) 
• Manual occupation %) 26 19 16 27 0.41 
• Presence of stroke (%) 3 13 5 3 0.02 
• Mean insulin AUC 37274 50799 38020 0.0001 (pmoI!L.min) (16696) (21095) (23764) 
• MMSE score :<':25 %) 28 41 37 52 0.02 
• Mean number of incor- 3.7 4.7 4.0 4.9 the 0.01 rect responses on (2.7) (3.2) (2.8) (2.9) MMSE:j: 
Rate ratios p·trend 
• Unadjusted 1.00 1.26 1.08 1.31 0.01 
(1.02·1.55) (0.86·1.36) (1.07-1.60) 
• Adjusted§ 1.00 1.18 1.16 1.23 0.01 
(0.98-1.41) (0.91-1.48) ( 1.04-1.46) 
IGT = impaired glucose tolerance; AUC = area under the curve 
'* Kruskall-Wallis test for continuous variables and chi-square test for 
categorical variables 
t (SO) 
* MMSE score = 30 - mean number of incorrect responses 
§ adjusted for age, occupation and cigarette smoking 
diabetic subjects was low (r~O.19, p<O.OOI). Stroke was considerably 
more frequent in subjects with impaired glucose tolerance. 
The prevalence of poor cognitive function (MMSE score ~23) was 
highest in subjects with impaired glucose tolerance. After correction for 
confounding factors, including age, the number of erroneous anSWers on 
the MMSE increased with increasing glucose intolerance level (p-
trend~O.OI) (Table 2). Known diabetic subjects made 23% more errors 
in the MMSE, newly diagnosed diabetic subjects 16%, and subjects 
with impaired glucose tolerance 18%, compared with subjects with nor-
mal glucose tolerance. The results did not change when potentially 
mediating factors such as stroke, other cardiovascular diseases and 
variables associated with the insulin resistance syndrome, were taken 
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into account. There were no significant interactions between age and 
levels of glucose tolerance (p>O.I). 
When the analyses were confined to known and newly diagnosed 
diabetic patients (n~75) only, fasting glucose concentration was positively 
associated with the number of erroneous answers on the MMSE. Me-
dian fasting glucose concentration of the subjects with diabetes was 8.0 
mmol/L (10th centile: 6.3 mmol/L, 90th centile: 12.4 mmol/L). For each 
increase of 2 mmol/L subjects made 5% more errors in the MMSE, 
after adjustment for age and occupation (RR~1.05, 95% CI:0.98-1.19). 
Eight of the 37 known diabetic patients were using insulin. Their mean 
age at clinical diagnosis of diabetes mellitus was 61.5 years (range 40-84 
years). Exclusion of these eight subjects did not change the results. 
Cognitive function and hyperinsulinaemia 
Among the 386 non-diabetic subjects age, occupation, and presence of 
stroke was comparable aCross the quartiles of the area under the insulin 
curve (Table 3). The percentage with poor cognitive function (MMSE 
score :'>23) as well as the percentage with borderline cognitive function 
(MMSE score 24-25) increased from the lowest to the highest quartile 
of the area under the insulin curve. The mean MMSE score decreased 
from 26.5 in the lowest quartile to 25.5 in the highest quartile (p~O.OI). 
After adjustment for possible confounding effects of age, occupation 
and cigarette smoking, the subjects in the highest insulin quartile gave 
25% more erroneous answers on the MMSE items compared with sub-
jects in the lowest quartile (Table 3). Adjustment for potentially mediat-
ing factors, including cardiovascular diseases and factors associated with 
the insulin resistance syndrome, did not change the coefficient. 
Analyses pointed to a possible interaction between age and insulin 
quartiles (p~0.09), suggesting that the association between hyperinsulin-
aemia and cognitive impairment was stronger in the older (>75 years) 
than in the younger (:'>75 years) age group. Persons older than 75 years 
in the highest insulin quartile made 45% more errors in the MMSE 
compared with those in the lowest quartile after adjustment for poten-
tial confounders (RR~1.45, 95% CI: 1.14-1.85). Cognitive impairment was 
more strongly associated with the area under the insulin curve than 
with the fasting or post-load insulin concentrations. Comparing the high-
est to the lowest quartiles of hourly insulin measures, the RR for 1-
hour and 2-hour insulin concentrations was 1.16 (95% CI:0.96-1.39) and 
1.11 (95% CI:0.92-1.33) respectively. The lowest RR was found for the 
fasting insulin concentrations (RR~1.08, 95% CI:O.89-1.32). 
The glucose tolerance and hyperinsulinaemia results were essentially 
the same when subjects with stroke were excluded from the analyses 
(results not shown). Additional adjustment for fasting insulin in the 
analysis on glucose tolerance did not change the results (p-trend~O.OI), 
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Table 3 
Selected characteristics and rate ratios (95% confidence interval) of the 
number of incorrect responses to the MMSE by the level of area under the 
insulin curve in men free of diabetes mellitus: the Zutphen Elderly Study, 
1990. 
Quartiles of area under the insulin curve· 
First Second Third Fourth 
(n~97) (n~96) (n~96) (n~97) 
Characteristics pt 
• Mean fasting insulin 42.5 58.9 71.8 96.9 
(pmol/L) (l1.7)t (16.5) (21.5) (38.8) 
• Mean I-hr post-load 239.6 373.1 512.3 761.3 
insulin (pmol[L) (65.1) (54.9) (78.9) (183.7) 
• Mean 2-hr post-load 150.7 221.7 307.8 491.5 
insulin (pmol[L) (70.5) (85.4) (113.4) (233.2) 
• Mean age (years) 74.8 75.3 75.0 75.1 0.81 (4.8) (4.7) (4.3) (4.6) 
• Manual occupation (%) 27 25 24 25 0.95 
• Presence of stroke (%) 4 4 3 5 0.93 
• MMSE score 525 (%) 24 27 30 40 0.1 
• Mean number of incor- 3.5 3.8 3.7 4.5 
rect responses on the (2.8) (2.6) (2.7) (2.8) 0.01 
MMSE§ 
Rate ratios p-trend 
• Unadjusted 1.00 1.08 1.06 1.29 0.02 
(0.88-1.33) (0.85-1.31) (1.05-1.57) 
• Adjusted'll 1.00 1.06 1.05 1.25 0.02 
(0.87-1.29) (0.85-1.30) (1.04-1.50) 
• First quartile: area under the insulin CurVe (pmol/L.min) ~26347J second 
quartile: >26347 to 35660, third quartile: >35660 to 48065, fourth quartile: 
>48065 
t Kruskall-Wallis test for continuous variables and chi-square test for 
categorical variables 
* (SO) 
§ MMSE score = 30 - mean number of incorrect responses 
1: Adjusted for age, occupation and cigarette smoking 
neither did adjustment for glucose tolerance in the analyses on hyperin-
sulinaemia (p-trend~0.02). 
In the joint analysis in non-diabetic subjects with the 2-hr glucose 
and the area under the insulin curve as continuous measures, the rate 
ratio for 2-hr glucose was 1.01 per mmol/L (95% CI: 0.97-1.05) and 1.04 
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per 10 nmol/L.min (95% CI: 1.00-1.07) for the area under the insulin 
curve. These rate ratio's were not different from those obtained when 
each variable was entered seperately in the model. There were no 
significant interactions between levels of glucose tolerance and insulin 
quartiles (p>O.l), meaning that the relation between glucose tolerance 
and cognitive function did not vary across the quartiles of area under 
the insulin curve and vice versa. 
Discussion 
We found that non-diabetic subjects with impaired glucose tolerance 
and hyperinsulinaemia had impaired cognitive function as measured by 
the MMSE. Among diabetic patients cognitive function was even more 
impaired and decreased with increasing concentrations of fasting plasma 
glucose, which is an index of short-term glycaemic control. These results 
could not be explained by differences in age, occupation or smoking 
behaviour. Nor were they altered when subjects with stroke or diabetic 
patients using insulin were excluded. Joint analysis showed that hyperin-
sulinaemia was related to cognitive impairment, independent of glucose 
tolerance. Furthermore, diabetes and impaired glucose tolerance were 
related to cognitive impairment, independent of fasting insulin. Among 
non-diabetic subjects, the relation of cognitive function to 2-hr glucose 
and area under the insulin curve did not change when both glucose 
levels and area under the insulin curve were entered into the model. 
There are a few methodological issues that should be taken into 
account when interpreting our results. First, as our study was cross-sec-
tional, caution is needed regarding the direction of causality. Possibly, 
severe cognitive impairment leads to a deterioration of glycaemic control 
in diabetic patients. It is however not likely that cognitive impairment 
leads to glucose intolerance (i.e. diabetes mellitus or impaired glucose 
tolerance) or hyperinsulinaemia. Furthermore, selective non-response or 
survival may have affected the validity of this study. In another study, 
cognitive impairment and diabetes mellitus were shown to be more fre-
quent in non-responders than responders.23 It is also possible that per-
sons in whom diabetes and cognitive impairment are both present, have 
relatively higher mortality rates. If these selection biases apply to our 
study, it would probably result in an underestimation of the association 
between cognitive impairment and glucose intolerance or hyperinsulin-
aemia. We used the area under the insulin curve as indicator of hyper-
insulinaemia, rather than a single measurement of insulin. This area 
under the curve was a better predictor of cognitive function. This might 
be so because the within-person variation of the area under the insulin 
curve is smaller than that of the hourly insulin measures. 24 Finally, se-
rum insulin was measured with a conventional immunoassay, which is 
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known to cross-react with proinsulin. Although proinsulin is known to 
be increased in diabetes and impaired glucose tolerance, it constitutes 
only a minor part of the total insulin measured2S and is therefore 
probably not responsible for the observed association with cognitive 
function. 
Our findings of impaired cognitive function in diabetic patients 
agree with earlier clinical studies showing first, that elderly patients with 
non-insulin-dependent diabetes mellitus (NIDDM) had poorer cognitive 
function compared with normal controls().8,26, and secondly, that increas-
ing levels of glycosylated haemoglobin in NIDDM patients were associ-
ated with poorer performance.6,7 Meneilly et al. 26 showed that improve-
ment of glycaemic control in patients with NIDDM increased selected 
aspects of cognition. In contrast, a longitudinal study found no signifi-
cant relation between NIDDM and cognitive impairment.27 However, 
the subjects with NIDDM were young and had a high level of formal 
education. U'ren et aLB found that persons not known to have diabetes 
but who had raised glycosylated haemoglobin (>10%), showed levels of 
cognitive performance! intermediate between normal and diabetic sub-
jects. This study is consistent with our finding that subjects with im-
paired glucose tolerance perform more poorly on the cognitive test com-
pared to normoglycaemic subjects. Our finding of an association between 
hyperinsulinaemia and cognitive impairment is consistent with that of 
Kuusisto et a1.9, who found that hyperinsulinaemia identified a subgroup 
of hypertensive subjects with particularly impaired cognition. 
We examined some potential explanatory mechanisms for the rela-
tion between glucose intolerance, hyperinsulinaemia and cognitive func-
tion. First, we investigated risk factors associated with the insulin "resis-
tance syndrome (hypertension, obesity, decreased HDL cholesterol, in-
creased triglyceride concentrations and increased fibrinogen)2-4 as mediat-
ing factors. The inclusion of these factors did not alter the results. Sec-
ond, our adjustment for cardiovascular disease, as clinical manifestations 
of atherosclerosis, did not change the outcome. Moreover, exclusion of 
subjects with stroke did not alter the results. There is substantial evi-
dence that glucose intolerance and hyperinsulinaemia are associated with 
atherosclerosis, thrombosis and hypertension1,4,2B, all of which may lead 
to cognitive impairment through cerebral infarcts or white matter dis-
ease.s Since atherosclerosis was not directly measured and we had no 
information on the severity of the cardiovascular disease, we cannot ex-
clude this process as a mechanism explaining the association between 
glucose intolerance, hyperinsulinaemia and cognitive impairment. Fur-
thermore, other mechanisms may be responsible for the poorer cognitive 
function in subjects with glucose intolerance and hyperinsulinaemia. The 
cognitive impairment of diabetic patients may be due to hypoglycae-
mia29, increased free radical generation3o, or the same axonal damage as 
occurs in peripheral neuropathy.31 Hyperinsulinaemia might affect cogni-
so METABOLISM AND COGNITION 
tive function through vascular processes regulated by the sympathetic 
nervous system32 or by influencing synaptic activity in the brain.33 In 
future studies, information on the degree of atherosclerosis, the presence 
of cerebral infarcts or white matter disease, and the activity of the 
sympathetic nervous system, by measurement of plasma norepinephrine, 
would help to clarify the mechanisms through which insulin can affect 
cognitive function. Also important is to test aspects of cognitive function 
not measured by the MMSE, but that can be affected in diabetes, such 
as complex psychomotor function. 34 Further studies may also help to 
explain why dose-response was not strong and why the association be-
tween insulin and cognition varied by age. 
In conclusion, cognitive function might not only be impaired in 
diabetic patients, but also in elderly subjects with impaired glucose tol-
erance and hyperinsulinaemia. In addition, poorer glycaemic control was 
associated with poorer cognitive function in diabetic patients. Clinicians 
should be alert of the possibility that patients with diabetes mellitus, 
impaired glucose tolerance or hyperinsulinaemia may be at risk for cog-
nitive impairment. 
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HOMOCYSTEINE AND 
COGNITIVE DECLINE 
The Rotterdam Study 
Abstract 
Chapter 
Objective - To investigate the association of homocysteine to cognitive 
decline. 
Design - A prospective cohort study with a mean duration of follow-up 
of 2.9 years. 
Setting and Participants - 472 Community-dwelling respondents of the 
Rotterdam Study, aged 55 years or over. 
Main Outcome Measure - Cognitive decline, estimated with the Mini-
Mental State Examination (MMSE), defined as a drop in the MMSE 
score of >1 point/year. 
Results - Logistic regression was used to calculate odds ratios (OR) and 
95% confidence intervals (CI) of the association between elevated total 
homocysteine levels (;;:15.8 f.lmol/l, i.e. 66th percentile) and cognitive 
decline, adjusted for age, sex, education, alcohol consumption, smokin& 
and baseline MMSE score. There was a small nonsignificant relationship 
between total homocysteine and cognitive decline in the total group 
(adjusted OR~1.4, 95%Cl' 0.7-2.8). In subjects <75 years and in JVomen, 
high homocysteine level was more strongly associated with cognitive 
decline (OR~2.3, 95%Cl' 1.0-5.6 and OR~2.Z. 95%Cl' 0.9-5.5, 
respectively). The associations did not change after additional adjustment 
for indicators of atherosclerosis. 
Conclusions - Elevated total homocysteine levels may be associated 
with cognitive dec/ine, particularly in women and subjects under 75 
years of age. Since supplementation with folate is a safe way to reduce 
homocysteine levels, these resuits, when confirmed by other prospective 
studies, may have important implicadons to individuals at risk for 
cognitive dec/ine. 
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Introduction 
The prevalence and incidence of dementia increases dramatically with 
age. Cognitive decline is one of the major symptoms of dementia. As 
the proportion of older people in our society increases, we can expect a 
rise in the number of people with cognitive decline. Therefore, it is 
important to search for modifiable risk factors. The amino acid, homo-
cysteine, may be such a risk factor. I Several cross-sectional and longitu-
dinal studies have shown that homocysteine is associated with an in-
creased risk of strokez.s, coronary heart disease2,6,7 and carotid artery 
atherosclerosis.2,8,9 Both cardiovascular disease and carotid atherosclerosis 
have been related to cognitive impairment and dementia. IO•12 Homocys-
teine levels can be modified, as several intervention studies have shown 
a decrease in homocysteine concentration after supplementation with 
folateY There have been two small cross-sectional studies that found 
an association between homocysteine and cognitive function. 14,15 
We investigated the association between non-fasting total homocys-
teine levels and cognitive decline in a random sample of 472 Dutch 
subjects from a prospective population-based study of older persons. In 
addition, we examined whether atherosclerosis was a possible mediating 
factor in the association between total homocysteine and cognitive de-
cline. 
Methods 
Study population 
Data are from the Rotterdam Study, which is a single-center prospective 
population-based study, designed to investigate determinants of selected 
chronic diseases and disabilities in older persons. 16 The conduct of the 
study was approved by the Medical Ethics Committee of Erasmus Uni-
versity and written informed consent was obtained from all participants. 
All residents of a suburb of Rotterdam, aged 55 years or over, were 
invited to participate. The baseline examination took place between 
1990 and 1993. Of the 10,275 eligible subjects, 7,983 (78%) agreed to 
participate. During a home visit, trained interviewers administered a 
questionnaire covering, among other areas, sociodemographic background, 
medical history, and medication use. This was followed by two visits to 
the research center, where subjects underwent clinical examinations, in-
cluding neuropsychological testing. Subjects living in homes for the el-
derly were visited at home. The follow-up examination took place in 
1993 and 1994. Of the 7,215 subjects who were still alive, 6,315 (88%) 
participated in the follow-up examination. 
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We randomly selected 630 subjects from all those who performed a 
Mini-Mental State Examination (MMSE) at baseline and at follow-up 
(n~5535) for determination of serum total homocysteine. This sample 
did not differ from the population from which they were selected in 
age, sex or education. To increase power, we additionally selected a 
sample of subjects with a decline in the MMSE score of >1 point/year 
(n~75), resulting in a total sample size of 70S subjects. Our analyses 
were performed on 472 of the 70S respondents for whom complete in-
formation on total homocysteine, cognitive decline and all confounding 
and mediating factors was available. Indicators of atherosclerosis were 
missing for 231 subjects. These subjects were older (68.9 vs 67.4, 
p~0.04), had a lower median baseline MMSE score (28 vs 29, p~O.Ol), 
and less often consumed alcohol than subjects included in our analyses. 
Total homocysteine level, educational attainment, sex ratio, smoking 
habits, and prevalence of stroke did not differ between these groups 
(results not shown). 
Based on the findings of a previous study2, we assessed whether 
our results were affected by selective mortality and non-response. In 
order to do this, we randomly selected an additional sample, propor-
tional to the percentage in the total study population, of subjects who 
had died during follow-up (n~56) or who for other reasons did not par-
ticipate at the follow-up examination (n~67). 
Homocysteine determination 
At baseline, non-fasting serum samples were obtained. They were put 
on ice directly and were processed within sixty minutes, which has 
been shown to be sufficient to prevent increases in total homocysteine 
concentration due to ex vivo generation. 17 Serum was kept frozen at 
-20'C until determination of total homocysteine in 1995 and 1996. Aver-
age storage duration was 4.3 (SD~O.4) years for subjects without cogni-
tive decline and 4.5 (SD~0.6) years for those with cognitive decline 
(p~O.OI). Total homocysteine was determined at the clinical chemistry 
laboratory of the University Hospital Rotterdam, the Netherlands, as a 
fluorescence derivative, using HPLC according to Araki and Sakol8, as 
modified by Ubbink and co-workers. 19 A number of quality control 
samples was incorporated into runs. The estimation of the total homo-
cysteine concentration of these samples had to be within two standard 
deviations of the level of the control serum. The within-run coefficient 
of variation ranged from 2.3% to 4.0% and the day-to-day coefficient of 
variation from 3.2% to 4.0%, for elevated and normal total homocysteine 
concentrations, respectively. A total homocysteine level of 215.8 f.lmol/t1 
(66th percentile) was a priori considered as an elevated level. 
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Mini-Mental State Examination 
Global cognitive function was tested with the Netherlands version of 
the 30-point MMSE during the visit to the research center20, as de-
scribed earlier. 1O The test was administered by specially trained research 
assistants. The MMSE includes questions on orientation to time and 
place, registration, attention and calculation, recall, language and visual 
construction. This screening test was originally created for a clinical set-
ting20, and is extensively used in epidemiologic studies.21 If less than 
four individual items (out of 20) were not answered by the subject, 
these were rated as errors.22 If a subject did not answer four or more 
individual items, the total MMSE score was considered missing. Cogni-
tive decline was defined as a drop in the MMSE score of > 1 point/year 
(approximately > 1 SO). Mean follow-up duration between the first and 
second MMSE was 2.9 years (SO ~ 0.4). 
Other measurements 
The following variables were considered as possible confounding variab-
les: age (continuous); sex; cigarette smoking (current, former, never); 
alcohol consumption (none, d drink (13.2 g), 1-2 drinks, :2:3 drinks per 
day), assessed with a semi-quantitative food frequency questionnaire23; 
baseline MMSE score (continuous); level of education, grouped into four 
levels (completed primary education, lower vocational or general educa-
tion, intermediate vocational or general education, and higher vocational 
training, college or university (Unesco, Paris, 1976»; and hypertension, 
which was defined in accordance with the WH024 as a systolic blood 
pressure of 160 mmHg or more, or a diastolic blood pressure of 95 
mmHg or more, or the use of anti-hypertensive medication. 
Given previous studies8,9,1I, atherosclerosis was considered as a pos-
sible intermediate of the association between total homocysteine and 
cognitive decline. Three indicators of atherosclerosis measured at base-
line were used: thickening of the carotid artery intima-media wall 
(:2:0.9mm), presence of plaques in the carotid arteries, and presence of 
peripheral arterial disease (ankle-brachial index <0.90). Plaques and wall 
thickness were assessed by ultrasonography of both carotid arteries using 
a 7.5 MHz linear array transducer and an ATL UM4 Duplex scanner, 
as described in detail elsewhere.25 An average of three frozen images of 
both the left and the right near and far wall of the common carotid 
arteries was calculated. The common carotid artery and the carotid bi-
furcation were evaluated for the presence (yes/no) of atherosclerotic 
plaques, defined as any focal widening relative to adjacent segments 
with protrusion into the lumen.26 The ankle-brachial index was obtained 
by dividing the systolic blood pressure of the posterial tibial artery by 
the brachial pressure on each side (the lowest value was used). The 
ankle pressure was measured with a Doppler probe (Huntleigh 500 0, 
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Huntleigh Technology, Bedfordshire, UK) and a random-zero sphygmo-
manometer.25 To obtain a measure of total atherosclerotic burden a 
score was developed by assigning one point to the presence of each of 
the indicators of atherosclerosis.2 The categories with two and three 
points were grouped together. We also examined whether stroke medi-
ated the association between total homocysteine and cognitive decline. A 
history of stroke was considered present if a self-reported event was 
confirmed by either a detailed history, neuroimaging, or discharge re-
ports collected from the general practitioner or neurologist. 27 
Statistical analysis 
Differences in baseline characteristics, adjusted for, age and sex, were 
tested with analysis of covariance. We used logistic regression to esti-
mate odds ratios (OR) and 95% confidence intervals (GI) for the asso-
ciation between total homocysteine and cognitive decline, adjusting for 
confounding variables. We investigated whether atherosclerosis or stroke 
were intermediates in the association between total homocysteine and 
cognitive decline, by including these variables separately as covariates in 
the model. To test for interaction between total homocysteine and sex, 
age, or hypertension their product terms were put in the modeI.2.4.8 
To investigate selective mortality and non-response, we performed a 
sensitivity analysis in which we included the sample of those who were 
lost to follow-up in our analysis. The following two extreme options 
were examined: first, we assumed that those lost to follow-up would all 
have shown cognitive decline; secondly, we assumed that none of them 
would have shown cognitive decline. Since we expected selective loss to 
follow-up to be present in the older age group, we performed the sen-
sitivity analyses in two age strata «75 years and "?75 years). All tests 
were two-sided and a p-value of less than 0.05 was considered to be 
statistically significant. Data analyses were performed using BMDP sta-
tistical software. 
Results 
The mean age of the participants at baseline was 67.4 years (SD = 7.0). 
Sixty-three percent of the sample was female. The median baseline 
MMSE score was 29 (range: 16 to 30) and the mean total homocysteine 
concentration was 15.4 Ilmol/l (SD = 9.7). After adjustment for sex, the 
average age was higher in subjects with elevated total homocysteine 
levels and after adjustment for age, the percentage of women was lower 
in these subjects (Table I). A history of stroke was more frequent in 
subjects with hyperhomocysteinemia. Subjects with a drop in the 
MMSE score of > 1 point/year more often had a primary education as 
the highest attained level. In addition, they less often consumed alcohol, 
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Table 1 
Age and sex adjusted baseline characteristics and cognitive function 
according to total homocysteine level. 
Total homocysteine level 
<15.8 ~15.8 
Ilmol/L IlmollL p-value* 
(n=310) 
Mean MMSE score 28.2 (0.1O)t 
Mean age (yrs) 66.1 (0.39) 
Sex (% female) 68% 
Primary education (%) 38% 
Current smokers (%) 24% 
Alcohol consumers (%) 69% 
Mean alcohol consumption (g/day)t 14.7 (1.22) 
Intima-media thickness ~O. 9 mm (%) 13% 
Plaques in carotid arteries (%) 48% 
Peripheral arterial disease (%) 7% 
History of stroke (%) 3% 
MMSE = Mini-Mental State Examination 
"" Analysis of covariance 
t Standard error between parentheses 
t Among alcohol consumers (n=329) 
(n=162) 
28.2 (0.14) 
69.9 (0.54) 
52% 
32% 
29% 
70% 
17.0 (1.69) 
18% 
47% 
9% 
6% 
0.91 
<0.001 
0.001 
0.23 
0.27 
0.85 
0.27 
0.17 
0.84 
0.47 
0.09 
and plaques in the carotid arteries were slightly more frequent (data not 
shown). 
After adjustment for age, the association between high total homo-
cysteine levels and cognitive decline was non-significant (OR=1.2, 95% 
CI:0.6-2.2). After additional adjustment for sex, education, alcohol con-
sumption, smoking, and baseline MMSE score, the OR was 1.4 (95% 
CI: 0.7-2.8). In stratified analyses, high total homocysteine levels were 
more strongly associated with an increased risk of cognitive decline in 
subjects under 75 years of age and in women (Table 2). The p-values 
for interaction with age and sex were not significant, however (p=OA 
and p=O.2, respectively). There was no interaction with hypertension 
(p=O.9). When the atherosclerosis score was included in the model none 
of the above results essentially changed (Table 2). Neither did they 
change when the indicators were included in the model separately 
(results not shown). Adjustment for a history of stroke did not alter the 
associations either. 
Sensitivity analyses 
Subjects who died during follow-up had a higher age-adjusted total ho-
mocysteine concentration than those who participated at follow-up (18.6 
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Table 2 
Adjusted odds ratios (95% confidence intervals) for cognitive decline' 
according to total homocysteine level. 
Homo- % N Cognitive OR (95% CI) 
cysteine decline 
Strata 
Model I Model II 
< 75 years normal 272 6.6% I (ref) I (ref) 
59 
high 123 9.8% 2.3 (1.0-5.6) 2.3 (0.9-5.5) 
2 75 years normal 38 23.7% I (ref) I (ref) 
high 39 15.4% 0.4 (0.1-2.3) 0.5 (0.1-2.7) 
Men normal 98 8.2% I (ref) I (ref) 
high 78 7.7% 0.7 (0.2-2.3) 0.5 (0.1-2.0) 
Women normal 212 9.0% I (ref) I (ref) 
high 84 14.3% 2.2 (0.9-5.5) 2.6 (1.1-6.5) 
OR = odds ratio; CI = confidence interval 
.. Defined as a drop in the Mini-Mental State Examination score of >1 
point/year 
Model I: adjusted for age, sex, education. alcohol consumption. smoking, 
baseline Mini-Mental State Examination SCore 
Model II: adjusted for age, sex, education, alcohol consumption, smoking, 
baseline Mini-Mental State Examination score, atherosclerosis score 
(thickening of the intima-media carotid artery wall, carotid plaques in 
either common carotid artery or carotid bifurcation, and presence of 
peripheral arterial disease) 
vs 15.6 Ilmol/I, p=0.07), and a lower median baseline MMSE score (26 
vs 29, p<O.01). Non-respondents at the follow-up examination had a 
lower median baseline MMSE score (26 vs 29, p<O.OI), but no higher 
age-adjusted total homocysteine concentration (16.1 vs 15.6 Ilmol/I, 
p=0.7). Twenty-five (20%) of the subjects who died or did not respond 
at follow-up were younger than 75 years and had normal total homocys-
teine levels, 20 (16%) were younger than 75 years and had elevated 
total homocysteine levels, 29 (24%) were older than 75 years and had 
normal total homocysteine levels, and 49 (40%) were older than 75 years 
and had elevated total homocysteine levels. 
If we placed all those who did not attend the follow-up 
examination in the cognitive decline groups, the ORs were 1.7 (0.9-3.1) 
for subjects <75 years, and 1.2 (0.4-3.0) for those 275 years (Table 3). 
If we placed them in the groups without cognitive decline, these ORs 
were similar to the results without the sensitivity analyses, 2.3 (1.0-5.3) 
for those <75 years and 0.3 (0.1-1.4) for those 275 years. 
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Table 3 
Sensitivity analysis: adjusted odds ratios (95% confidence intervals)' for 
cognitive decJinet according to total homocysteine level, with those lost to 
follow-up in the cognitive decline group. 
Strata Homo- N % Cognitive OR (95% GI) 
cysteine decline 
< 75 years normal 297 14.5% 1 (ref) 
high 143 22.4% 1.7 (0.9-3.1) 
:2: 75 years normal 67 56.7% 1 (ref) 
high 88 62.5% 1.2 (0.4-3.0) 
Men normal 116 22.4% 1 (ref) 
high 102 29.4% 0.9 (0.4-2.1) 
Women normal 247 21.9% 1 (ref) 
high 130 43.8% 2.0 (1.1-3.8) 
OR = odds ratio; GI = confidence interval 
• Adjusted for age, sex, education, alcohol consumption, smoking. and 
baseline Mini-Mental State Examination score 
t Defined as a drop in the Mini-Mental State Examination score of > 1 
point/year 
Discussion 
In this prospective population-based study of elderly subjects, there was 
a small nonsignificant association between elevated total homocysteine 
levels and subsequent cognitive decline. In women and in subjects un-
der 75 years of age, total homocysteine was more strongly related to 
cognitive decline. These results were independent of differences in edu-
cation, alcohol consumption and cigarette smoking. 
There are a number of methodological issues that need to be dis-
cussed before we can interpret our findings. Total homocysteine was 
measured in non-fasting serum that had been stored for approximately 
four years. Serum total homocysteine is stable for at least ten years 
when stored at _20'G.28 Still, differences in food intake before blood 
was obtained and reduction of total homocysteine levels over time 
stored can lead to random misclassification I7,28, which would dilute our 
estimates. The average storage duration was slightly longer in subjects 
with cognitive decline compared with those without. But the same 
technique and protocol were used for the estimation of total homocyste-
ine during the whole study period and the day-to-day vanatlOn of the 
estimation was small. If anything, the longer storage duration would 
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have led to lower total homocysteine levels in subjects with cognitive 
decline, in which case our results would have been attenuated. 
Another methodological issue is that the MMSE was not created to 
estimate change in cognitive function. One study examined the reliabil-
ity of change in the MMSE in patients with dementia. They found 
that for a time interval between the MMSE's of one year or more the 
reliability was around 0.74, which is reasonable.Z9 No such studies were 
performed in a general population, though. We defined cognitive decline 
as a drop in the MMSE of >1 point/year, which is on average >2.9 
points for the total follow-up period. This change would be significant 
at the 5% level (one-tailed) for an individual, based on the standard 
error of measurement (1.96·SEM=2.6). If misclassification occurred, it 
probably has been random, leading to dilution of our results. 
This study has a number of strong points. It is a prospective 
study, in which total homocysteine levels are measured at baseline and 
thus are not influenced by the outcome, cognitive decline. Furthermore, 
we took a random sample of subjects participating at baseline and at 
follow-up. And, we were able to investigate whether selective loss to 
follow-up biased our findings. 
Subjects who died after the baseline examination had higher total 
homocysteine levels. Both subjects who died or who for other reasons 
did not participate at the follow-up examination were older and had a 
lower baseline MMSE score. Since we found no association between 
total homocysteine and cognitive decline in subjects over 7S years of 
age we were especially interested whether this might have been the 
result of selective loss to follow-up. Perhaps older subjects with elevated 
total homocysteine levels who died were more susceptible to the harm-
ful effects of total homocysteine and those who were still alive less sus-
ceptible. When we included our random sample of those who were lost 
to follow-up in the cognitive decline group, the non-significant inverse 
association became a non-significant small positive association in subjects 
over 7S years of age. In those under 7S years the association was not 
slightly reduced, but still borderline significant. This suggests that espe-
cially in the older age group there may have been selective loss to fol-
low-up, leading to alteration of our estimates. 
Next to the stronger association between total homocysteine and 
cognitive decline in those under 7S years of age, we found a stronger 
relation among women. This modification is not likely to be due to an 
age difference of the sexes, since the proportion of subjects under 75 
years of age did not differ between men and women. When we includ-
ed the sample of those who were lost to follow-up in the cognitive 
decline group, the estimates for men did not change, suggesting that 
selective loss to follow-up is not a likely explanation for the lack of an 
association in men. Some other studiesB•3o and a meta-analysis31 found 
that the association between homocysteine and cardiovascular events was 
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stronger in women than in men as well. Reasons for this are not clear. 
It was found that homocysteine levels were lower in healthy premeno-
pausal women than in men of the same age and that homocysteine 
levels in women abruptly increased after menopause.32 So men were 
exposed to elevated homocysteine levels for a longer period than 
women. 
One of the mechanisms for an association between total homocyste-
ine and cognitive decline may be atherosclerosis.33•34 We investigated 
whether indicators of atherosclerosis were mediating factors in the asso-
ciation between total homocysteine and cognitive decline. But, the asso-
ciations did not change when we entered these indicators into the 
model. The reason for this may be that in this sample the association 
between atherosclerosis and total homocysteine levels or between athero-
sclerosis and cognitive decline was not very strong. which may be due 
to the relatively small sample size. Another possible explanation for the 
fact that atherosclerosis did not attenuate our results may be that we 
used atherosclerosis data measured at the same time as the total homo-
cysteine levels, instead of in between the total homocysteine and cogni-
tive decline measurement. 
Total homocysteine could be associated with cognitive decline 
through other mechanisms than atherosclerosis, such as thrombosis35 or a 
direct neurotoxic effect.36 Furthermore, elevated total homocysteine lev-
els might be seen as an indicator of vitamin B12 and folate deficiency, 
which have been related to cognitive impairment and dementia in a 
number of studies37-39, although the evidence of an association between 
these vitamins and cognitive impairment is not consistent.t4,37.40 
In summary, total homocysteine did not appear to be a major risk 
factor for cognitive decline in a general population of elderly. Total ho-
mocysteine seemed, however, to increase the risk of cognitive decline in 
women and subjects under 75 years of age. The non-significant inverse 
association in those over 75 years of age may be the result of selective 
survival. Since homocysteine is a modifiable risk factor, it is important 
that other larger prospective studies examine whether elevated homocys-
teine levels increase the risk of cognitive decline. 
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CORTISOL, DEHYDROEPI-
ANDROSTERONE SULFATE, 
AND COGNITIVE FUNCTION 
The Rotterdam Study 
Abstract 
Objective - To investigate the relation between the peripheral concen-
trations of the adrenal steroid hormones cortisol and dehydroepi-
androsterone suffine (DHEAS) and cognitive impairment and decline. 
Design - A prospective population-based study. 
Setting - A suburb of Rotterdam, the Netherlands. 
Population - A random sample of 189 participants Hom the Rotterdam 
Study, aged 55-80 years, who Were invited for an additional examination 
at baseline. Follow-up examinations took place after an average of 1.9 
years. 
Measurements - Fasting blood levels of cortisol and corticosteroid-
binding-globulin (CBG) before and after 1 mg dexamethasone overnight, 
and of DHEAS lVere obtained The 30-point Mini-Mental State Exam-
ination (MMSE) was used to assess cognition. The association with cog-
nitive impairment (MMSE score <26, 6% of the population) and the 
risk of cognitive dec/ine (drop in MMSE score >1 point/yr, 24%) was 
estimated using logistic regression, with adjustment for age, sex, and 
education. 
Results - The OR for the association with cognitive impairment accord-
ing to one standard deviation (SD) increase in the cortisol/CBG ratio 
(SD~0.21), a measure of the '!fee' cortisol leve/, was 1.7 (95%Cl' 0.9-
3.1). One standard deviation increase in the natural logarithm of cortisol 
after 1 mg of dexamethasone (SD~0.68) was associated with an in-
creased risk of cognitive decline (OR~I.5 (95%C1-1.0-2.3)). One SD in-
crease in DHEAS (SD~Z.10 umol/l) was inversely but nonsignificantly 
related to cognitive impairment (OR~0.5 (95%Cl·0.2-1.1)) and cognitive 
decline (OR-0.6 (95%C1:0.4-1.1)). The ratio of cortisol over DHEAS was 
significantly related to cognitive impairment (OR~1.8 (95%C1:1.2-2.8)). 
Conclusion - This longitudinal study among elderly subjects suggests 
that there is a positive association between cortisol and cognitive impair-
ment, and that high cortisol after dexamethason increases the risk of 
cognitive decline. There seemed to be an inverse association between 
DHEAS and cognitive impairment and decline. 
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Introduction 
Cortisol and dehydroepiandrosterone (DHEA) are adrenal steroid hor-
mones with multiple effects on the function of the hippocampus, which 
is involved in learning and memory processes. 1,2 These adrenal steroids 
may thus be associated with cognitive impairment, which is a major 
symptom of dementia. 
Hypothalamo-pituitary-adrenal (HPA) axis overacttv,ty, which is re-
lated to stress and possibly also to aging, leads to increased cortisol 
levels:' Sustained cortisol exposure in rodents and primates results in 
damage of the hippocampus.4 In human studies, increased cortisol levels 
and HPA axis overactlvlty have been associated with cognitive 
impairment and dementia.3,s-ll These studies were, however, mostly 
cross-sectional, making it impossible to determine the direction of the 
association. 
DHEA and its sulfate DHEAS are regarded as markers of aging.12 
DHEAS may affect the excitability and plasticity of hippocampal 
neurons.2 In animal experiments DHEAS has been shown to enhance 
neuronal and glial survival and differentiation in cultureI3.14, and 
injection of DHEAS into the brains of mice improved long-term mem-
ory.13 There are a number of case-control studies on the association 
between DHEAS and Alzheimer's disease; however, these yielded con-
flicting results. ls.21 In one prospective population-based study there was 
no consistent association between DHEAS and subsequent cognitive 
function. 22 
In this prospective population-based study we examined whether 
peripheral levels of the steroid hormones cortisol and DHEAS are relat-
ed to cognitive impairment and decline. 
Methods 
Study population 
The Rotterdam Study is a single-centre prospective population-based 
study23, designed to investigate determinants of chronic disabling dis-
eases in the elderly. The conduct of the study was approved by the 
Medical Ethics Committee of the Erasmus University and written con-
sent was obtained from all participants. All residents of Ommoord, a 
suburb in Rotterdam, aged 55 years or over, including those living in 
homes for the elderly, were invited to participate. The baseline exami-
nations started in May 1990 and continued until June 1993. Of the 
10,275 eligible subjects, 7983 (78%) agreed to participate. During a 
home visit, trained interviewers administered a questionnaire, covering, 
among other areas, sociodemographic background, medical history, and 
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medication use. This was followed by two clinical examinations at the 
research centre, including neuropsychological testing. The follow-up ex-
amination started in September 1993 and lasted until December 1994. 
Of the 7215 subjects who were still alive, 6315 (88%) agreed to partici-
pate. 
For the present additional examination, a random sample (n~219) 
was taken of participants from the Rotterdam Study, who had complet-
ed the baseline examination in the preceding six months, were between 
55 and 80 years old, had no history of psychiatric or endocrine diseases, 
including diabetes mellitus treated with medication. One subject who 
was using hydrocortisone and one subject who had a greatly elevated 
DHEAS level (15.1 umol/I) were excluded from the analyses. There 
were no differences in age, sex, or education between our sample and 
the other participants of the Rotterdam Study in the same age range 
and without dementia or known diabetes mellitus. The mean baseline 
Mini-Mental State Examination (MMSE) score was higher in our sample 
(28.1 (SD~1.6) vs 27.6 (SD~1.9), p~0.002). Complete information on 
cognitive function at baseline was available for 189 subjects. There were 
no differences in age, sex, cortisol or DHEAS levels between subjects 
with and subjects without complete information on cognitive function. 
Follow-up data on cognitive decline were available for 169 subjects. 
Compared with subjects who attended the follow-up examination 
(n~169), those who did not (n~20) were older (71.1 vs 66.9 years, 
p~0.002) and had a lower median MMSE score (27 vs 28, p~O.OO O. 
There were no differences in the cortisol/corticosteroid-binding-globulin 
(CBG) ratio (0.69 vs 0.72, p=0.70) or DHEAS levels (3.29 vs 3.38, 
p=0.75) between these groups. 
Blood measurements 
Blood was obtained after an overnight fast at the research centre be-
tween 8.00 and 9.00 AM, and allowed to coagulate for 30 minutes. Se-
rum was separated by centrifugation and quickly frozen in liquid nitro-
gen. In addition, an overnight dexamethasone suppression test was per-
formed. 24 Participants were given a tablet of 1 mg dexamethasone and 
were instructed to take this at 11.00 PM. Next morning, at the same 
time as the previous day, a fasting blood sample was obtained in the 
same manner. Measurements included cortisol and CBG before and after 
dexamethasone, and DHEAS before dexamethasone. Radioimmunoassays 
were used for determination of CBG (Medgenix Diagnostics, Brussels, 
Belgium) and of cortisol and DHEAS (Diagnostic Product Corporation, 
Los Angeles, CA, USA). The coefficients of variation of these assays 
were less than 12.0%, 12.5%, and 6.0%, respectively. To estimate the 
level of free circulating cortisol, the ratio of cortisol over CBG was 
used. Diminished suppression of cortisol after dexamethasone can be 
regarded as an indicator of HPA axis overactivity. Because the cortisol 
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level after dexamethasone was not normally distributed, we took the 
natural logarithm. 
Mini-Mental State Examination 
Global cognitive function was tested with the Dutch version of the 30-
point MMSE during the (first) visit to the research centre.25 It was 
administered by specially trained research assistants. The MMSE in-
cludes questions on orientation to time and place, registration, attention 
and calculation, recall, language and visual construction. This screening 
test was originally created for a clinical setting25, and is extensively used 
in epidemiological studies.26 Although it tests mainly cortical functions, 
these are important to daily functioning and severely affected in 
dementia. If less than four individual items (out of 20) were not an-
swered by the subject, these were rated as errors.27 If a subject did not 
answer four or more individual items the total MMSE score was 
considered missing. Cognitive impairment was defined as a score of 
<2628, and cognitive decline as a drop in the MMSE score of >1 
point/year (approximately >1 SO). Mean follow-up time between the 
first and second MMSE was 1.9 years (SO = 0.23). 
Other measurements 
A number of factors were considered as possible confounding variables: 
age, sex, and education, classified into four levels: completed primary 
education; lower vocational or general education; intermediate vocational 
or general education; and higher vocational training, college or university 
(Unesco, Paris, 1976). Body mass index (weight/height2) was considered 
as a possible confounding factor, because low food intake and low body 
weight might induce relative resistance to the dexamethasone suppres-
sion test. Symptoms of depression were assessed at the follow-up ex-
amination with translated versions of the Center for Epidemiologic 
Studies Depression Scale (CES-D)29 in the first 112 participants and the 
Hospital Anxiety and Depression Scale (HADS)30 in the last 43 
participants. In 14 participants, there was no depression scale available. 
We used the standard cut-off of ~16 for the CES-D29 and a cut-off of 
~8 for the HADS (after exclusion of the anxiety items)30 to identify 
subjects with depressive symptoms. For the analyses on cortisol, 
estrogen users (n=2) and users of anti-epileptics (n=4) were excluded, 
because these medications can influence cortisol and/or CBG levels and 
the sensitivity to dexamethasone. Subjects were asked to show all vials 
of the medication they were currently using during the home visit. In 
the analyses on cognitive decline we additionally adjusted for baseline 
MMSE score. 
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Statistical analysis 
Differences in baseline characteristics according to cogmtlVe impairment 
and according to steroid hormone levels above and below the median 
were tested with the Mann-Whitney test for continuous and the Chi-
square test for categorical variables. Logistic regression was used to es-
timate odds ratios (OR) and 95% confidence intervals (CI) for the risk 
of cognitive impairment and decline. The independent variables of in-
terest were total cortisol, the cortisol/CBO ratio, the natural logarithm of 
cortisol after dexamethasone, and OHEAS. We also investigated the ra-
tio of cortisol over OHEAS, because OHEAS may antagonize the ac-
tions of cortisol.31 •33 We included confounding variables in the model. 
We also investigated whether there was effect modification by gender34 
by including the product term as covariate in the model. All tests were 
two-sided and a p-value of less than 0.05 was considered statistically 
significant. Data analyses were performed using BMOP statistical 
software. 
Results 
The mean age of the participants at baseline was 67.3 years (SO = 5.7). 
Fifty percent of the sample was female. The median baseline MMSE 
score was 28 (range=20-30) and 6.3% of the subjects was cognitively 
impaired. The mean drop in the MMSE per year was 0.22 (SO = 0.95) 
and 24% showed a drop in the MMSE score > 1 point/year. Subjects 
with cognitive impairment were older, more often had symptoms of de-
pression at follow-up, and had a lower OHEAS concentration (Table I). 
Subjects with a total cortisol level above the median (506.5 nmol/i) had 
a lower body mass index than those below the median (25.8 (SO=3.8) 
vs 27.1 (SO=3.4), p=O.OI). Subjects with a cortisol/CBO ratio above the 
median were older and less often female, which is the result of a 
higher CBO level in women (Table 2). Participants with OHEAS levels 
below the median were more often female (66% vs 34%, p<O.OOI). 
Multiple logistic regression analyses showed that total cortisol levels 
were not related to cognitive impairment or decline (Table 3). Subjects 
with a higher cortisol/CBO ratio more often seemed to be cognitively 
impaired. CBO levels were not associated with cognitive function (data 
not shown). The natural logarithm of cortisol after dexamethasone was 
associated with an increased risk of cognitive decline. Subjects with high 
OHEAS levels less often seemed to be cognitively impaired. For one 
standard deviation increase in OHEAS level there was a 40% reduced 
risk of cognitive decline, although this was not significant. The ratio of 
cortisol over OHEAS was significantly associated with cognitive impair-
ment (OR=1.8, 95%CI: 1.2-2.8). Adjustment for body mass' index or 
symptoms of depression at follow-up did not change the results. Exclu-
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Table 1 
Baseline characteristics according to cognitive impairment. * 
The Rotterdam Study. 
Mean age (yrs) 
Sex (% female) 
Only primary education (%) 
Body mass index (kg/m2) 
Depressive symptoms at follow-up (%) 
Mean cortisol (nmol!l)§ 
Mean cortisol/CBC ratio§'1 
Mean logarithm of cortisol after 
dexamethasone (nmol/I)§ 
Mean dehydroepiandrosterone sulfate 
(umol/I) 
Mean cortisol/dehydroepiandrosterone 
sulfate ratio§ 
CBC = corticosteroid-binding-globulin 
Cognitive impairment 
Absent Present 
(n=177) (n=12) 
67.1 (5.7)t 71.3 (4.0) 
50% 58% 
32% 42% 
26.4 (3.7) 26.2 (3.7) 
8% 17% 
512 (134) 544 (142) 
0.70 (0.20) 0.80 (0.27) 
3.12 (0.68) 3.32 (0.61) 
3.36 (2.09) 2.25 (2.00) 
242 (238) 543 (645) 
p-valuet 
0,01 
0.56 
0.72 
0.86 
0,03 
0.45 
0.16 
0.29 
0.03 
0,03 
'* Defined as a Mini-Mental State Examination score of <26 at baseline 
t Mann-Whitney or Chi-square test 
t Standard deviation in parentheses 
§ Six subjects were excluded because they were using estrogens or anti-
epileptics 
'I Csed as an estimate of the free cortisol level 
sion of subjects with depressive symptoms (n=16) essentially yielded the 
same estimates) but confidence intervals were wider because of the 
smaller sample size (results not shown). There were no significant inter-
actions between the variables of interest and sex. 
Additionally, we investigated the association with the memory item 
of the MMSE35, since cortisol and DHEAS are believed to influence 
the function of the hippocampus, which is involved in memory proces-
ses. Fifty-three percent of the subjects scored less than three points on 
the recall of three words. There was no significant association of the 
cortisol/CBC ratio or DHEAS with memory impairment (OR=1.0, 
9S%CI: 0.7-1.4 and OR=1.2, 9S%CI: 0.9-1.7, respectively). 
Discussion 
In this prospective population-based study we investigated the associa-
tion between the peripheral concentrations of two adrenal steroid hor-
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Table 2 
Characteristics according to the cortisol/CBG ratio' above and below the 
median. The Rotterdam Study. 
Cortisol/CBG ratio 
73 
< 0.68 ;" 0.68 p-valuet 
Mean age (yrs) 
Sex (% female) 
Only primary education (%) 
Body mass index (kg/m2) 
Depressive symptoms at follow-up (%) 
CBG = corticosteroid-binding-globulin 
(n=89)t (n=94)t 
66.2 (5.8)§ 
58% 
34% 
26.3 (3.5) 
5% 
68.3 (5.5) 
40% 
29% 
26.6 (3.9) 
13% 
0.04 
0.01 
0.20 
0.96 
0.11 
.. Used as an estimate of the free cortisol level 
t In total, six subjects were excluded because they were using estrogens 
or anti-epileptics 
* Mann-Whitney or Chi-square test 
§ Standard deviation in parentheses 
Table 3 
Adjusted' odds ratios (95% confidence intervals) for the risk of cognitive 
impairment and declinet according to one standard deviation increase in 
total cortisol, the cortisol/CBG ratio, cortisol after dexamethasone, and 
dehydroepiandrosterone sulfate. 
Risk of 
Cognitive Cognitive 
SO impairment decline 
(n=12/189) (n=40/169) 
Total cortisol (nmol/I) 140.1 1.3 (0.7-2.3)* 0.9 (0.6-1.3)* 
Cortisol/CBG ratio§ 0.21 1.7 (0.9-3.1)* 0.9 (0.6-1.3)* 
Cortisol after dexamethasone 0.68 1.2 (0.7-2.1)* 1.5 (1.0-2.3)* (nmol/I)'I 
Dehydroepiandrosterone sulfate 2.10 0.5 (0.2-1.1) 0.6 (0.4-1.1) (umol/I) 
CortisoIldehydroepiandrosterone 295 1.7 (1.1-2.6)* 1.0 (0.6-1.6)* 
sulfate ratio 
CBG = corticosteroid-binding-globulin; SO = standard deviation 
• Adjusted for age, sex, and education (and baseline Mini-Mental State 
Examination score in the analyses on cognitive decline) 
t Cognitive impairment: Mini-Mental State Examination score of: <26 at 
baseline; and cognitive decline: drop in the Mini-Mental State Examina-
tion score of > 1 point/year 
:I: Six subjects were excluded because they were using estrogens or anti-
epileptics 
§ t.:sed as an estimate of the free cortisol level 
'I After logarithmic transformation 
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mones and cognitive function. The results suggest that a high corti-
sol/CBG ratio, as an estimate of free cortisol, is related to cognitive im-
pairment. The cortisol level after dexamethasone, as an indicator of 
HPA axis activity, was associated with an increased risk of cognitive 
decline. DHEAS, which may antagonize the actions of glucocorticoid, 
appears to be inversely related to cognitive impairment and decline. 
The ratio of cortisol over DHEAS was significantly related to cognitive 
impairment. These associations could not be explained by differences in 
age, sex, education, body mass index, or depressive symptomatology at 
follow-up. 
Methodological issues 
It could be argued that selection bias may have affected the validity of 
our results. Subjects were healthy and relatively young and follow-up 
duration was short, leading on average to only a small drop in the 
MMSE score. Combined with the small sample size, this would only 
impede the detection of a significant modest association. Furthermore, 
subjects who were lost to follow-up (due to death or non-response) had 
a significantly lower baseline MMSE score and were older than subjects 
who were not lost to follow-up. However, there were no differences in 
cortisol or DHEAS levels, making selective loss to follow"up less likely. 
Another methodological issue is that we may not have adequately 
adjusted for depression. Depression is strongly associated with cognitive 
impairment36 and also with increased cortisol levels and diminished 
suppression of cortisol after dexamethasone.37 Thus, depression is 
potentially an important confounder. The use of two different question-
naires might not have been optimal. The CES"D has been designed for 
epidemiologic research, whereas the HADS has been designed for a 
clinical setting. Both have been validated, but the CES-D is probably 
more reliable, especially in this setting.29 Furthermore, we adjusted for 
symptoms of depression at follow-up and not at baseline. Thus, there 
may be residual confounding in our results on cognitive impairment, but 
less in our results on cognitive decline. 
Cortisol and HP A axis overactivity 
This study represents the only prospective population-based study that 
we are aware of that investigated the association between cortisol and 
cognition. Our results confirm and extend the findings of previous 
studies. Increasing cortisol levels and diminished suppression of cortisol 
to dexamethasone have been associated with cognitive impairment and 
decline in small samples of healthy elderly subjects.3,s,8 A number of 
case"control studies showed that HPA axis overactivity is more frequent 
and that cortisol levels are higher among patients with Alzheimer's dis-
ease.5,11.38 In addition, cortisol has been associated with severity of 
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dementia and cogmtIve decline in demented patients.9,10 Furthermore, 
patients with Cushing's syndrome more often present with cognitive 
impairment39, whereas their memory deficits tend to recover after cure.39 
Finally, one of the side effects of treatment with synthetic cortico-
steroids has been cognitive deterioration.40 
In experimental animal studies increased cortisol levels have been 
found to be neurotoxic to certain vulnerable nerve cells, e.g. those in 
the hippocampus.4 The hippocampal neurons modulate HPA axis ac-
tivity, i.e. they are involved in the negative feedback of glucocorticoid 
secretion. Damage to hippocampal cells therefore might lead to HPA 
axis overactivity and subsequently to increased cortisol levels. This is 
described as the 'glucocorticoid cascade' of aging.41 Since hippocampal 
damage is one of the main neuropathological findings in Alzheimer's 
disease, it may be possible that Alzheimer's disease leads to HPA axis 
overactivity. It could however also be that stress-induced HPA axis 
overactivity and increased cortisol levels cause hippocampal damage and, 
subsequently, cognitive decline. But of course, both sequences of events 
may proceed at the same time. Our observation of an association be-
tween cortisol after dexamethasone and subsequent cognitive decline 
may support the latter pathway, but cortisol after dexamethasone may 
also be an early marker of the pathological processes behind Alzheimer's 
disease. For the conisol/CBG ratio, which is considered to be represen-
tative of the biologically active free cortisol levels, we found an associa-
tion with cognitive impairment, but not with cognitive decline. 
Dehydroepiandrosterone sulfate 
There has been one previous prospective population-based study that 
investigated the relationship between DHEAS and subsequent cognitive 
impairment, in which no consistent association was found. 22 Follow-up 
duration was quite long (16 years) and subjects with lower DHEAS 
levels at baseline had a higher mortality, suggesting there may have 
been selective survival bias. There have been a number of case-control 
studies on DHEAS levels and Alzheimer's disease. Some found that 
Alzheimer's disease patients had lower DHEAS levels than con-
trols I5,16,42, but this could not be confirmed by others. 17•21 These studies 
were mostly based on small numbers of patients and controls, thereby 
increasing the possibility of false negative results. In the present study 
we found an association between DHEAS levels and cognitive decline, 
although not significantly, suggesting that decreased DHEAS levels may 
precede changes in cognition. This is in agreement with a small pilot 
study among patients with major depression, who showed improvement 
of selective memory functions after DHEA administration.43 
Serum levels of DHEAS are the highest of all steroids in human 
beings, but the physiological function of DHEAS remains unknown. 
Cerebrospinal fluid levels of DHEA and DHEAS correlated significantly 
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with peripheral concentrations.44 Animal experiments showed that 
DHEAS can enhance neuronal and glial survival and differentiation in 
culture13•14, and that it can improve memory in mice. 13 The memory 
improvement may be explained by the fact that DHEAS affects the 
excitability and plasticity of the hippocampal neuronsz, possibly through 
induction of changes in GABAergic transmission.45 Another explanation 
for the aSSOCIatIOn with cognition may be that DHEA can be 
transformed into estrogens in peripheral tissues.46 The risk of Alz-
heimer's disease has been shown to be reduced in women using estro-
gen compared with those who did not.47 Furthermore, DHEA may act 
as a glucocorticoid antagonist, as described for a number of systems.31 -33 
So a high ratio of cortisol over DHEAS may especially lead to hippo-
campal damageI6, and thus to cognitive impairment. Indeed, the present 
study showed a significant association between the cortisol/DHEAS ratio 
and cognitive impairment. Finally, DHEAS may be regarded as a 
marker of general health status and could therefore be related with 
cognitive function. 
Conclusion 
In conclusion, this small population-based prospective study indicates 
that there may be an association between adrenal steroid hormones and 
cognitive function. The cortisol/CBG ratio seemed to be associated with 
cognitive impairment and cortisol after dexamethasone increased the risk 
of cognitive decline. DHEAS was inversely, but not significantly, associ-
ated with cognitive impairment and decline. However, these results are 
preliminary and larger follow-up studies of longer duration are needed 
to verify these findings. It remains unclear if the observed cognitive 
impairment and decline are the direct result of the changing levels of 
the peripheral steroids, or vice versa, or if another factor influences both 
the adrenal steroid biosynthesis and the processes leading to reduced 
cognitive function. 
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Part III 
Genetics and cognition 

THE APOLIPOPROTEIN E4 
ALLELE, EDUCATION, 
AND COGNITIVE DECLINE 
The Zutphen Elderly Study 
Introduction 
Chapter 
A number of studies have shown that less educated subjects have an 
increased risk of cognitive decline. I Several biological mechanism have 
been postulated to explain these findings. Some have suggested that the 
activation of nerve cells in higher educated subjects protects these cells 
against degeneration2, thereby delaying the pathological process leading 
to cognitive decline. Higher education could also lead to an increased 
brain reserve capacity, so that other neurons can take over the tasks of 
dead neurons.3 This would retard the onset of cognitive decline. How-
ever, the association could be due to confounding by factors related to 
lifestyle. 
The apolipoprotein e4 allele on chromosome 19 is an important risk 
factor for cognitive decline, as shown previously.4 In the present study, 
we examine the association between education and cognitive decline in 
elderly men with and without the e4 allele, to see whether this genetic 
risk factor modifies the association between education and cognition. 
Methods and results 
The Zutphen Elderly Study is a longitudinal study on risk factors for 
chronic diseases in men living in Zutphen, the Netherlands (4). In 1985 
939 men participated, and in 1990, 560 of 718 (78%) surviving men 
were re-examined. The examinations were repeated in 1993 on 390 of 
553 (71%) surviving men. Complete information was available for 356 
men participating both in 1990 and 1993. 
Global cognitive function was tested with the Dutch version of the 
30-point Mini-Mental State Examination. Cognitive decline was defined 
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Table. 
Adjusted odds ratios for cognitive decline* according to level of education in 
the total group and in apolipoprotein e4 allele strata. The Zutphen Elderly 
Study, 1990-1993. 
Total Carrier of the e4 allele population 
Education n (n=356) No (n=272) Yes (n=84) 
Adjustment for age 
> 6 yrs 313 It It It 
~ 6 yrs 43 1.8 2.6 0.7 
(0.8-4.0)t (1.0-7.1) (0.2-3.1) 
Adjustment for age 
and baseline MMSE 
> 6 yrs 313 It It It 
~ 6 yrs 43 2.1 3.1 0.9 
(0.9-4.9) (1.1-8.8) (0.2-3.8) 
MMSE = Mini-Mental State Examination 
• Defined as a drop of > 2 points on the Mini-Mental State Examination 
t Reference 
t 95% confidence interval between parentheses 
as a drop of more than two points (> 1 standard deviation) from 1990 to 
1993, which corresponded to the 14th percentile of change. Years of 
formal education was obtained in 1990 and divided into two categories 
~ 6 and > 6 years). Serum samples were obtained in 1990 and frozen 
at -20'C until determination of the apolipoprotein E phenotype in 1993. 
The phenotype was determined by isoelectric focusing of deli pi dated 
plasma samples followed by immunoblotting. Logistic regression was 
used to examine the association between education and cognitive de-
cline in the total group and the two apolipoprotein e4 strata, adjusting 
for age and baseline Mini-Mental State Examination score. 
The mean age of the participants in 1990 was 74.6 (standard de-
viation = 4.2) years. The median Mini-Mental State Examination score 
was 27 (lOth centile:· 23, 90th centile: 29). The association between 
education and cognitive decline was strong in non-carriers of e41 but 
absent in carriers of e4 (table). The test for interaction was not signifi-
cant (p-value = 0.10. Additional adjustment for a history of cardiovascu-
lar diseases did not change these results. The association between edu-
cation and cognitive impairment in 1990 was similar in 1993 non-partici-
pants and 1993 participants, within strata of the e4 allele (results not 
shown). 
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Discussion 
We observed a significant increased risk of cognItIVe decline associated 
with a lower level of education in subjects without an apolipoprotein e4 
allele. In contrast, there was no association between education and cog-
nitive decline in carriers of the e4 allele. 
Several explanations can be offered for the lack of an association 
with three-year cognitive decline in subjects carrying an e4 allele. It 
may be due to selective survival and non-response. However, our data 
do not suggest that lower educated people with e4 who did not partici-
pate in 1993 had a different risk of cognitive impairment than those 
who participated. We do not know though, whether the risk of cogni-
tive decline differed between the groups. Furthermore, the e4 allele 
may be such a strong risk factor for cognitive decline, that cognitive 
performance in carriers of an e4 allele will deteriorate, regardless of 
educational level. Alternatively, apolipoprotein e4 may play a role in in-
hibiting neuronal growthS, which in turn can play a role in the develop-
ment of Alzheimer's disease2; e4 may thus block the putative stimulat-
ing effect of education on neuronal growth. Finally, we cannot exclude 
the possibility that our results are a chance finding. 
In conclusion, the results of the present study suggest that the 
apolipoprotein e4 allele may modify the association between education 
and cognitive decline. Since this study was relatively small, our findings 
need to be confirmed by larger studies. 
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THE APOLIPOPROTEIN E4 
ALLELE, CEREBROVASCULAR 
DISEASE, AND COGNITIVE 
DECLINE 
The Zutphen Elderly Study 
Abstract 
Chapter 
Background and purpose. Cerebrovascular disease and the apoliprotein 
e4 (APOE*4) allele are both important risk fi1ctors for cognitive dec/ine. 
We investigated the combined effect of APOE*4 and cerebrovascular 
disease on cognitive dec/ine. 
Methods. Data are /Tom a cohort of 353 men, aged 69-89 years at 
baseline, living in Zutphen, the Netherlands. The 30-point Mini-Mental 
State Examination (MMSE) was used to measure cognitive dec/ine (drop 
of >2 points) /Tom 1990 to 1993 (14% of the sample). Odds ratios (OR 
(95% confidence interval)) for cognitive dec/ine were adjusted for age, 
education and baseline MMSE score. 
Results. Compared with those without APOE*4 and without a history 
of cerebrovascular disease, the adjusted OR was 4.7 (1.7-12.7) for 
subjects without APOE*4 but with cerebrovascular disease, 3.3 (1.6-6.8) 
for those with APOE*4 and no cerebrovascular disease, and 17.2 (2.7-
110.0) for those with both risk fi1ctors. The risk for cerebrovascular 
disease and APOE*4 combined was more than expected /Tom the 
separate effects. The combined risk of coronary heart disease and 
APOE*4 was 6.1 (1.7-22.3). The analysis of cardiovascular risk fi1ctors 
showed that the risk of cognitive dec/ine was highest in subjects with 
both APOE#4 and a high cholesterol level, high fibrinogen level, normal 
blood pressure, or diabetes mellitus. 
Conclusions. Cerebrovascular disease and APOE"4 may have a 
synergistic effect on cognitive decline. 
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Introduction 
Cerebrovascular diseases have been associated with an increased risk of 
cognitive impairment and vascular dementia. t•z Other cardiovascular dis-
eases, such as coronary heart disease and peripheral arterial disease, have 
also been related to cognitive impairment2 or vascular dementia.3 Fur-
thermore, several studies observed an association of cognitive impairment 
to cardiovascular risk factors. such as hypertension. diabetes mellitus. 
total cholesterol level. and fibrinogen level.4-s 
In addition. several studies have shown that the apolipoprotein e4 
allele (APOE'4) on chromosome 19 is an important risk factor for Alz-
heimer's disease,9-1J This was also demonstrated for cognitive impair-
ment. which is a major component of dementia. 12-14 Feskens et al. 12 
estimated that 22% of the incident cases of cognitive impairment in a 
community-based sample of elderly men were attributable to the 
APOE'4 allele and that subjects with APOE'4 were at a two fold in-
creased risk of developing impaired cognitive function. Furthermore. 
APOE'4 has been related to cardiovascular diseases and their risk fac-
tors. Apolipoprotein E is a constituent of plasma chylomicrons. lipopro-
teins and their remnants. It serves as a ligand for their receptor medi-
ated uptake. Total and LDL cholesterol concentrations are higher in 
subjects carrying the APOE'4 allele. 15 Carriers of APOE'4 may also 
have an increased risk of coronary heart disease lS-17 and cerebrovascular 
disease. IS 
In this study we examined whether the combined effect of cardio-
vascular diseases and the APOE'4 allele may lead to a higher risk of 
cognitive decline than would be expected from the separate effects. 
The existence of subgroups with an especially high risk may throw light 
on the etiology of cognitive impairment and could have important impli-
cations for preventive intervention. These relations were examined In 
the context of a community-based longitudinal study of elderly men. 
Methods 
Study population 
The Zutphen Elderly Study is a longitudinal study of risk factors for 
chronic diseases in men living in ZutpheoJ a town in the eastern part 
of the Netherlands. 19 It is the continuation of the Zutphen Study. 
which was initiated in 1960 as the Dutch contribution to the Seven 
Countries Study.2o In 1985. 1266 men were asked to participate. 555 
from the original cohort and 711 from a randomly selected sample from 
all other men living in Zutphen in the same age range. In 1985. 939 
agreed to participate. and in 1990. 560 of 718 surviving men (78%) were 
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re-examined. The examinations were repeated in 1993 on 390 of 553 
surviving men (71 %). Complete information on all risk factors was avail-
able for 353 men participating in both 1990 and 1993. The study has 
been approved by the medical ethics committee of the University of 
Leiden, the Netherlands and informed consent was obtained from all 
participants. 
Mini-Mental State Examination 
Global cognitive function was tested with the Dutch version of the 30-
point Mini-Mental State Examination (MMSE).21 The MMSE includes 
questions on orientation to time and place, registration, attention and 
calculation, recall, language and visual construction. This screening test 
was originally created for a clinical setting21 , and is extensively used in 
epidemiological studies.22 Although it tests a limited set of cognitive 
functions, these are important to daily functioning and severely affected 
in dementia. In 1990, it was administered in a controlled hospital set-
ting, and in 1993 it was administered at the subject's homes. If fewer 
than four individual items (of a total of 20 items) were not answered 
by the subject, these were rated as errors23, unless items could not be 
performed because of severe physical disability, in which case a 
weighted total score was given. If a subject did not answer four or 
more individual items the total MMSE score was considered missing. 
Before we performed the analyses, we defined the cut-off point for 
cognitive decline as a drop in the MMSE of >2 points (> 1 SO) from 
1990 to 1993, which corresponded to the 14th percentile of change. In 
test-retest studies it was found that the maximum difference between 
two mean measurements was 2.1 points with a standard error varying 
between 0.4 and 0.7.24 
Apolipoprotein E phenotype 
During the examination in 1990 serum samples were obtained and fro-
zen at -20'C until determination of phenotype in 1993. For 19 subjects 
samples stored at the same temperature from 1985 were used. The 
apolipoprotein E phenotype was determined by isoelectric focusing of 
delipidated plasma samples followed by immunoblotting. 25 The use of 
stored serum for this purpose has been judged to be valid.25 Because of 
a relatively small sample size, homozygotes (2.5%) and heterozygotes 
(20.7%) for the APOE'4 allele were considered together. 
Cardiovascular disease 
In the Spring of 1990 interviews and physical examinations by trained 
physicians were performed at home and in a study center. History of 
myocardial infarction, angina pectoris and intermittent claudication was 
obtained from the Dutch translation of a questionnaire developed at the 
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London School of Hygiene and Tropical Medicine. 26 A history of stroke, 
transient ischemic attack and diabetes was assessed with a standardized 
questionnaire. Medical records, including electrocardiograms, hospital dis-
charge data and written information from general practitioners, were 
collected to verify diagnoses. All information was uniformly coded by 
two trained medical staff members. Cerebrovascular disease was consid-
ered present when either stroke or transient ischemic attack was diag-
nosed, and coronary heart disease was considered present when either 
myocardial infarction or angina pectoris was diagnosed. Diabetes mellitus 
was defined as known or newly diagnosed diabetes, as defined by a 
fasting glucose concentration >7.8 mmol/I or a 2-hour post-load glucose 
concentration > 11.1 mmol/l.27 
Cardiovascular risk factors 
Systolic and diastolic (fifth Korotkoff phase) blood pressure were meas-
ured with a random zero sphygmomanometer in duplicate on the right 
arm with the subject in supine position at the end of the physical ex-
amination. The mean of the two blood pressure values was used in the 
analyses. Hypertension was defined as a systolic blood pressure ~160 
mmHg or a diastolic blood pressure ~95 mmHg or the use of anti-hy-
pertensive medication, regardless of blood pressure level.28 Blood was 
taken to determine the concentrations of lipids and hemostatic factors. 
Total and HDL cholesterol were analyzed in non-fasting blood samples 
by the standardized Lipid Laboratory at the Department of Human Nu-
trition, Wageningen Agricultural University, The Netherlands. Serum 
cholesterol was determined enzymatically with the CHOD-PAP mono-
testkit from Boehringer Mannheim.29 It was dichotomized and a concen-
tration of s6.5 mmol/I was taken as the reference category. Serum HDL 
cholesterol was determined enzymatically after precipitation of apolipo-
protein B containing particles by dextran sulphate-Mg2+.3o HDL choles-
terol was dichotomized and a concentration of SO.9 mmol/I was used as 
the reference category. Fibrinogen concentration was determined in ci-
trate plasma by the method of Clauss.31 Analyses were performed at the 
Laboratory of the Department of Human Biology, University of Lim-
burg, Maastricht, The Netherlands. We used the upper tertile of fibrin-
ogen (3.8 gil) as cut-off point, because there is no consensus on this 
matter. Age (continuous) and education (s6 years, 7-12 years and >12 
years of education) were considered as confounding variables. 
Statistical analysis 
Differences in baseline characteristics were evaluated between carriers, 
defined as either homozygote or heterozygote for the APOE*4 allele, 
and non-carriers. We used the nonparametric Mann-Whitney test for 
continuous variables, and the Chi-square test for categorical variables. 
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The proportion of men with cognitive decline according to the presence 
or absence of cardiovascular factors Was calculated for the total group 
and for the two APOE*4 strata separately. These percentages Were ad-
justed for age and education by multiple linear regression analysis. 
Next, we investigated whether the combined effect of the APOE'4 
allele and cardiovascular factors on cognitive decline was different from 
the separate effects.32 We categorized subjects into four groups: subjects 
without the APOE'4 allele and the risk factor (reference group); sub-
jects without APOE'4 and with the risk factor; subjects with APOE'4 
and without the risk factor; and subjects in whom both APOE'4 and 
the risk factor were present. These groups were entered into a multiple 
logistic regression model as dummy variables. We adjusted for age, edu-
cation, and baseline MMSE score. We additionally adjusted for the 
score on the self-rating depression scale that was available for a sub-
group. Since the results did not essentially change we decided not to 
present the results with adjustment for depression. 
We examined whether subjects who did and did not participate in 
1993 differed at baseline (1990). In addition, we investigated whether 
the relation between cardiovascular diseases, APOE'4, and cognitive im-
pairment at baseline was different for those who dropped out of our 
study population compared with those who did not. All tests were 
two-sided and a value of p<O.OS was considered statistically significant. 
The SAS-program, version 6.10, was used. 
Results 
The mean age of the partIcIpants at baseline (1990) was 74.6 (SD = 
4.2) years. The median MMSE score was 27 (10th centile: 23, 90th 
centile: 29). Fourteen percent (n=51) showed a drop in the MMSE of 
>2 points. Carriers of the APOE'4 allele more often showed cognitive 
decline and had a higher serum cholesterol concentration (Table I). 
In the total group, a history of cerebrovascular disease was signifi-
cantly associated with cognitive decline, after adjustment for age, educa-
tion and baseline MMSE score (OR=4.3, 95% confidence interval (CI): 
1.8-9.9). A history of coronary heart disease slightly increased the risk of 
cognitive decline (OR=I.7, 95% CI: 0.8-3.5). Intermittent claudication 
and cardiovascular risk factors were not significantly associated with 
cognitive decline in the total group. 
After adjustment for age and education, the proportion of subjects 
with cognitive decline in those without APOE'4 and without a history 
of cerebrovascular disease was 9%, and in those without APOE*4 and 
with cerebrovascular disease it was 32% (Table 2). Therefore, among 
non-carriers, the difference in the percentage of men with cognitive 
decline in those with cerebrovascular disease and those without was 
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Table 1 
Baseline characteristics in 1990 according to presence of the APOE*4 
allele. The Zutphen Elderly Study (1990-1993). 
APOE'4 allele 
Variable Absent Present p-value 
(n=271) (n=82) 
Baseline MMSE score 26.5 (2.5)" 26.1 (2.6) 0.2 
Age (yrs) 74.7 (4.2) 74.5 (4.3) 0.7 
Higher education (>12. yrs) 25% 20% 0.3 
History of! 
Cerebrovascular disease 9% 7 % 0.7 
• Coronary heart disease 19 % 15 % 0.3 
• Intermittent claudication 9% 6% 0.4 
Hypertensiont 40 % 34 % 0.4 
Diabetes mellitust 13 % 18 % 0.3 
Total cholesterol (010101/1) 6.05 (1.08) 6.42 (1.17) om 
HDL cholesterol (mmol/I) 1.15 (0.28) 1.13 (0.27) 0.7 
Fibrinogen (gil) 3.7 (0.4) 3.7 (0.3) 0.7 
MMSE = Mini-Mental State Examination; APOE"4 = apolipoprotein e4 
allele 
4 Standard deviation between parentheses 
t Defined as diastolic blood pressure 295 mmHg and/or systolic blood 
pressure 2160 mmHg or use of antihypertensive medication 
t Known and newly diagnosed diabetes 
23%. In the stratum of APOE"4 carriers. the proportion of subjects with 
cognitive decline in those without cerebrovascular disease was 22%. and 
in those with cerebrovascular disease it was 66% 
Thus among APOE"4 carriers. the difference in the percentage of 
men with a decline in those with cerebrovascular disease and those 
without was 44%. This percentage (44%) was· approximately twice as 
high as in the non-carriers (23%). The difference in percentage of men 
with cognitive decline in those with and without coronary heart disease 
was also two times higher in carriers of APOE"4 compared with the 
non-carriers (13% vs 6%). Intermittent claudication was not associated 
with cognitive decline among non-carriers. but 11% more subjects expe-
rienced cognitive decline among APOE"4 carriers. which was not signifi-
cant. 
The results of the logistic regression analysis. in which subjects 
without the cardiovascular disease and without the APOE"4 allele were 
taken as the reference grouP. are shown in Figure 1. The presence of 
both the APOE"4 allele and cerebrovascular disease increased the risk 
of cognitive decline substantially to 17.2 (95% CI, 2.7-110.0) (Figure 
Table 2 
Proportion of men with cognitive decline* according to the history of cardiovascular diseases in the total group and 
APOE*4 strata, adjusted for age and education. The Zutphen Elderly Study. 
Total population Carrier of the APOE*4 allele 
(n=353) No (n=271) Yes (n=82) 
Hist0!1 of disease: No Yes Differencet No Yes Difference No Yes Difference 
Cerebrovascular disease 12% 38% 26%§ 9% 32% 23%§ 22% 66% 44%1 (323):j: (30) (247) (24) (76) (6) 
Coronary heart disease 13% 20% 7% 10% 16% 6% 24% 37% 13% (289) (64) (219) (52) (70) (12) 
Intermittent claudication 14% 14% 0% 11% 11% 0% 25% 36% 11% (323) (30) (246) (25) (77) (5) 
APOE*4 = apolipoprotein E e4 allele 
., Defined as a drop of >2 points on the Mini-Mental State Examination 
t Difference in the proportion of men with cognitive decline between those with and without the cardiovascular disease 
:j: Number of men in this group 
§ p<O.OOI, for the difference in proportion of cognitive decline comparing subjects with and without disease 
1 p<0.05, idem 
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Interaction between APOE*4 and cardiovascular diseases - The Zutphen 
Elderly Study. 
ORs are adjusted for age, education and baseline Mini-Mental State 
Examination score; no APOE*4 and no disease = reference. APOE*4 = 
apolipoprotein E e4 allele. 
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lA}. This OR was more than would be expected from the sum of the 
separate ORs (4.7 and 3.3), suggesting that the effect of the two factors 
together on cognitive decline was synergistic. 33 The same synergy, al-
though not as strong, may be present for coronary heart disease and the 
APOE*4 allele (Figure lB). The OR for subjects with APOE*4 and 
coronary heart disease was 6.1 (95% CI: 1.7-22.3). Intermittent claudica-
tion did not seem to be related to cognitive decline, whether APOE*4 
Was present or not (results not shown). 
The analysis of cardiovascular risk factors showed that in the 
APOE*4 stratum, there were proportionally more men with cognitive 
decline in the high than in the low category of total cholesterol, HDL 
cholesterol and fibrinogen, although these differences were not signifi-
cant (Table 3). None of the ORs of the cardiovascular risk factors were 
significantly increased in the absence of APOE*4 (Table 4). The risk of 
cognitive decline was highest in subjects with both APOE*4 and a high 
cholesterol or high fibrinogen level or diabetes mellitus. On the other 
hand, the risk of cognitive decline appeared to be lower in subjects 
with APOE*4 and hypertension than in those with APOE*4 and with-
out hypertension. 
Cognitive impairment in 1990 (MMSE score <26) and a history of 
major cardiovascular diseases (stroke or myocardial infarction) Was more 
frequent in those who did not participate in 1993 than in those who 
did (results not shown). The APOE*4 frequency was not significantly 
different between these groups. In both non-participants and participants 
the percentage of men with cognitive impairment at baseline tended to 
be higher in those with an APOE*4 allele than in those without (42% 
vs 36% and 38% vs 27%, respectively). In both non-participants and 
participants the percentage of men with cognitive impairment did not 
differ significantly between those with a history of cardiovascular disease 
and those without (45% vs 39% and 26% vs 30%, respectively). There 
was no significant interaction between participation status and one of 
these risk factors (p>O.l). 
Discussion 
Our study was a community-based prospective study in which the 
change in cognitive function was measured. To our knowledge, this is 
one of the first studies that investigated the combined effect of cardio-
vascular diseases and APOE'4 on cognitive decline. We found that 
APOE'4 carriers who suffered a stroke or transient ischemic attack had 
a particularly increased risk of cognitive decline, which was more than 
could be expected from the separate effects of these risk factors com-
bined. This suggests synergism.33 The same synergy may be present 
between coronary heart disease and APOE*4, although this was less 
Table 3 
Proportion of men with cognitive decline' according to the presence of cardiovascular risk factors in the total group 
and APOE*4 strata, adjusted for age and education. The Zutphen Elderly Study. 
Total population Carrier of the APOE'4 allele 
(n=353) No (n=271) Yes (n=82) 
Risk factor eresent: No Yes Difference t No Yes Difference No Yes Difference 
Hypertension:j: 14% 15% 1% 10% 13% 3% 27% 22% -5% (217)§ (136) (163) (108) (54) (28) 
High total cholesterol 13% 17% 4% 11% 12% 1% 21% 31% 10% (237) (116) (191) (80) (46) (36) 
High HDL cholesterol 11% 15% 4% 8% 12% 4% 20% 28% 8% (73) (280) (52) (219) (21) (61) 
High fibrinogen 15% 14% 
-1% 12% 10% -2% 23% 32% 9% (235) (118) (178) (93) (57) (25) 
Diabetes mellitus1 14% 11% 
-3 12% 3% 
-9% 24% 29% 5% (282) (47) (216) (33) (66) (14) 
APOE'4 = apolipoprotein E e4 allele 
"" Defined as a drop of >2 points on the Mini-Mental State Examination 
t Difference in the proportion of men with cognitive decline comparing those with and without the cardiovascular risk 
factor 
:j: Defined as diastolic blood pressure <:95 mmHg and/or systolic blood pressure <:160 mmHg or use of antihypertensive 
medication 
§ Number of men in this group 
1 Known and newly diagnosed diabetes; analyses on 329 men due to missing values 
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Table 4 
Odds ratios for cognitive decline* according to presence of cardiovascular 
risk factors and APOE*4, adjusted for age, education, and baseline Mini-
Mental State Examination score. The Zutphen Elderly Study. 
Carrier of the APOE"4 allele 
No (n~271) Yes (n~B2) 
Risk factor ~resent: No Yes No Yes 
Hypertension t 1.0 1.3 3.7 2.7 
(0.6-2.B)* (1.6-B.6) (0.9-8.3) 
High total cholesterol 1.0 1.0 2.5 4.0 
(0.4-2.6) (1.0-6.0) (1.6-10.0) 
High HDL cholesterol 1.0 2.0 3.7 6.2 
(0.6-7.1) (0.7-19.2) (1.6-23.6) 
High fibrinogen 1.0 0.9 2.6 3.6 
(0.4-2.1) (1.2-6.0) (1.3-10.4) 
Diabetes mellitus§ 1.0 0.2 2.7 4.0 
(0.03-1.9) (1.3-5.7) ( 1.0-IS.B) 
APOE'4 ~ apolipoprotein E e4 allele 
• Defined as a drop of >2 points on the Mini-Mental State Examination 
t Defined as diastolic blood pressure ~9S mmHg and/or systolic blood 
pressure ~160 mmHg or use of antihypertensive medication 
* 95% confidence interval between parentheses 
§ Known and newly diagnosed diabetes; analyses on 329 men due to 
missing values 
clear. These results were independent of age, education, baseline 
MMSE score and depression. However, there is still a possibility that 
our results are due to residual confounding. 
The MMSE is a reliable and valid indicator of cognitive impair-
ment.34 We used the MMSE to assess change in cognitive function, for 
which it was not originally created. One study examined the reliability 
of change in the MMSE in patients with dementia. They found that 
for a time interval between the MMSE's of one year or more the reli-
ability was approximately 0.74, which is reasonable.35 We chose a cut-off 
point of a drop in the MMSE of >2 points, which may not be pathol-
ogically significant on an individual level, but can be of major impor-
tance on a population level. 
The synergism we observed may suggest that APOE'4 potentiates 
the effect of cerebrovascular disease on cognitive decline. Frisoni et al.36 
hypothesized that different insults, either degenerative or vascular, might 
result in greater damage when a particular apolipoprotein E isoform alle-
le is present. The possibility that cerebrovascular disease is more harm-
ful in carriers of APOE"4 is suggested in a study showing that after 
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hemorrhagic stroke the functional neurological outcome in subjects with 
an APOE*4 allele was worse and survival reduced, compared with sub-
jects with no APOE*4 alleleY This may result from reduced neuronal 
repair in APOE*"4 carriers.38 Alternatively, cerebrovascular disease may 
potentiate the effect of APOE'4 on cognitive decline by increasing the 
susceptibility of the brain to the effects of APOE·4. Coronary heart 
disease and peripheral arterial disease are associated with an increased 
risk of cerebral damage. Thus, the same mechanisms may account for 
the association between these diseases, APOE*4 and cognitive decline. 
However, in this study there was no obvious synergism between coro-
nary heart disease and APOE*4. In addition, intermittent claudication 
was not clearly associated with cognItIVe decline, irrespective of 
APOE·4. This may be due to the relatively small number of subjects 
with intermittent claudication in our study and to the fact that our di-
agnosis was based on typical symptoms and information on peripheral 
atherosclerosis was lacking. 
Total cholesterol, fibrinogen, hypertension and diabetes mellitus 
were not independently associated with cognitive decline. However, the 
data suggest that the risk of cognitive decline was increased in subjects 
with APOE*4 and one of these cardiovascular risk factors, except for 
hypertension. Perhaps these risk factors have an effect on cognition only 
when the brain tissue is altered by the effects of APOE*4. Our results 
on total cholesterol correspond to a recent case~control study, which 
suggested that the association between apolipoprotein E genotype and 
Alzheimer's disease was stronger when cholesterol levels were higher.39 
We found that high HDL cholesterol was insignificantly associated with 
an increased risk of cognitive decline, irrespective of APOE*4. Addi-
tional adjustment for cigarette smoking and alcohol consumption did not 
essentially alter this association, while additional adjustment for choles-
terol reduced it only slightly. Several other studies have not found an 
association between cognitive function and HDL cholesterol. 14•40 We can 
not exclude the possibility that this is a chance finding. 
We investigated the possibility of selection bias due to non-partici-
pation. The association between APOE"4 and cognitive impairment in 
1990 was not different for those who participated in 1993 compared 
with those who did not, nor was the association between a history of 
cardiovascular disease and cognitive impairment. This suggests that our 
results were probably not biased by selective non-participation. 
From this study we conclude that cerebrovascular disease and the 
APOE*4 allele may have a synergistic effect on cognitive decline. In 
addition, coronary heart disease and cardiovascular risk factors may inter-
act with APOE*4 to increase the risk of cognitive decline above and 
beyond the effect of APOE"4 alone. This study suggests that genetic 
risk factors are important to consider when studying the association be-
tween cardiovascular diseases and cognitive function. Additional studies 
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will be needed to determine whether synergism is also suggested when 
the risk of dementing disorders such as Alzheimer's disease and vascular 
dementia is examined. 
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Part IV 
Survival and cognition 

DEMENTIA AND 
CAUSE-SPECIFIC MORTALITY 
The Rotterdam Study 
Abstract 
Background - Dementia has been associated with an increased 
mortality, but few studies investigated cause-specific fllOrtality. We 
investigated the association between subtypes of dementia and total and 
cause-specific mortality. 
Methods - Data are from the population-based Rotterdam Study. 
Participants were aged 55 years or over and living in a suburb of 
Rotterdam. At baseline we screened for dementia with a three step 
protocol, that included a clinical examination. Subdiagnoses were made 
according to international criteria. Causes of death were obtained from 
general practitioners and medical records. The risk for mortality (RR 
(95% CI)) was assessed with proportional hazards analysis, adjusting for 
age, sex, education, smoking, and alcohol consumption. Afrer a mean 
follow-up time of four years (SD~I.2), 751 (10.8%) of the 6985 subjects 
with information on prevalent dementia and with complete follow-up 
had died 
Results - Subjects with dementia had an increased risk of dying 
(RR~2.0 (1.6-2.4)). This risk was 2.9 (1.9-4.3) for subjects with vascular 
dementia, and 1.8 (1.5-2.3) for subjects with Alzheimer's disease. In 
addition, the age-adjusted percentage of subjects that died from cancer 
was lower among demented than non-demented subjects (13.3% vs 
24.9%, p<o.OI), whereas the percentage that died from 
noncardiovascufar-noncancerous causes lVas higher among demented 
subjects (49.2% vs 31.3%, p<O.OOI). 
Conclusion - This study suggests that there is a shifr in the 
distribution of the causes of death among demented subjects towards 
less deaths from malignancies and more deaths from noncardiovascular-
noncancerous causes. 
lOS 
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Introduction 
Dementing diseases are associated with an increased mortalityl-S, with 
mortality risks varying from 1.4 to 5.4 for Alzheimer's disease.3•s The 
number of life years lost due to dementia is considerable.6 For the next 
50 years, the number of deaths attributable to dementia in the United 
States is expected to increase by 180% as a result of demographic 
changes.1 
For relatives and caregivers of demented subjects and for clinicians and 
planners of health care facilities it is important to have detailed infor-
mation on the prognosis of dementia. To shed more light on the in-
creased mortality of demented subjects. we examined the association 
between (subtypes of) dementia and cause-specific mortality. These re-
lations were studied in a population-based follow· up study of elderly 
subjects. 
Methods 
Study population 
We used data from the Rotterdam Study, a single-centre prospective 
population-based study, designed to investigate determinants of selected 
chronic diseases and disabilities in older persons.s The conduct of the 
study was approved by the Medical Ethics Committee of Erasmus Uni-
versity and written consent was obtained from all participants. All resi-
dents of the Ommoord suburb of Rotterdam, the Netherlands, aged 55 
years or over, were invited and of the 10,275 eligible subjects, 7,983 
(78%) agreed to participate. Baseline data were collected from May 1990 
to June 1993. During a home visit, trained interviewers administered a 
questionnaire, covering, among other areas, sociodemographic background, 
medical history, and medication use. This was followed by two clinical 
examinations at the research centre. Subjects living in nursing homes 
were visited at home. 
Dementia case-finding 
Prevalence of dementia was ascertained on the basis of a study exami-
nation, in which 7528 subjects participated. Screening consisted of a 
three stage procedure.9 First, all participants were screened with the 
30-point Mini-Mental State Examination lO and the short version of the 
Geriatric Mental State schedule (GMS·A, organic level}.ll Subjects with 
an MMSE score below 26, or a GMS score greater than 0 were 
considered screen-positive. They were subsequently examined with the 
Cambridge Examination of Mental Disorders in the Elderly (CAMDEX), 
which included an informant interview. 12 Participants who were judged 
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to be demented or suspected of dementia after the CAMDEX, were 
examined by a neurologist and tested by a neuropsychologist; a part also 
underwent magnetic resonance imaging (MRI) of the brain. In addition, 
medical files were used to diagnose dementia. Dementia was diagnosed 
according to the American Psychiatric Association's criteria (DSM-III-
R).13 The subdiagnosis of Alzheimer's disease was based on 
NINCDS-ADRDA criteria.14 The presence of cerebrovascular disorders 
did not prohibit a diagnosis of Alzheimer's disease. In accordance with 
above-mentioned criteria, a subdivision was made into Alzheimer's dis-
ease patients with and without cerebrovascular disease. In Alzheimer's 
disease patients with cerebrovascular disease, this disease was not con-
sidered to be directly etiologically related to the dementia. Vascular de-
mentia was diagnosed conform NINDS-AIREN criteria. IS In these pa-
tients the onset of dementia was related to cerebrovascular disease. 
They generally had an acute onset of dementia symptoms with stepwise 
progression of the disease. DSM-III-R criteria were used to classify 
other dementias, but they were not included in our analyses. 
Other measurements 
The following variables were considered as possible confounding vari-
ables: age; sex; cigarette smoking (never, former and current); alcohol 
consumption (none, <1 drink (13.2g), 1-2 drinks, ;:>:3 drinks per day), 
assessed with a semi-quantitative food frequency questionnairel6; level of 
education (completed primary education; lower vocational or general 
education; intermediate vocational or general education; and higher vo-
cational training, college or university) (UNESCO); body mass index 
(weight/height2); and hypertension, which was defined as a systolic blood 
pressure of 160 mmHg or over, or a diastolic blood pressure of 95 
mmHg or over, or the use of anti-hypertensive medication,17 
Follow-up 
Vital status of the participants was obtained in several ways. Information 
on vital status was acquired at regular intervals from the municipal 
authorities of Rotterdam. In addition, general practitioners working in 
the study district of Ommoord regularly gave computerized reports on 
the deaths of all participants from the Rotterdam Study. For all report-
ed deaths, study physicians investigated the causes of death using medi-
cal records from the general practitioners and hospital discharge records 
in case of admittance or referral. All general practitioners working in 
Rotterdam, but outside the district of Ommoord, who had patients who 
participated in the Rotterdam Study, were visited to obtain information 
on vital status, and if applicable, on the cause of death. Participants 
who had left Rotterdam (n-543, 6.8%) were not further tracked for this 
analysis. These subjects were older than the 6985 with information on 
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prevalent dementia and vital status (74.2 years (SD~11.7) vs 70.1 years 
(SD~9.5), p<O.OOl). In addition, they were more often female (68% vs 
61 %, p~0.002) and had a much higher prevalence of dementia (20% vs 
5%, p<O.OOl). The end of the follow-up period was set at April 30, 
1996. Mean duration of follow-up was 4.0 (SD~1.2) years. 
The underlying causes of death were coded independently by two 
study physicians. Any discrepancy was discussed until consensus was 
reached. Cause of death was coded according to the 10th Revision of 
the International Classification of Diseases.IS The end-points investigated 
were all-cause mortality, mortality from cardiovascular disease (codes 100-
199), from ischemic stroke (codes 163-169), from coronary heart disease 
(codes 120-125), from malignancies (codes COO-C97), and from noncardio-
vascular-noncancerous causes. The latter category was further subdivided 
in mortality from mental and behavioral diseases (codes FOO-F99), from 
diseases of the respiratory system (codes JOO-J99), from diseases of the 
digestive system (codes KOO-K93), from diseases of the genitourinary 
system (codes NOO-N99), from external causes (codes SOO to Y98), from 
unknown causes (codes R96, R98 and R99), and from other causes. 
Statistical analysis 
Complete information on baseline dementia and subsequent mortality 
was available for 6985 subjects. Baseline characteristics according to de-
mentia and vital status after adjustment for age were tested with analy-
sis of covariance. The frequency distribution of the causes of death 
among demented and nondemented subjects was tested with analysis of 
covariance as well. Cox's proportional hazards analysis was carried out to 
investigate the association between prevalent dementia (subtypes) and 
mortality. We included confounding variables in the model. Additional 
adjustment for age squared did not improve the model (likelihood ratio 
test: XZ~3.54 with Idf, p>0.05) and it did not change the estimate for 
dementia. Adjustment for 5-yr age groups instead of age as a continuous 
variable did not change the estimate either. For missing values of con-
founding variables, an indicator variable was created. Since we investi-
gated the mortality risk of subjects with prevalent dementia, for whom 
the onset of dementia was not kno\vn, we additionally examined 
whether the severity of dementia, as a proxy for the duration of the 
disease, was associated with mortality. The severity of dementia was 
categorized into four groups according to the clinical dementia rating 
scale and the Mini-Mental State Examination scorel9: mild, minimal, 
moderate and severe dementia. The first two and the latter two groups 
were combined because of small numbers. All tests were two-sided and 
a p-value of less than 0.05 was considered to be statistically significant. 
Data analyses were performed using BMDP statistical software. 
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Table 1 
Age-adjusted baseline characteristics according to vital status and 
dementia. The Rotterdam Study. 
Alive 
Mean age (yrs) 
Sex (% female) 
Primary education only 
Current smokers 
Body mass index (kg/ml ) 
Hypertension 
No 
dementia 
(n~6028) 
68.5 (8.5)' 
62% 
38% 
21% 
26.4 (O.O)t 
31% 
'*' Standard deviation in parentheses 
t Standard error in parentheses 
Results 
Dementia 
(n~206) 
82.7 (7.8) 
67% 
37% 
22% 
25.7 (0.4) 
32% 
Dead 
No 
dementia 
(n~585) 
77.7 (9.2) 
47% 
39% 
30% 
25.4 (0.2) 
35% 
Dementia 
(n~166) 
85.7 (6.5) 
60% 
39% 
27% 
24.4 (0.3) 
13% 
The mean age of the participants at baseline was 70.1 years (SO ~ 9.5). 
Of the 6985 participants, 372 (5.3%) were demented at baseline; 245 
(3.6%) were classified as having 'pure' Alzheimer's disease, 31 (0.4%) as 
having Alzheimer's disease with cerebrovascular disease, 54 (0.8%) as 
having vascular dementia, and 42 (0.6%) as having other types of de-
mentia. After a mean follow-up period of four years (SO~1.2), 751 
(10.8%) subjects had died. Age-adjusted baseline characteristics according 
to dementia and vital status are described in Table 1. 
Total mortality risk was twice as high in demented subjects com-
pared with non-demented subjects, after adjustment for age, sex, educa-
tion, smoking, and alcohol consumption (RR~2.0, 95% C[: 1.6-2.4). The 
5.5 year survival for a 75 year old man without dementia was 80%, and 
with dementia approximately 65% (Figure). A 75 year old woman with-
out dementia had a 90% chance of surviving 5.5 years, a woman with 
dementia 80%. For subjects with Alzheimer's disease the risk of dying 
was 1.8 (95%C[: 1.5-2.3), for subjects with vascular dementia it was 2.9 
(95%C[: 1.9-4.3). Additional adjustment for body mass index or hyper-
tension did not essentially alter these results. Mortality risk for subjects 
with mild and minimal dementia (RR~1.9, 95% C[: 1.5-2.4)) was not 
essentially different from the mortality risk for those with moderate and 
severe dementia (RR~2.0 (95% C[: 1.5-2.7). 
To examine whether there was a shift in the distribution of the 
causes of death in subjects with dementia compared with those without 
dementia, we calculated the age-adjusted frequencies of the causes of 
death among all those who died. Approximately two- fifth of the non-
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Figure 
Survival curves for a 75 year old man and woman with or without 
dementia. The Rotterdam Study. 
Table 2 
Age-adjusted frequency distribution of the causes of death among demented and nondemented subjects who died. The 
Rotterdam Study. 
Mortality from No dementia Total dementia Alzheimer's Vascular dementia disease (n=585) (n=166) (n=105) (n=44) 
Cardiovascular disease 43.7%t 37.5% 34.8% 45.2% 
Ischemic stroke 11.4% 13.9% 12.9% 15.0% 
• Coronary heart disease 12.7% 7.2% 7.1% 8.7% 
Malignancies 24.9% 13.3%" 14.8%' 10.2%' 
Noncardiovascular noncancerous causes+ 31.3% 49.2%'" 50.4%'" 44.6% 
t Percentage of subjects of all those who died in this group 
4: Included are: mortality from mental and behavioural diseases, diseases of the respiratory system, diseases of the 
digestive system, diseases of the genitourinary system, external causes, cause unknown, and other causes 
• p<0.05, •• p<O.OI, and .,. p<O.OOI for the age-adjusted difference with nondemented subjects 
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demented subjects that died, died from cardiovascular disease (Table 2). 
This proportion was about the same among demented subjects, but 
somewhat lower among subjects with Alzheimer's disease and somewhat 
higher among subjects with vascular dementia, although the difference 
was not significant. The percentage of subjects that died from ischemic 
stroke was not significantly higher among participants with vascular de-
mentia than among those without dementia. A quarter of the non-de-
mented participants that died, died from malignancies, whereas this pro-
portion was significantly lower among demented participants that died. 
Relatively more demented than non-demented participants died from 
noncardiovascular-noncancerous causes, including mental and behavioural 
diseases (5.5% vs 0.3%, p<O.OOI), diseases of the respiratory system (only 
significant for Alzheimer's disease patients (10.8% vs 5.1%, p<0.05», and 
unknown causes (19.1% vs 11.5%, p<0.05). Additional adjustment for 
education did not essentially alter these results. Age at time of death 
was lower among subjects who died from cancer than among those who 
died from other causes (74.3 yrs (SD~8.8) vs 81.0 yrs (SD~8.8». 
Discussion 
This large population-based prospective follow-up study suggested that 
demented subjects had an increased overall mortality compared with 
non demented subjects. Mortality risk was higher for subjects with vascu-
lar dementia than for subjects with Alzheimer's disease. The results 
were independent of age, sex, education, smoking, alcohol consumption, 
body mass index, and hypertension. Furthermore, taking age into ac-
count, there was a shift in the distribution of the causes of death 
among demented subjects towards less deaths from malignancies and 
more deaths from noncardiovascular-noncancerous causes. There were no 
large differences in the frequencies of the cardiovascular causes of 
death. 
This was a large study, allowing us to examine cause-specific mor-
tality risks in subgroups. In addition, it was population-based, including 
demented subjects from institutions as well as those who lived inde-
pendently, thereby increasing the generalizability of our results. The 
results were based on prevalent and not on incident dementia cases, 
which presumably resulted in a more heterogeneous sample of de-
mented subjects, who were in different stages of the disease. Since the 
duration of dementia varies among subjects with prevalent dementia, the 
mortality risk will be different among prevalent compared with incident 
demented subjects. However, severity of dementia, as a proxy for the 
duration of the disease, did not influence mortality risks. But perhaps 
severity was not an appropriate proxy for duration of disease. Further-
more, the follow-up period in this study was relatively short, which may 
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have lead to an overrepresentation of rapidly progressive dementias 
among the demented subjects that died. This might have influenced 
our findings on cause-specific mortality. Finally, some subjects with vas-
cular dementia may have been misclassified as having Alzheimer's dis-
ease, or vice versa. However, the criteria we used for the diagnosis of 
Alzheimer's disease have a high sensitivity and specificity.20 
It could be argued that selective loss to follow-up has affected the 
validity of our results. Subjects who were lost to follow-up were older 
and more often demented at baseline. It is likely that the mortality rate 
was higher among those who were lost to follow-up. If anything, this 
would probably have attenuated our results on all-cause mortality. It is 
however not clear, how selective loss to follow-up may have influenced 
our findings on cause-specific mortality. 
A number of community-based studies investigated the assoclatton 
of dementia and its subtypes with mortality.I-S.21 They consistently 
found an increased mortality risk in demented compared with non-de-
mented subjects, and a higher mortality for subjects with vascular de-
mentia than for subjects with Alzheimer's disease l,3,21, which is in 
agreement with our results. To our knowledge, three previous studies 
examined the causes of death in demented subjects, but these studies 
were not population-based and causes of death were obtained mostly 
from death certificates.22.24 Kukull et al.22 studied the causes of death 
among newly recognized dementia cases from a registry, and compared 
them with those who failed to meet the criteria for dementia. Dementia 
and pneumonia were more common causes of death in severe Alzhei-
mer's disease patients, and stroke in mildly impaired Alzheimer patients. 
These results were crude and no significance was tested. Nielsen et 
alP studied causes of death 15 years after a geronto-psychiatric preva-
lence study. Pneumonia was a more frequent cause of death among 
demented subjects compared with subjects without any mental illness. 
Again, results were not adjusted for age, or other covariates. In the 
study by Molsa et a1. 24, demented subjects from a community-based 
study had a lower frequency of deaths from malignancies and cardiovas-
cular disease and a higher frequency of deaths from dementing diseases 
than subjects from a general population of 75 years or over. Cerebrovas-
cular disease seemed to be a more common Cause of death in patients 
with multi-infarct dementia. However, no significance was tested. 
There was a shift in the distribution of the causes of death among 
demented participants towards less deaths from cancer. This may be 
due to the fact that subjects who died of cancer were on average 
younger at time of death than those who died of other causes, and 
therefore had a lower .probability of being demented. Additionally, per-
haps demented subjects are less able to recognize suspicious symptoms 
and signs, or they less often get a thorough diagnostic work-up in case 
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of suspicious symptoms and signs, thereby reducing the chance of being 
diagnosed with cancer. 
There was a shift towards more deaths from noncardiovascular-non-
cancerous causes among demented persons. These causes included men-
tal and behavioral diseases, diseases of the respiratory system and death 
from unknown causes (i.e. sudden death, cause unknown; unattended 
death; and other ill-defined causes of mortality). The increase in deaths 
from unknown causes may be explained by the fact that demented 
subjects more often die in nursing homes instead of in the hospital, 
where the cause of death is more easily assessed. There were no rc-
ports of suicide or euthanasia among the causes of death. Suicide and 
euthanasia are probably often under-reported causes of death. Suicide 
may occur more often in subjects with dementia, especially early de-
mentia, than in those without.25 There is considerable debate about ac-
tive euthanasia of demented patients, and it is not clear how often this 
is performed.26 Passive euthanasia probably occurs more often in de-
mented than non-demented subjects. A study conducted in the Nether-
lands on the frequency of decisions to forgo (artificial) feeding and hy-
dration with hastening of death as a possible result, showed that this 
had occurred in 23% of the deaths attended by nursing home physi-
cians, compared with 4% of those attended by general practitioner or 
specialists. Most of the persons that died this way were incompetent 
and the reported cause of death was often a psychiatric disturbance.27 It 
is possible that suicide and euthanasia were coded as death due to un-
known cause, which would then partly explain the increased frequency 
of unknown causes of death among demented persons. 
This large population-based follow-up study showed that subjects 
with dementia had an increased all-cause mortality, with mortality risk 
being higher in subjects with vascular dementia than in subjects with 
Alzheimer's disease. There was a shift in the distribution of the causes 
of death among demented subjects towards less deaths from malignan-
cies and more deaths from non cardiovascular-noncancerous causes. Clini-
cians who are involved in the treatment of demented subjects and 
planners of health care facilities may use this information to improve 
the care of demented subjects. 
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General discussion 

GENERAL DISCUSSION 
Knowledge on risk factors for dementia has expanded consider-ably during the past decade, demonstrating important risk in-dicators and risk factors, such as age, sex, education, and fam-ily history.' In this thesis several new potential risk factors for 
cognitive decline and dementia have been identified. The rationale for 
investigating these risk factors is that vascular, oxidative, inflammatory, 
and stress-related processes may play a role in the pathogenesis of cog-
nitive decline and dementia. Most of the risk factors we studied can be 
modified, which creates the possibility of delaying the onset of demen-
tia. This could be of significant public health importance. In addition, 
our findings may give new clues to the etiology of dementia and pro-
vide ideas for further epidemiologic and basic research. 
After a brief discussion of the main findings, some methodological 
problems specific for this study will be discussed. Furthermore, the hy-
potheses on the mechanisms behind the associations with cognitive de-
cline and dementia will be addressed in the light of our findings. Final-
ly, some ideas will be presented for future research on risk factors for 
cognitive decline and dementia. 
Main findings 
The main results on nutritional risk factors for cognitive decline and 
dementia described in this thesis are summarized in Table 1. In con-
clusion, we did not find a consistent inverse association between anti-
oxidants and cognitive decline or dementia.z However, we did find evi-
dence for a relationship between fatty acids and cognition or dementia. 
In addition, fish consumption was inversely associated with dementia, 
cognitive impairment and decline. 
In our investigation of metabolic risk factors we found an associa-
tion of diabetes mellitus, but also of impaired glucose tolerance and 
hyperinsulinemia, with cognitive impairment (Table 2). Diabetes mellitus 
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Table 1 
Odds ratios (95% confidence interval) for the association between 
nutritional risk factors and cognition or dementia. 
Cognitive Cognitive Dementia 
imEairmentt decline* 
Risk factors' ZES RS ZES RS RS 
Antioxidants 
Vitamin E 1.4 1.l§ 1.2 (0.7-2.8) (0.7-1.7) (0.4·3.3) 
Beta~carotene 1.3 0.6§ 0.7 (0.8-2.1) (0.4-1.0) (0.3-1.5) 
Vitamin C 1.2 0.8§ 2.0 (0.7-2.0) (0.6-1.3) (0.9·4.5) 
Flavonoids 1.4 0.9 (0.9-2.4) (0.4-1. 9) 
Fatty acids 
Total fat 2.4 ( 1.1-5.2) 
• Saturated fat 1.9 (0.9-4.0) 
• Cholesterol 1.7 (0.9-3.2) 
Linoleic acid 1.8 1.l 0.6 (1.0-3.0) (0.5·2.3) (0.3-1.2) 
N-3 PUFA 1.0 0.8 (0.6-1.6) (0.4-1. 7) 
Fish 0.6 0.5 0.4 (0.3-1.2) (0.2-1.2) (0.2-0.9) 
ZES = the Zutphen Elderly Study; RS the Rotterdam Study; PUFA = 
poly-unsaturated fatty acids 
• Low intake is the reference category 
t MMSE score <26 
* >2 points decline in the MMSE score in 3 yrs 
§ Based on findings not described in this thesis2 
also increased the risk of dementia.3 The adrenal steroid cortisol was 
positively associated with impaired cognitive performance, the adrenal 
steroid dehydroepiandrosterone sulfate was inversely associated with 
cognitive impairment and decline, and the amino acid homocysteine was 
related to cognitive decline among subjects under 75 years of age and 
among women. 
For a better understanding of the etiology of cognitive decline and 
dementia, it is important to examine the interaction between genetic 
and environmental risk factors. Therefore, we examined the interaction 
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Table 2 
Odds ratios (95% confidence interval) for the association between 
metabolic risk factors and cognition or dementia. 
121 
Cognitive 
impairment 
Cognitive 
decline 
Dementia 
Risk factors 
Diabetes mellitus 
IGT 
Hyperinsulinemia 
Serum cortisol 
Serum DHEAS 
Serum homocysteine 
< 75 years 
;:: 75 years 
ZES' RSt 
1.2 
( 1.0-1.5) 
1.2 
(1.0-1.4) 
1.3 
( 1.0-1.5) 
1.7 
(0.9-1.3) 
0.5 
(0.2-1.1) 
ZES RSt 
0.9 
(0.6-1.3) 
0.6 
(0.4-1.1 ) 
2.3 
(1.0-5.6) 
0.4 
(0.1-2.3) 
RS 
1.9§ 
(1.3-2.8) 
ZES = the Zutphen Elderly Study; RS the Rotterdam Study; lOT = 
impaired glucose tolerance; DHEAS = dehydroepiandrosterone sulfate 
.. Error rate ratio for number of erroneous answers on the MMSE 
t MMSE score <26 
t Drop in the MMSE score of > 1 point/year 
§ Not described in this thesisS 
Table 3 
Gene-environment interaction in relation to cognitive decline. * 
The Zutphen Elderly Study. 
Carrier of the APOE'4 allele 
No Yes 
Risk factor ~resent No Yes No Yes 
Education 56 years ref 3.1 ref 0.9 (1.1-8.8) (0.2-3.8) 
History of cerebrovascular 
ref 4.7 3.3 17.2 disease (1.7-12.7) (1.6-6.8) (2.7-110.0) 
History of coronary heart 
ref 1.8 3.1 6.1 disease (0.7-4.3) (1.5-6.6) (1.7-22.3) 
• >2 points decline in the MMSE score in 3 yrs 
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between the e4 allele of the apolipoprotein E gene and some environ-
mental risk factors for cognitive decline, i.e. education and a history of 
cardiovascular disease. Low education was associated with an increased 
risk of cognitive decline, only in subjects without an e4 allele. The 
combined presence of the e4 allele and a history of cerebrovascular dis-
ease increased the risk of cognitive decline dramatically, suggesting syn-
ergism between these two risk factors. Hence, an interaction could be 
found between important environmental risk factors and a major sus-
ceptibility gene for cognitive decline. 
Finally, we examined the prognosis of dementia among particIpants 
from the Rotterdam Study. Subjects with dementia had an increased 
risk of dying (RR=2.0, 95%CI: 1.6-2.4). There was a shift in the distri-
bution of the causes of death among demented persons towards less 
deaths from malignancies and more deaths from noncardiovascular-non-
cancerous causes. 
Methodological considerations 
Exposure measurement 
Dietary assessment - Measurement error is a major problem in nutri-
tional epidemiologic research. In general, two types of error exist: differ-
ential and non-differential. Differential error can lead to under- or OVer-
estimation of the true effect, while non-differential error usually leads to 
attenuation of the effect. 
Differential error may arise when the error in estimating dietary 
intake is different in subjects with the disease than in those without 
the disease. In cross-sectional studies on cognitive impairment or de-
mentia it is conceivable that subjects with memory problems give less 
reliable information about their usual diet than subjects without memory 
problems.4 We dealt with this in various ways, which is discussed in 
Chapter 2. In longitudinal studies, in which the dietary intake is assess-
ed before the disease (i.e. dementia) occurs, differential error is less 
likely. 
Non-differential error is a problem especially when true associations 
are weak and contrast in dietary intake is small. It can lead to a type 
II error or a false negative finding. This may explain the finding in 
Chapter 2 of no association between antioxidants and cognitive impair-
ment and decline. However, we used the average of two measurements, 
which reduces the effect of measurement error. Further reduction of the 
influence of measurement error could be obtained by using the com-
bined information from dietary intake and biochemical markers, by in-
creasing the contrast of the dietary intake by doing e.g. a multi-center 
study, or by estimating the amount of measurement error and adjust for 
it afterwards. 
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Metabolic jactO/·s - When studying metabolic risk factors, a number of 
practical issues should be considered. Generally, fasting blood levels are 
more reliable than non-fasting levels. It is, however, not always feasible 
to obtain fasting blood in a large epidemiologic study, and therefore, 
homocysteine levels were determined in non-fasting serum. Intake of 
food may effect the plasma homocysteine concentrationS and may thus 
lead to measurement error, which however probably will be random. 
Furthermore, sometimes blood levels after a loading test gives valuable 
additional information. For example, data on homocysteine levels after a 
methionine loading test could classify a considerable additional propor-
tion of subjects as having hyperhomocysteinemia.6 A loading test is also 
necessary for measurement of cortisol suppression after dexamethasone 
and for the measurement of glucose intolerance. However, a loading test 
is generally only practical in smaller sample sizes. Misclassification due 
to altered concentrations because of prolonged storage of the blood can 
be a problem. Homocysteine determinations were performed in blood 
that was stored at -20'C for approximately four years. Serum homocyste-
ine is stable for years when stored at -20'C7, so this has probably not 
influenced our findings. Serum values of glucose, insulin, cortisol and 
DHEAS were determined in blood that not had been stored for longer 
than a few months. Finally, it is probably optimal to measure the cere-
brospinal fluid level or the cerebral tissue level of the metabolic factors 
we studied, since the peripheral concentrations may not reflect the bio-
logically relevant concentration in the brain. For example, there seems 
to be an upregulation of glucose transport across the blood-brain barrier 
in case of chronic hypoglycemia.s Measurement of the cerebrospinal 
fluid level however, is not possible in a population-based study. 
Another issue when studying metabolic risk factors, as when 
studying dietary factors, is non-differential error because of the usually 
high intra-individual variation for these factors. This variation is due to 
measurement error, but also to real temporary biological variations from 
the 'usual' level. Repeated measurements will reduce non-differential 
error, but often only a single measurement is available, as in our studies 
on metabolic risk factors. 
Outcome measurement 
The Mini-Mental State Examination - The 30 point Mini-Mental State 
Examination (MMSE) was developed as a brief screening instrument for 
dementia.9 It measures the following cognitive functions or domains: 
orientation to time and place, registration, attention and calculation, re-
call, language and visual construction. Although, it was originally meant 
to be used in a clinical setting9, it has also been widely used in epi-
demiologic studies. 1O It is a valid and reliable test for measuring cogni-
tive impairment. I I The MMSE score correlates well with other cognitive 
tests, and with measures of instrumental activities of daily living.1l Test-
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retest reliability for normal and cognitively impaired subjects ranges from 
0.80 to 0.95." In a clinical setting a cut-off of <24 is most widely used. 
The positive predictive value for dementia when using this cut-off point 
was 79% in most studies. We used a score of <26 as cut-off point for 
cognitive impairment, since this cut-off has a higher sensitivity and the 
same specificity in detecting early stages of Alzheimer's disease than a 
cut-off of <24.12.13 One of the drawbacks of the MMSE is that it is not 
very sensitive to mild cognitive impairment, and that it can not discrim-
inate between mildly demented and normal subjects. 
There are a number of different ways in which the analyses using 
the MMSE score, can be performed. Neither the MMSE score, nor its 
logarithmic transformation, are normally distributed. Therefore, linear 
regression analyses does not apply when the MMSE score is the out-
come. The number of erroneous answers on the MMSE (i.e. 30 minus 
the MMSE score) follows a Poisson distribution. So Poisson regression 
can be performed to estimate the rate ratio of the number of erroneous 
answers. This was described in Chapter 4. Alternatively, the MMSE 
score can be dichotomized, in which case logistic regression analysis can 
be used. The latter estimates the odds ratio for being cognitively im-
paired, which is easier to interpret. This was done in Chapters 2, 5, 
and 6. 
The change in the MMSE score is normally distributed. Therefore, 
linear regression analysis applies, yielding the change in the MMSE 
score per unit increase of the independent variable. The change in the 
MMSE score can also be dichotomized. By using logistic regression 
analysis, one can then estimate the odds ratio for a specific decline in 
the MMSE. Again, the latter analysis may be easier to interpret, and 
has therefore been used in this thesis. 
The cut-off points we used to define cognitive decline (>2 points 
in 3 yrs and > 1 point/yr) may not be pathologically and clinically signif-
icant on an individual level. But, a small decline in cognitive function 
of a large part of the population can increase the proportion of subjects 
with cognitive impairment to a large extent, and may therefore be of 
major public health importance. It is not clear whether a drop of one 
point in the MMSE is more clinically meaningful when the initial score 
is high than when the initial score is low. To minimize this effect we 
adjusted for initial score when analyzing cognitive decline. 
Subtypes 0/ dementia - Dementia and its major subtypes, i.e. Alzheimer's 
disease and vascular dementia, were diagnosed according to standard 
international criteria. The differentiation between Alzheimer's disease 
and vascular dementia is not straightforward, especially when a cerebro-
vascular event has occurred. If the onset of dementia was related to 
cerebrovascular disease, vascular dementia was diagnosed. Because in the 
Rotterdam Study no autopsy information was available, a definite diag-
nosis could not be made. However, the criteria we used have a high 
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sensitivity and specificity.14 Furthermore, to reduce the chance of mis-
classifying vascular dementia as Alzheimer's disease, we grouped subjects 
with Alzheimer's disease with cerebrovascular disease together with sub-
jects with vascular dementia in Chapter 3. Recently, it has been found 
that 47% of the demented subjects in the Nun Study had Alzheimer's 
disease and large or small brain infarcts. IS In addition, a number of vas-
cular risk factors have been associated with an increased risk of 
Alzheimer's disease.3,16, this thesis So, it may be questioned whether it is 
possible to make a clear distinction between vascular dementia and AD. 
Confounding and mediating factors 
Confounding factors - Not adequately adjusting for confounding is a 
major threat to the validity of the results of epidemiologic studies. For 
cognitive decline and dementia, age is probably the most important con-
founder, since age shows a strong exponential relation with cognitive 
decline, independent of other risk factors. Age is also related to most 
risk factors studied in this thesis. Education is a potentially important 
confounder as well. It may be a real risk factor, indicating a lower brain 
reserve, it may be a marker for other (unknown) risk factors, but it also 
may lead to psychometric bias, because subjects with a lower education 
are less able to perform the cognitive test. Considering our results on 
the interaction between education and the apolipoprotein E gene, the 
latter explanation is less likely. In the Netherlands most subjects had at 
least six years of education and illiteracy is rare. Still, there is a large 
variation in educational background and education is related to most risk 
factors studied, making it necessary to adjust for it. Another important 
confounder is gender. Women may be at greater risk of developing de-
mentia, even when longevity is taken into account. 17 In addition, most 
risk factors vary according to gender. 
Cigarette smoking is another potential confounder. The association 
between smoking and dementia or cognitive decline is not clear yet. A 
number of studies have found that smoking was inversely related to 
dementia, but these studies were mostly cross-sectional.1 8 Results from 
the prospective Rotterdam Study and the prospective Honolulu-Asia 
Aging Study showed that smoking increased the risk of dementia and 
cognitive impairment, respectively.19,20 Since smoking can be related to a 
number of other risk factors, such as diet, homocysteine, and diabetes, 
it may be a confounder when investigating these risk factors. Alcohol 
consumption may be a confounder as well. Recently, it was found that 
moderate alcohol consumption may protect against dementia.21 In con-
trast, it is well known that heavy alcohol consumption is associated with 
an increased risk of dementia. Risk factors, as for example diet and 
homocysteine, may also be related to alcohol consumption. An important 
confounder in the relation between diet and dementia or cognitive de-
cline is total energy intake. Demented subjects often have a lower body 
126 GENERAL DISCUSSION 
mass index than non-demented subjectsZZ, probably because their total 
energy intake is lower. Nutrient intake is obviously related to total en-
ergy intake as well. Finally, hypertension may be a confounder. Hyper-
tension at middle age has been associated with an increased risk of 
cognitive impairment at older age. A low blood pressure at older age 
seemed to be associated with an increased risk of cognitive impair-
mentZ3, perhaps because high blood pressures are needed to guarantee a 
sufficient perfusion of the atherosclerotic brain vessels. Hypertension 
may also be related to risk factors, as for example homocysteine. 
Mediatillg factors - In this thesis we have also examined a number of 
mediating factors, e.g. a history of cardiovascular disease and atheroscle-
rosis, measured as plaques in and intima-media thickness of the carotid 
arteries, and ankle-brachial index. These factors may have been inter-
mediates in the associations between diabetes and cognition, homocyste-
ine and cognition, and diet and cognition. In some contexts, these me-
diating factors may have been confounders as well. To judge whether a 
factor is a confounder or an intermediate one has to rely on the exist-
ing knowledge about the biologic mechanisms underlying the relation-
ship between the exposure and the outcome. For instance, apart from 
being an intermediate, a history of cardiovascular disease may be a con-
founder in the association between diet and cognitive decline. Cardio-
vascular disease might be associated with the exposure, because it often 
leads to changes in dietary habits. Additionally, it may, independently of 
diet, be associated with the outcome, i.e. cognitive decline.24 So the 
association between cognitive decline and the intake of linoleic acid, 
saturated fat, cholesterol, or fish, may have been confounded by a his-
tory of cardiovascular disease. 
When a risk factor is a confounder, one should adjust for it in the 
analysis in order to get a valid estimate. \Vhen a factor is an intermedi-
ate, however, adjustment would lead to overadjustment, taking away 
most of the effect. A very rough method to deal with this problem is 
to compare the results with and without adjustment for this risk factor. 
There are also more sophisticated and complicated methods to deal with 
this, as for example G-estimation.25 For this analysis, however, the con-
founding and mediating factor has to be measured twice at different 
points in time. In the studies described in this thesis, adjustment for 
the possible intermediates (cardiovascular disease and atherosclerosis) did 
not attenuate our estimates, which may suggest that these factors were 
neither confounders nor intermediates. But of course, other explanations 
can be offered for the lack of attenuation, such as measurement error, 
or wrong timing of the measurement. Additionally, these variables may 
not constitute the true intermediating factors. 
Effect modificatioll - The investigation of interaction may point at the 
existence of high risk groups for whom modification of risk factors may 
GENERAL DISCUSSION 127 
especially be beneficial. We found an interaction between tbe e4 allele 
of the apolipoprotein E gene and some major risk factors, i.e. education 
and a history of stroke, in relation to cognitive decline. Statistical inter-
action is usually examined on a multiplicative level, i.e. with the cross-
product of the risk factors as interaction term in the regression model. 
Biological interaction, however, is considered present when the joint ef-
fect of two risk factors is more, or less, than the sum of the effects of 
each risk factor acting without the other.26 When biological interaction is 
present, it means that two risk factors arc not acting independently, but 
have a synergistic or antagonistic effect on the outcome. To examine 
this, subjects should be categorized into four groups: none of the two 
risk factors present (reference group); one risk factor present; the other 
risk factor present; and both risk factors present.27 
Differences in cross-sectional and longitudinal studies 
In this thesis, two major types of study design are used to investigate 
risk factors for cognition and dementia: cross-sectional and longitudinal 
cohort analyses. The cross-sectional and longitudinal results were not 
always similar. This may be due to the fact that a different outcome 
was measured, or that cross-sectional and longitudinal studies may be 
prone to different types of bias. 
Cognitive impairment Vet'Slts cognitive decline - Some results of the 
cross-sectional analyses could not be confirmed in the longitudinal analy-
ses. An explanation for this may be that the outcome in the longitudi-
nal analyses, i.e. cognitive decline, is a less reliable measure than the 
outcome in the cross-sectional analysis, i.e. cognitive impairment. The 
MMSE was not originally created to meaSUre cognitive decline. In a 
sample of healthy elderly or in relatively young subjects the MMSE has 
a ceiling effect. Therefore, the MMSE may not be very sensitive to 
small cognitive changes in subjects with a normal cognition. In a longi-
tudinal study among cognitively intact elderly subjects the MMSE score 
declined only slightly after one to five years28, which was similar in our 
studies. Furthermore, the MMSE is less sensitive to progressive decline 
in severe dementia. Another problem is that, as with any variable, the 
change in the MMSE score has a larger intra-individual variation than a 
single MMSE score. Additionally, the second MMSE measurement will 
show regression towards the mean. Moreover, a practice effect may oc-
cur, leading to a smaller drop in the MMSE. Different testing site may 
influence cognitive decline, since some studies reported that scores 
tended to be higher at home than in a clinical setting. In the Zutphen 
Elderly Study, the first MMSE was administered in a clinical setting, 
whereas the second one was administered at home. If follow-up dura-
tion is short, no cognitive decline may be present, but if the duration is 
too long, selective loss to follow-up will have a larger influence on the 
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estimation of cognitive decline. One of the difficulties to be tackled, is 
to make an assumption about the induction period. If this induction 
period is very long, a longitudinal study is not very efficient. If the 
follow-up period is too short, it will lead to underestimation of the ex-
posure-outcome association. This may be one of the explanations for the 
finding of a different relation between linoleic acid and cognitive im-
pairment (positive) as compared with the relation between linoleic acid 
and cognitive decline (absent). Follow-up duration may have been too 
short for an effect of linoleic acid on cognitive decline (Chapter 2). 
Selection bias - Selection bias and information bias may either lead to 
an underestimation or an overestimation of the true association and one 
can not correct for their effect in the analysis. 
In a cohort study, selection bias occurs when nonresponse is related 
to the exposure as well as to the outcome. Nonresponse may be a 
problem in both cross-sectional and longitudinal cohort studies, especially 
when response rates are low. Nonrespondents often differ with regard to 
motivation, attitude towards health, and risk factor status. Even if the 
estimates acc not biased, nonresponse can reduce the generalizability of 
the results. A way to evaluate whether nonresponse may have biased 
the estimates is to investigate whether nonrespondents and respondents 
are different with regard to major baseline characteristics, such as age, 
gender and socioeconomic status, and to risk factors, if this information 
is present. This was done in most of our analyses and nonresponse 
probably has not influenced our results. 
Information bias - Information bias, in the form of differential misclas-
sification, is the result of a systematic error in the measurement of the 
outcome which differs according to exposure status, or of a systematic 
error in the measurement of the exposure, which differs according to 
the outcome. 
In a cross-sectional study, the exposure and the outcome are meas-
ured at the same point in time. This does not present a problem when 
the exposure does not change over time, such as the apolipoprotein E 
genotype. A critical problem arises when the risk factor changes after 
(or perhaps even some time before) the development of the disease. 
This may lead to information bias. Risk factors for which we found a 
cross-sectional relation with cognitive impairment include diabetes, die-
tary factors and adrenal steroids. It is not very likely that the occurren-
ce of diabetes is influenced by the presence of cognitive impairment. 
Information on diet, or the dietary intake itself, can change as a result 
of cognitive impairment. We dealt with this in various ways, as is dis-
cussed in Chapter 2. Furthermore, adrenal steroids can be influenced by 
cognitive impairment, because cognitive impairment is often associated 
with loss of hippocampal neurons, which control adrenal steroid biosyn-
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thesis. Therefore, from OUf cross-sectional results we can not conclude 
that altered adrenal steroid levels preceded cognitive impairment. 
In a prospective cohort study, one type of information bias that can 
occur is loss of subjects during follow-up, which is related to both the 
exposure and the outcome. There are different ways to deal with this 
problem. First of all, it is of course preferable to keep loss to follow-up 
to a minimum. Furthermorel one can examine whether the exposure Of 
other risk factors at baseline are systematically different in those who 
are lost to follow-up compared to those who are not. This was exam-
ined in some of the analyses, in which selective loss to follow-up was 
considered not very likely. A more quantitative approach is to do a 
sensitivity analysis. In this analysis the estimates are calculated assuming 
the two most extreme situations: firstly, it is assumed that all those who 
were lost to follow-up developed the outcome of interest, and secondly, 
it is assumed that all those who were lost to follow-up did not develop 
the outcome of interest. The true association will lie somewhere in be-
tween these two estimates. In Chapter 5, sensitivity analyses were per-
formed. The results suggested that selective loss to follow-up may have 
led to the nonsignificant inverse association between homocysteine and 
cognitive decline in subjects 'C.75 years of age. 
Etiology of cognitive decline and dementia 
Vascular processes 
We examined metabolic, nutritional and genetic risk factors for cognItIve 
decline and dementia, including Alzheimer's disease. One of the main 
hypotheses behind the examined associations was that atherosclerosis 
and cerebrovascular disease may increase the risk of cognitive decline 
and dementia. We found a positive association of impaired cognitive 
function or dementia to a high total and saturated fat intake, fish con-
sumption, diabetes, hyperinsulinemia, and, in women and those <75 
years of age, to serum total homocysteine. These risk factors have all 
been associated with a higher risk of atherosclerosis and cerebrovascular 
disease. Therefore, the observed associations fit well with the hypothesis 
that cognitive impairment and dementia are partly caused by vascular 
processes. 
Oxidation 
It has been suggested that oxidation may play a role in the etiology of 
dementia.29 This, however, could not be verified by our results on the 
association between antioxidants and cognition. Previous studies that 
investigated the association between intake of antioxidants and cognition 
were mostly cross-sectional, and results were inconsistent.2,30-32 The only 
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controlled trial so far showed a delay in the progression of Alzheimer's 
disease in subjects receiving alpha-tocopherol and selegiline.33 However, 
there was no improvement in cognitive function. Results of studies on 
the association between antioxidants and coronary heart disease have 
been contradictory as well. 34 The positive association between linoleic 
acid and cognitive impairment would fit in the oxidation hypothesis. But 
this association could not be confirmed in relation to cognitive decline 
and dementia. 
Inflammation 
The possible protective effect of fish consumption on cognitive decline 
and especially on Alzheimer's disease could be due to the anti-inflam-
matory properties of n-3 PUF As, the main fatty acids in fish. These n-3 
PUFAs can decrease the production of proinflammatory cytokines in 
humans.35 Immune processes are believed to be involved in the patho-
genesis of Alzheimer's disease. Increased concentrations of acute phase 
reactants and other markers of immune processes, such as cytokines, 
have been found in brain tissue of patients with Alzheimer's disease.36 
In addition, interleukin-l may regulate the amyloid precursor protein 
synthesis, resulting in amyloid depositsY 
Stress-hypothesis 
A higher level of stress leads to overactivity of the hypothalamic-pitui-
tary-adrenal axis, which results in high cortisol concentrations. These 
high concentrations are toxic to neurons, especially those in the hippo-
campus. The hippocampal neurons are involved in memory processes, 
but also in inhibitory feedback to the hypothalamic-pituitary-adrenal axis. 
So damage of hippocampal neurons will lead to HPA-axis overactivity, 
keeping cortisol concentrations high, thereby damaging more hippocam-
pal neurons, which will eventually lead to cognitive decline. This is de-
scribed as the glucocorticoid cascade of aging.38 Our results on the ad-
renal steroids were in agreement with this hypothesis. 
Genetic factors 
It is well known that genetic risk factors, e.g. the e4 allele of the 
apolipoprotein E gene, contribute to the occurrence of dementia and 
cognitive decline.39,40 Examination of gene-environment interaction may 
give clues to the etiology of cognitive decline and dementia. We found 
an interaction with two environmental risk factors, i.e. education and a 
history of cerebrovascular disease. Education was only associated with 
cognitive decline in subjects without the e4 allele. An explanation for 
this may be that the e4 allele plays a role in inhibiting neuronal 
growth41 , thereby blocking the putative stimulating effect of a high 
education on neuronal growth. Furthermore, there seemed to be a syn-
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erglstlC effect of the e4 allele and a history of cerebrovascular disease 
on cognitive decline. This may result from reduced neuronal repair in 
e4 carriers41 , which could then lead to greater damage after cerebro-
vascular disease. 
Cognitive impairment versus dementia 
A question that arises when studying risk factors for cognItive impair-
ment and dementia, is whether the pathological mechanisms behind 
dementia and cognitive impairment are the same? This would be the 
case if cognitive impairment represented the pre-clinical phase of de-
mentia and if everybody with cognitive impairment eventually would 
develop dementia. We did not investigate this problem, but it may be 
important for the interpretation of our findings to know whether this is 
true or not. 
There are a number of factors which indicate that cognitive im-
pairment represents the pre-clinical phase of dementia. In a study on 
subjects with isolated memory loss, almost half of them developed de-
mentia after a follow-up of two and a half years.42 In another study, all 
subjects who became demented after a two year interval were cognitive-
ly impaired at baseline.43 Senile plaques and neurofibrillary tangles, the 
major pathological findings in Alzheimer's disease, the extent of brain 
atrophy, and ventricular volume all correlate well with cognitive per-
formance. 44 White matter lesions, which represent the pathological sub-
strate of vascular dementia, are also more often present in subjects with 
cognitive impairment.45 Furthermore, in a representative community 
sample of elderly women the variables that are associated with demen-
tia, such as cognitive function, showed a continuous unimodal distribu-
tion, and not a bimodal distribution.46 This does however not perse in-
dicate that dementia is not distinct from cognitive impairment or normal 
aging.47 
From these findings, one can conclude that a number of the pro-
cesses that occur in dementia are also observed in cognitive impairment. 
On the other hand, a decline in cognitive functions can also be regard-
ed as part of usual aging. The above arguments do not prove that eve-
rybody with cognitive impairment eventually, if they lived long enough, 
would develop dementia. Therefore, it is important to examine risk fac-
tors for cognitive impairment as well as for dementia. 
Future research issues 
Dementia and cognitive decline impose a major burden on individuals 
and on society. They limit the independent functioning of an individual 
and have a negative impact on the quality of life. Subjects with de-
mentia often have to be institutionalized, which imposes a great demand 
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on health care costs. Therefore, it is important to search for possibly 
modifiable risk factors. Most of the risk factors examined in tbis thesis 
can be modified. It is however too early for preventive action. The re-
sults obtained, have to be confirmed by other large longitudinal popula-
tion-based studies on cognitive decline and dementia. 
Nutritional risk factors 
Diet is one of the major risk factors for mortality, coronary heart dis-
ease, and some types of cancer, but it has not received a lot of atten-
tion as a risk factor for dementia and cognitive decline.48 In the Report 
of a WHO Study Group on diet and the prevention of chronic diseases, 
dementia is not mentioned as being influenced by diet.48 Results pre-
sented in this thesis suggest that diet may play an important role in 
the development of cognitive decline and dementia. More research is 
however needed to confirm this. 
We did not find an association between antioxidant intake and 
cognitive decline or dementia. It could be that measurement error is 
responsible for these negative findings. It would therefore be preferable 
to use dietary intake and biochemical markers of antioxidants in 
combination. Furthermore, it may be useful to have information on the 
combination of the intake of different nutrients, because of its potential 
influence on the bioavailability. The time of the day and the frequency 
with which a nutrient is consumed might be important as well. To 
further elucidate the role of oxidation it may be preferable to examine 
the susceptibility of LDL to oxidation in combination with the anti-
oxidant status of an individual. It would also be interesting to examine 
the effect of food groups instead of specific nutrients. Vegetables and 
fruits, which are the major sources of many antioxidants, have been 
related to lungcancer49 and coronary heart disease.so The n-3 poly-un-
saturated fatty acids in fish may exert a protective effect through their 
anti-inflammatory properties.3s Markers of inflammation, such as inter-
leukines37 should be studied, to further clarify the role of inflammation 
in the pathogenesis of Alzheimer's disease. 
Metabolic risk factors 
Metabolic risk factors seem to play a role in the occurrence of cognitive 
decline and dementia as well. Future research on the role of 
homocysteine in cognitive decline should measure homocysteine in fast-
ing blood and possibly after a methionine loading test. In addition, in-
formation on the intake of vitamin B6, vitamin B 12 and folate, or on 
blood levels of these vitamins would be helpful for the interpretation of 
the findings. Instead of measuring insulin after an oral glucose load, 
insulin resistance could be measured quantitatively with a glucose clamp 
techniqueSI or an intravenous glucose tolerance test, which is however 
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not applicable in epidemiologic studies. Repeated measures of cortisol 
and DHEAS are preferred for more precise information on cortisol and 
DHEAS metabolism in an individual subject.52,53 Furthermore, interac-
tion with genetic risk factors like the apolipoprotein E gene should be 
studied for a better understanding of the underlying pathogenesis of 
cognitive decline and dementia. 
Clinical trials 
Experimental research is the only way to definitely establish a causal 
relationship between a certain risk factor and dementia or cognitive 
decline. In my opinion, for most risk factors described in this thesis, it 
would be premature to start intervention research examining the effect 
of modification of these risk factors on cognitive decline. It may be of 
great value, though, to measure cognitive decline as an additional end-
point in future trials investigating the role of risk factors in cardiovascu-
lar disease (e.g. antioxidant intake, fish consumption, fatty acid intake, 
glucose tolerance, and homocysteine levels). Recently, a controlled trial 
with selegiline and a-tocopherol has been conducted in patients with 
Alzheimer's disease, showing a delay in the progression.33 
Cognitive impairment versus dementia 
In future research, it is important to investigate different end points, i.e. 
cognitive decline, total dementia, Alzheimer's disease and vascular de-
mentia. The distinction between the latter two may not be very clear, 
especially in the oldest 0Id. 15,54 Therefore it is important to investigate 
both total dementia as well as Alzheimer's disease and vascular demen-
tia separately. Cognitive decline can be regarded as a pre-clinical stage 
of dementia, but it is an important end point perse. A disadvantage is 
that cognitive decline is a softer outcome than dementia, and perhaps 
also clinically less meaningful. There are however several advantages for 
taking cognitive decline as the outcome. It is easier to assess than 
dementia, because diagnosing dementia is difficult and time-consuming 
in large population-based studies. Since cognitive decline is a continuous 
measure, the study size needed will be smaller than for studying the 
risk of dementia. Especially in intervention studies the use of a 
continuous measure will shorten the necessary duration of follow-up 
considerably. Furthermore, there maybe an interest in the early phase of 
the disease process, when preventive action might still be possible. 
Investigators may also be especially interested in cognitive deterioration 
and not in the other, mainly behavioral, changes that occur in 
Alzheimer's disease. Finally, when studying cognitive function, more 
extensive domain-specific cognitive tests, such as memory tests, tests on 
sensorimotor speed and on complex information processing speed, should 
be used to be able to distinguish more subtle differences between 
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individuals and to obtain a more precise estimate of changes in 
cognitive performance. 
In conclusion, the results described in this thesis show that there 
are many possible new risk factors for cognitive decline and dementia. 
Modification of these risk factors may delay the underlying disease 
processes of cognitive decline and dementia, and could therefore have 
important implications for public health. Our results are however prelim-
inary, and the time for preventive action has not arrived yet. 
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SUMMARY 
I n this thesis studies on risk factors for cogmtlve decline and de-mentia are described. Deterioration of cognitive functions is one of the most important symptoms of dementia. The main cognitive functions are orientation to time and place, memory and recall, 
attention and concentration, language and abstract thinking, calculation, 
and constructive abilities. Diminished cognitive functioning reduces the 
independence of an individual and diminishes the quality of life. Be-
sides these disadvantages for the individual, cognitive decline and de-
mentia impose a major burden on the health care system, because of 
the great risk of institutionalization. Therefore, it is important to search 
for possibly modifiable risk factors for these disorders. For this thesis, 
we studied the relation of nutritional and metabolic risk factors to cog-
nitive decline and dementia. 
For the results presented in this thesis, data were used from two 
population-based studies on the elderly: the Zutphen Elderly Study and 
the Rotterdam Study. The Zutphen Elderly Study is the continuation 
of the Zutphen Study, which was part of the Seven Countries Study, 
that started in 1960. In 1990, 560 of the 718 surviving men (78%), born 
between 1900 and 1920, participated in the Zutphen Elderly Study. 
They were all extensively interviewed and examined. The level of 
cognitive function was assessed with the Mini-Mental State Examination 
(MMSE), which is a valid and widely used test. In 1993, these men 
were again invited to participate in the Zutphen Elderly Study; 390 
(71%) of the 553 participants who were still alive at the time agreed to 
participate. 
The Rotterdam Study is a prospective study among all inhabitants 
of the Ommoord suburb of Rotterdam, who were 55 years or older at 
the start of the study in 1990. Seventy-eight percent (n~7983) of the 
eligible men and women agreed to participate in extensive interviews 
and physical examinations. Cognitive function was tested with the 
MMSE, and additionally, subjects were screened for dementia. Partici-
pants who were suspected of having dementia after the screening were 
subsequently examined by a neurologist and a neuropsychologist; a part 
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also underwent magnetic resonance imaging of the brain. The final di-
agnosis and subtyping of dementia was made according to international 
criteria. In 1993 and 1994, 6315 (88%) of the 7215 subjects still alive 
participated in the second examination round of the Rotterdam Study, 
in which they were, among other things, again screened for dementia. 
We focused mainly on cardiovascular risk factors, because previous 
studies showed that atherosclerosis and cardiovascular diseases were as-
sociated with cognitive impairment and vascular dementia. Comprehen-
sive information on dietary intake of the participants in the Zutphen 
Elderly Study was used to examine the relation of linoleic acid and 
antioxidant intake (vitamin E, beta-carotene, vitamin C, and flavonoids) 
to cognitive function disorders (Chapter 2). Results showed that a high 
intake of antioxidants was not associated with a reduced risk of cogni-
tive impairment or decline. There was an association. however, between 
a high linoleic acid intake and cognitive impairment in 1990 (relative 
risk (RR) = 1.8), but not with cognitive decline from 1990 to 1993. 
In the Rotterdam Study, we investigated the relationship between 
fat and fish consumption and the risk of incident dementia (Chapter 3). 
The advantage of this study is that dietary intake was assessed at base-
line in subjects with normal cognition. A high fat intake, and especially 
a high saturated fat and cholesterol intake, increased the risk of de-
mentia 2.4 fold, and the risk of vascular dementia 3 fold. Fish con-
sumption on the other hand, decreased the risk of dementia by 60%, 
and the risk of Alzheimer's disease by 70%. The latter finding might 
be explained by the anti-inflammatory actions of the n-3 poly-unsatu-
rated fatty acids in fish. 
The first metabolic risk factors we examined were diabetes mellitus 
and preclinical stages of this disease, i.e. glucose intolerance and hyper-
insulinemia (Chapter 4). These disorders increase the risk of cardiovas-
cular diseases. In the Zutphen Elderly Study, men with diabetes were 
more often cognitively impaired than men without diabetes (RR = 1.2). 
Even in preclinical stages of the disease, there was a positive association 
with cognitive impairment. 
The amino acid homocysteine is a relatively new risk factor for 
cardiovascular disease. The homocysteine level in the blood can be re-
duced by folate suppletion. In a subpopulation of the Rotterdam Study, 
we have studied the association between homocysteine and cognitive 
decline (Chapter 5). In subjects under 75 years of age there was a 
positive relation between a high homocysteine level and cognitive de-
cline (RR = 2.3). Furthermore, the association between homocysteine 
and cognitive decline was present in women (RR = 2.2), but not in 
men. 
Cortisol and dehydroepiandrosterone sulfate (DHEAS) are adrenal 
steroids with opposite effects on the hippocampus. The hippocampus 
plays an important role in memory processes and is one of the brain 
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areas that is damaged in Alzheimer's disease. Previous investigations 
showed an association between these hormones and Alzheimer's disease, 
but, except for one study on DHEAS and cognition, they were all 
cross-sectional and not conducted in a general population. A number of 
participants of the Rotterdam Study (n~189) participated in an extensive 
additional examination on glucose metabolism, in which also serum corti-
sol and DHEAS was measured. Our study showed a positive relation of 
serum cortisol to cognitive impairment (RR ~ 1.7) (Chapter 6). There 
was an inverse association between DHEAS and cognitive impairment 
(RR ~ 0.5), and between DHEAS and cognitive decline (RR ~ 0.6). 
In Part III we studied the combined effect of the apolipoprotein E 
gene and environmental risk factors on the risk of cognitive decline. 
Previous studies showed that both the e4 allele of the apolipoprotein E 
gene and a low education were associated with cognitive decline and 
Alzheimer's disease. In the Zutphen Elderly Study, we found that a 
low education (only primary school) was only associated with cognitive 
decline in subjects without the e4 allele (RR ~ 3.1) (Chapter 7). 
It is widely known that a history of stroke increases the risk of 
cognitive decline. In the Zutphen Elderly Study, we examined whether 
the combination of a history of stroke and the e4 allele resulted in an 
even higher risk of cognitive decline (Chapter 8). It was found that 
men with both risk factors had a 17.2 fold increased risk of cognitive 
decline compared with men without these risk factors. This relative risk 
was much higher than the sum of separate relative risks for stroke and 
the e4 allele (RR ~ 4.7 and 3.3, respectively), which suggests a syn-
ergistic effect of these two factors on cognitive decline. 
Finally, we investigated the prognosis of dementia in the Rotterdam 
Study (Chapter 9). It is known that subjects with dementia have an 
increased mortality. Cause-specific mortality was not examined yet in a 
general population, though. Our results showed that subjects with de-
mentia have a 2.0 times increased risk of dying compared with subjects 
without dementia. There was a shift in the distribution of the causes of 
death. The percentage of subjects that died from cancer was lower 
among demented than among non-demented subjects (13.3% vs 24.9%), 
whereas the percentage that died from noncardiovascular-noncancerous 
causes was higher among demented subjects (49.2% vs 31.3%). 
In Chapter 10 our results are briefly summarized and some 
methodological problems are discussed. The hypotheses on the etiology 
of cognitive decline and dementia are addressed in the light of our 
findings, and finally, some ideas for future research are given. 
Until recently, not much was known on the relation between diet 
and cognition. This thesis shows that fatty acids may influence the 
occurrence of cognitive decline and dementia. Metabolic factors also 
seem to play a role in the underlying processes leading to these 
disorders. Our findings suggest that vascular processes and inflammation 
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are involved in the etiology of cognItive decline and dementia. Future 
research on risk factors should focus, among other things, on these 
processes. Although the investigated risk factors can be modified, our 
results should first be confirmed in other large population-based studies, 
before preventive measures can be taken. 
SAMENVA TTING 
I n dit proefschrift wordt onderzoek beschreven naae risicofactoren voor cognitieve achteruitgang en dementie. Achteruitgang in cogni-tieve functies is een van de belangrijkste symptomen van demen-tie. De voornaamste cognitieve functies zijn orientatie in tijd en 
plaats, inprenting en geheugen, waarneming, aandacht, taalgebruik en 
-begrip, rekenen, constructieve vaardigheden en ruimtelijke orientatie. 
Een slechter cognitief functioneren leidt tot een verminderde zelfstan-
digheid en tot een achteruitgang in de kwaliteit van leven. Naast deze 
nadelige consequenties voor het individu, leggen cognitieve achteruitgang 
en dementie een niet gering beslag op de gezondheidszorg door de ho-
gere kans op institutionalisering. Derhalve is het van belang te zoe ken 
naar risicofactoren voor deze aandoeningen die mogelijkerwijs gemodifi-
ceerd kunnen worden. In dit proefschrift wordt onderzocht of bepaalde 
voedingsfactoren en metabole parameters geassocieerd zijn met cognitie-
ve achteruitgang en dementie. 
Voor het in dit proefschrift beschreven onderzoek hebben we 
gegevens gebruikt van twee bevolkingsonderzoeken bij ouderen: de 
Zutphen Ouderen Studie en het Erasmus Rotterdam Gezondheid en 
Ouderen (ERGO) onderzoek. De Zutphen Ouderen Stu die is de 
voortzetting van de Zutphen Studie, dat deel uitmaakte van het in 1960 
gestarte Zeven Landen Onderzoek. In 1990 namen S60 van de 718 nog 
in leven zijnde mannen (78%), allen geboren tussen 1900 en 1920, deel 
aan de Zutphen Ouderen Studie. Zij werden uitgebreid geinterviewd en 
onderzocht. Een val ide en veelgebruikte cognitieve functietest, de Mini-
Mental State Examination (MMSE), werd bij hen afgenomen. 
Vervolgens werden deze mannen in 1993 opnieuw gevraagd deel te 
nemen aan de Zutphen Ouderen Studie; 390 (71%) van de SS3 nog in 
leven zijnde mannen stemden daarin toe. 
Het ERGO onderzoek is een prospectief onderzoek onder aile in-
woners van de Rotterdamse wijk Ommoord, die ten tijde van het begin 
van het onderzoek in 1990 SS jaar of ouder waren. Achtenzeventig 
procent (n~7983) van de mensen die in aanmerking kwamen deed mee 
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aan de uitgebreide interviews en lichamelijke onderzoeken. Ook bij hen 
werd de MMSE afgenomen en daarnaast werden ze gescreend op de-
mentie. Personen die naac aanleiding van deze screening verdacht wer-
den van dementie zijn vervolgens uitgebreider onrlerzocht door ceo ncu-
roloog en een neuropsycholoog. De uiteindelijke diagnose en subtypering 
van dementie werd gesteld volgens internationale criteria. In 1993 en 
1994 namen 6315 (88%) van de 7215 nog in leven zijnde deelnemers 
deel aan het vervolg van het ERGO onderzoek, waarin zij ondermeer 
opnieuw gescreend werden op dementie. 
Aangezien er een verband lijkt te bestaan tussen aderverkalking en 
hart- en vaatziekten enerzijds en ceo verminrlerd cognitief functioneren 
en vasculaire dementie anderzijds, richtten wij ons in dit onderzoek 
vooral op vasculaire risicofactoren. Met behulp van uitgebreide gegevens 
over de voedselinneming van de deelnemers aan de Zutphen Ouderen 
Studie werd het verband tussen inneming van linolzuur en antioxydan-
ten (vitamine E, beta-caroteen, vitamine C en flavonoi'den) en cognitieve 
functiestoornissen onderzocht (hoofdstuk 2). Hieruit bleek dat een hoge 
inneming van deze antioxydanten niet geassocieerd was met ceo vec-
laagd risico op cognitieve functiestooenissen. Wei bleek er een verband 
te bestaan tussen ceo hoge linolzuurinneming en eeo verminderd cogni-
tief functioneren in 1990 (relatief risico (RR) - 1,8), maar niet met cog-
nitieve achteruitgang tussen 1990 en 1993. 
In het ERGO onderzoek werd gekeken naar de relatie tussen vet-
en visconsumptie en het risico op het krijgen van dementie in de jaren 
daarm; (hoofdstuk 3). Het voordeel van deze studie is dat de voedings-
inneming werd bepaald bij mensen die op dat moment nog normaal 
cognitief functioneerden. Een hoge vetinneming, en vooral een hoge 
inneming van verzadigd vet en cholesterol, leidde tot een 2,4 maal ver-
hoogd risico op het krijgen van dementie in het algemeen, en vasculaire 
dementie in het bijzonder (RR - 3.0). Consumptie van vis daarentegen, 
verlaagde het risico op dementie met 60%, en het risico op de ziekte 
van Alzheimer met 70%. Dit laatste zou verklaard kunnen worden door 
de ontstekingsremmende werking van de n-3 meervoudig onverzadigde 
vetzuren in vis. 
De eerste metabole risicofactoren die we onderzochten waren sui-
kerziekte en voorstadia van suikerziekte, d.w.z. een gestoorde glucose-
tolerantie en hyperinsulinemie (hoofdstuk 4). Deze aandoeningen verho-
gen het risico op hart- en vaatziekten. In de Zutphen Ouderen Studie 
had den mannen met suikerziekte 1,2 maal zo vaak cognitieve functie-
stoornissen als mannen zonder suikerziekte. Zelfs in voorstadia van sui-
kerziekte bleek er een verhoogd risico op cognitieve stooenissen te 
bestaan. 
Het aminozuur homocysteIne is een betrekkelijk nieuwe risicofactor 
voor hart- en vaatziekten. Het homocystelnegehalte in het bloed kan 
vrij gemakkelijk verlaagd worden door middel van foliumzuursuppletie. 
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Wij hebben in een subpopulatie (n~472) van het ERGO onderzoek on-
derzocht of homocyste'ine oak gerelateerd was met cognitieve achteruit-
gang (hoofdstuk 5). In personen jonger dan 7S jaar was er een positieve 
associatie tussen een haag serum homocystei'negehalte en cognitieve 
achteruitgang (RR ~ 2,3). Verder was er een relatie tussen homocyste'ine 
en cognitieve achteruitgang in vrouwen (RR ~ 2,2), maar niet in man-
nen. 
Cortisol en dehydroepiandrosteronesulfaat (DHEAS) zijn bijnier-
schorshormonen die een effect hebben op de hippocampus. De hippo-
campus speelt een grote rol in geheugenprocessen en is een van de 
aangedane hersengebieden bij de ziekte van Alzheimer. Eerder onder-
zoek heeft een verband tussen deze hormonen en de ziekte van Alz-
heimer aangetoond, maar deze onderzoeken waren, op een onderzoek 
naac DHEAS en cognitie na, allen cross-sectioneel en niet uitgevoerd in 
een algemene populatie. Een kleine groep deelnemers (n~189) van het 
ERGO onderzoek heeft meegedaan aan een uitgebreider onderzoek naar 
de glucosestofwisseling, waarin onder meer het serum cortisol en 
DHEAS gehalte is gemeten. Ons onderzoek laat zien dat er een posi-
tieve associatie bestond tussen het serum cortisol gehalte en cognitieve 
functiestoornissen (RR ~ 1,7) (hoofdstuk 6). Er was een negatief ver-
band tussen DHEAS en cognitieve functiestoornissen (RR ~ 0,5), en 
tussen DHEAS en cognitieve achteruitgang (RR ~ 0,6). 
In Deel III wordt onderzocht hoe een mogelijke wisselwerking 
tussen het apolipoprotelne E gen en omgevingsfactoren het risico op 
cognitieve achteruitgang belnvloedt. Voorgaand onderzoek heeft aange-
toond dat zowel het e4 allel van het apolipoprotelne E gen, als een 
lager opleidingsniveau, geassocieerd zijn met cognitieve achteruitgang en 
de ziekte van Alzheimer. Wij vonden in de Zutphen Ouderen Stu die 
dat een lager opleidingsniveau (aileen lagere school) slechts geassocieerd 
bleek te zijn met cognitieve achteruitgang bij mensen zonder het e4 
allel van het apolipoprotelne E gen (RR ~ 3,1) (hoofdstuk 7). 
Het is alom bekend dat het doormaken van een cerebrovasculair 
accident (CVA) het risico op cognitieve achteruitgang verhoogt. In de 
Zutphen Ouderen Stu die is onderzocht of de combinatie van een CVA 
en het e4 allel een nog sterker verhoogd risico geeft op cognitieve 
achteruitgang (hoofdstuk 8). Het bleek dat mannen met beide risicofac-
toren een 17.2 maal verhoogde kans hadden op cognitieve achteruitgang 
dan mannen zander deze risicofactoren. Oit relatieve risico was veel ho-
ger dan de som van de afzonderlijke relatieve risico's behorende bij een 
CVA en het e4 allel (RR ~ 4,7 en 3,3, respectievelijk), wat suggereert 
dat deze factoren een synergistisch effect hebben op cognitie. 
Als laatste hebben we de prognose van dementie onderzocht in het 
ERGO onderzoek (hoofdstuk 9). Het is bekend dat personen met de-
mentie een verhoogde sterftekans hebben. Er is echter weinig bekend 
over oorzaakspecifieke sterfte bij personen met dementie. Het blijkt dat 
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personen met dementie 2 maal zoveel kans hebben om te overlijden 
dan mensen zonder dementie. Er was eeo verschuiving in de verdeHng 
van de doodsoorzaken. Het percentage mensen dat overleed aan kanker 
was lager onder dementen dan onder niet-demente personen (respec-
tievelijk 13.3% en 24.9%), terwijl het percentage dat overleed aan 
andere oorzaken dan kanker en hart- en vaatziekten hoger was onder 
demente personen (49.2% in vergelijking met 31.3%). 
Hoofdstuk 10 gaat in op de resultaten van dit proefschrift en de 
problemen die zich bij dit onderzoek kunnen voordoen. Tevens wordt 
ingegaan op de hypotheses omtrent het ontstaan van cognitieve achter-
uitgang en dementie in het Heht van ooze bevindingen, en worden 
enkele ideeen gegeven vaoe toekomstig onderzoek. 
Tot voor kort was nog weinig bekend over de relatie tussen 
voeding en cognitie. Oit proefschrift laat zien dat vetzuren van invloed 
kunnen zijn op het ontstaan van cognitieve achteruitgang en dementie. 
Ook metabole factoren lijken een rol te spelen in de onderliggende 
processen die leiden tot cognitieve achteruitgang en dementie. Deze 
bevindingen suggereren dat vasculaire processen en ontstekings-
mechanismen betrokken zijn bij het ontstaan van deze aandoeningen. 
Toekomstig onderzoek naar risicofactoren voor cognitieve achteruitgang 
en dementie zou zich dan ook onder andere op deze processen moeten 
richten. Alhoewel de beschreven risicofactoren modificeerbaar zijn, zullen 
ooze resultaten eerst bevestigd moeten worden in andere grote 
bevolkingsonderzoeken alvorens over te gaan tot preventieve maat-
regelen. 
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